

SCHOOL OF PHARMACEUTICAL SCIENCES
GENEVA - LAUSANNE

SCIENTIFIC PRODUCTIONS 2012



UNIVERSITÉ
DE GENÈVE

Ecole de Pharmacie
EPGL
Genève – Lausanne

Unil
UNIL | Université de Lausanne

CHAPTERS

2012 at a Glance	5
BIOPHARMACEUTICS	7
1. Publications	7
2. Posters presentations	8
3. Oral Presentations	10
4. Thesis presented	11
LIFE SCIENCE MASS SPECTROMETRY	13
1. Publications	13
2. Posters presentations	14
3. Oral presentations	15
4. Thesis presented	15
PHARMACEUTICAL ANALYTICAL CHEMISTRY	17
1. Publications	17
2. Posters presentations	19
3. Oral presentations	21
4. Thesis presented	25
PHARMACEUTICAL BIOCHEMISTRY	27
1. Publications	27
2. Posters presentations	29
3. Oral presentations	31
4. Thesis presented	32
PHARMACEUTICAL TECHNOLOGIES	33
1. Publications	33
2. Posters presentations	34
3 Oral presentations	35
4. Thesis presented	36
PHARMACOCHEMISTRY	37
1. Publications	37
2. Posters presentation	38
3. Oral presentations	39
4. Thesis presented	40
PHARMACOGNOSY	41
1. Publications	41
2. Posters presentations	42
3. Oral presentations	42

PHARMACOLOGY	43
1. <i>Publications</i>	43
2. <i>Posters presentations</i>	44
3. <i>Oral presentations</i>	44
PHYTOCHEMISTRY AND BIOACTIVE NATURAL PRODUCTS	45
1. <i>Publications</i>	45
2. <i>Posters presentations</i>	46
3. <i>Oral presentations</i>	48
4. <i>Radio/Television/Media Intervention</i>	51
CLINICAL PHARMACY	53
1. <i>Publications</i>	53
2. <i>Posters presentations</i>	54
3. <i>Oral presentations</i>	55
COMMUNITY PHARMACY	57
1. <i>Publications</i>	57
2. <i>Posters presentations</i>	60
3. <i>Oral presentations</i>	60
4. <i>Thesis presented</i>	65
HOSPITAL PHARMACY	67
1. <i>Publications</i>	67
2. <i>Posters presentations</i>	70
3. <i>Oral presentations</i>	72
4. <i>Thesis presented</i>	76
HONORARY PROFESSORS	77
1. <i>Publications</i>	77
2. <i>Posters presentations</i>	78
3. <i>awards and distinctions</i>	79
4. <i>Oral presentations</i>	79

2012 AT A GLANCE

Publications with impact factor	145
Publications without impact factor	40
Books or books chapters	28
Presentations & posters	192
Congresses & Symposia	185
Continuing Education & Open tot the public lectures	125
Radio/TV-Media Interventions	4
Number of projects at FNSR and assimilated	44
Projects of collaboration with the industry	47
Ph.D. Thesis presented in 2012	14
Patents	12

BIOPHARMACEUTICS



PROFESSOR

BORCHARD Gerrit

MER

JORDAN Olivier

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	10
1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)	3
2.1 POSTERS PRESENTATIONS	15
3.1 CONGRESSES & SYMPOSIA	15
4.1 THESIS PRESENTED (INTRA-MUROS)	2

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

Carbohydrate Polymers	3.99
International Journal of Pharmaceutics	3.87
Journal of Pharmaceutical Sciences	3.54
Regulatory Pharmacology and Toxicology	2.40
Journal of Microencapsulation	1.84
Chimia	1.21
Journal Drug Delivery Science and Technology	0.68

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. A. HANSSON, O. JORDAN, P. ROUSSELLE, F. FALSON, G. BORCHARD 3.87
The use of small synthetic RGD peptides in wound healing: Promotion of cell adhesion and migration in keratinocytes and fibroblasts.
International Journal of Pharmaceutics, 439, 73-80,
10.1016/j.ijpharm.2012.09.053 (2012).
2. M. MOHAMED, G. BORCHARD, O. JORDAN 0.68
In situ forming implant for combined chemotherapy and hyperthermia of bone tumors.
Journal of Drug Delivery Science and Technology, 22, 393-408, ISSN: 17732247 (2012).
3. G. VACHER, C. GREMION, C. MOSER, S.A. STOFFEL, M. AMACKER, R. GURNY, G. BORCHARD 0.68
Virosomal *C. albicans* vaccine for vaginal application: Formulation development and toxicity/immunogenicity studies.
Journal Drug Delivery Science and Technology, 22, 447-452, ISSN: 17732247 (2012).
4. G. BORCHARD, B. FLÜHMANN, S. MÜHLEBACH. 2.40
Nanoparticle iron medicinal products – Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies.
Regulatory Pharmacology and Toxicology, 64, 324-328,
10.1016/j.yrtph.2012.08.009 (2012).

5. A. HANSSON, N. HASHOM, F. FALSON, P. ROUSSELLE, O. JORDAN, G. BORCHARD 3.99
In vitro evaluation of an RGD-functionalized chitosan derivate for enhanced cell adhesion. Carbohydrate Polymers, 90, 1494-1500, 10.1016/j.carbpol.2012.07.020 (2012).
6. C. MUELLER, M.A.H. CAPELLE, E. SEYREK, S. MARTEL, P.-A. CARRUPT, T. ARVINTE, G. BORCHARD 3.54
Non-covalent PEGylation: various PEG-based excipients revealing differing effects on the aggregation of biopharmaceuticals. Journal of Pharmaceutical Sciences, 101, 1995-2008, 10.1002/jps.23110 (2012).
7. R. BOUBEVA, C. REICHERT, R. HANDRICK, C. MÜLLER, J. HANNEMANN, G. BORCHARD 1.21
New expression method and characterization of recombinant human granulocyte colony stimulating factor in a stable protein formulation. Chimia, 5, 281-285, 10.2533/chimia.2012.281 (2012).
8. A. CHAURASIYA, A.K. SINGH, G.K. JAIN, M.H. WARSI, F.J. AHMAD, E. SUBLET, G. BORCHARD, R.K. KHAR 1.84
Dual approach utilizing self micro-emulsifying technique and novel P-gp inhibitor for effective oral delivery of taxanes. Journal of Microencapsulation, 29, 583-595, 10.3109/02652048.2012.668959 (2012).
9. S. HEUKING, G. BORCHARD 3.54
Toll-like receptor-7 agonist decoration enhances the adjuvanticity of chitosan-DNA nanoparticles. Journal of Pharmaceutical Sciences, 101, 1166-1177, 10.1002/jps.23017 (2012).
10. J. PRADAL, O. JORDAN, E. ALLÉMANN. 0.68
Intra-articular drug delivery for arthritis diseases: the value of extended release and targeting strategies. Journal of Drug Delivery Science and Technology 22, 409-419, ISSN: 17732247 (2012).

1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)

1. G. BORCHARD, E. ALLEMANN
Pharmaceutical technology and biopharmaceutics at the School of Pharmacy Geneva-Lausanne. Editorial, Journal of Drug Delivery Science and Technology 22, 2012, 377-378.
2. G. BORCHARD, P.A. CARRUPT
The School of Pharmacy Geneva-Lausanne (EPGL) - The first ten years. Editorial, Chimia 66, 2012, 280.
3. G. BORCHARD
Thérapeutische Proteine: Zurück zur Natur?/Protéines thérapeutiques: Retour à la nature? Online academy No. 3, 2012.

2. PRESENTATIONS

2.1 POSTERS PRESENTATIONS

1. K. FUCHS, C. SIEGFRIED, A. DENYS, P. BIZE, O. DORMOND, E. DOELKER, G. BORCHARD, O. JORDAN
"Drug-eluting beads for transarterial chemoembolization: sunitinib loading, release properties and in vivo pharmacokinetics of DC Bead™ microspheres"
5th Swiss Pharma Science Day
August 29, 2012, Bern (Switzerland)
2. M. MOHAMED, V. BERNAU, H. HOFMANN, G. THALMANN, G. BORCHARD, O. JORDAN
"Localized and combined hyperthermia and chemotherapy : a novel approach to treat bone tumors"
5th Swiss Pharma Science Day
August 29, 2012, Bern (Switzerland)

3. S. KADERLI, R. GURNY, L. SCAPOZZA, A.L. ROUGEMONT, J.P. GILBERTO, B. H. WALPOTH, O. JORDAN
 "Novel biocompatible hyaluronic acid-chitosan hybrid hydrogel for osteoarthritis therapy"
 5th Swiss Pharma Science Day
 August 29, 2012, Bern (Switzerland)
4. S. RAGUPATHY, F. ESMAEILI, S. PASCHOUD, E. SUBLET, S. CITI, G. BORCHARD
 "Decrease in human bronchial epithelial cell monolayer permeability triggered by TLR2 ligation is mediated by atypical protein kinase C zeta"
 5th Swiss Pharma Science Day
 August 29, 2012, Bern (Switzerland)
5. M. MOHAMED, V. BERNAU, H. HOFMANN, G. THALMANN, G. BORCHARD, O. JORDAN
 "Bone cements for localized treatment of tumors through combined hyperthermia and chemotherapy"
 18th Annual meeting Swiss Society for Biomaterials
 May 3, 2012, Zürich (Switzerland)
6. L. LUCA, A.L. ROUGEMONT, B. WALPOTH, R. GURNY AND O. JORDAN
 "Hydrogels for BMP-2 delivery: Influence of carrier nature and pH on ectopic bone formation"
 22nd Interdisciplinary Research Conference on Injectable Osteoarticular Biomaterials and Bone Augmentation Procedures
 May 10-12, 2012, Uppsala (Sweden)
7. O. JORDAN, K. FUCHS, C. SIEGFRIED, N. BOULENS, G. BORCHARD, P. BIZE, E. DOELKER, A. DENYS
 "In vitro characterization of sunitinib-loaded DC Bead™: Loading and release characteristics"
 Global embolization symposia and technologies (GEST)
 May 3-6, 2012, New York (USA)
8. A. DENYS, O. JORDAN, O. DORMOND, R. DURAN, E. DOELKER, T. DE BAERE, P. BIZE
 "In vivo characterization of sunitinib-eluting beads (DC-SU)"
 Global embolization symposia and technologies (GEST)
 May 3-6, 2012, New York (USA)
9. K. FUCHS, C. SIEGFRIED, A. DENYS, P. BIZE, O. DORMOND, E. DOELKER, G. BORCHARD, O. JORDAN
 "Sunitinib-loaded microspheres for transarterial chemoembolization: Study of drug loading, release properties and in vivo pharmacokinetics of DC Bead™ microspheres"
 Controlled Release Society German Chapter Meeting
 March 29-30, 2012, Würzburg (Germany)
10. O. JORDAN, K. FUCHS, N. BOULENS, P.E. BIZE, E. DOELKER, A. DENYS
 "In vitro characterization of sunitinib eluting beads"
 Society for Interventional Radiology Annual Meeting
 March 24-29, 2012, San Francisco (USA)
11. L. LUCA, A.L. ROUGEMONT, B. WALPOTH, R. GURNY, O. JORDAN
 "Hydrogels for BMP-2 delivery: Influence of pH and hydrogel nature on bone formation in two animal models"
 8th Swiss Experimental Surgery Symposium
 January 19-20, 2012, Geneva (Switzerland)
12. S. JESUS, G. BORCHARD, O. BORGES
 "Chitosan/PCL and PCL nanoparticles as nasal vaccine delivery systems: preparation and characterization."
 National Biotech Conference (NBC)
 May 21-23, 2012, San Diego (USA)
13. F. LEBRE, G. BORCHARD, H. FANECÁ, M. PEDROSO DE LIMA, O. BORGES
 "Albumin loaded chitosan nanoparticles/DNA complexes for nasal immunization."
 National Biotech Conference (NBC)
 May 21-23, 2012, San Diego (USA)

14. J. POECHEIM, N. BENNANI ZIATNI, G. BORCHARD
"Nanocarriers for DNA vaccination: Simultaneous TLR9 and NLR2 stimulation leads to synergistic enhancement of pro-inflammatory cytokine release from murine macrophages"
5th Swiss Pharma Science Day
August 29, 2012, Bern (Switzerland)
15. O. S. SAKR, ACAR KÜBART, S.L. CUELLAR, G. BORCHARD
"CapsInject™: LbL coating technology for controlled delivery of biologicals."
AAPS Annual Conference
October 14-17, 2012, Chicago (USA)

3. ORAL PRESENTATIONS

3.1 CONGRESSES & SYMPOSIA

1. G. BORCHARD
"The future of pharmaceutical research."
Arab Innovation Network Annual Conference (AINAC)
December 3-7, 2012, Abu-Dhabi (UAE)
2. G. BORCHARD
"Non-Covalent PEGylation of therapeutic proteins."
Drug Delivery Australia (DDA2012)
November 26-27, 2012, Monash, Melbourne (Australia)
3. G. BORCHARD
"Artificial viruses: A nanotechnologist's view."
ITN Virus Entry meeting
May 12-14, 2012, Menorca (Spain)
4. G. BORCHARD
"Similar, not generic: Non-biological Complex Drugs."
2nd Open Forum on Pharmaceutics and Biopharmaceutics.
April 26-27, 2012, Marmara University, Istanbul (Turkey)
5. G. BORCHARD
"Formulation of therapeutic proteins."
Bioengineering seminar
April 5, 2012, University Hospital Zürich (Switzerland)
6. G. BORCHARD
"What makes mucosal vaccines antigenic? The role of adjuvants."
Symposium
March 11, 2012, Center for Neuroscience and Cell Biology (CNC), University of Coimbra (Portugal)
7. G. BORCHARD
"Induction of tolerance by allergen vaccines."
Symposium
March 10, 2012, Center for Neuroscience and Cell Biology (CNC), University of Coimbra (Portugal)
8. O. SHOUKRY SAKR, G. BORCHARD
"CapsInject: LBL coating technology for controlled delivery of biologicals."
8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology
March 18-21, 2012, Istanbul (Turkey)
9. G. BORCHARD
"How to write a world-class paper"
Author workshop
January 10, 2012, Medical University Vienna (Austria)
10. V. BERNAU, M. MOHAMED, O. JORDAN, M. CAPSTICK, H. HOFMANN
"Injectable nanocomposites for local hyperthermia"
9th Scientific and applications of magnetic carriers
May 22-26, 2012, Minneapolis (USA)

11. M. MOHAMED, V. BERNAU, H. HOFMANN, G. THALMANN, G. BORCHARD, O. JORDAN
 "Intraosseous forming implants for bone metastases treatment through locally combined hyperthermia and chemotherapy"
 22nd Interdisciplinary Research Conference on Injectable Osteoarticular Biomaterials and Bone Augmentation Procedures
 May 10-12, 2012, Uppsala (Sweden)
12. P.E. BIZE, O. JORDAN, O. DORMOND, R. DURAN, E. DOELKER, T. DE BAERE, A. DENYS
 "In vivo evaluation of the anti-tumoral effect of sunitinib eluting beads in the rabbit VX2 tumor model"
 Society for Interventional Radiology Annual Meeting
 March 24-29, 2012, San Francisco (USA)
13. P.E. BIZE, O. JORDAN, O. DORMOND, R. DURAN, E. DOELKER, T. DE BAERE, A. DENYS
 "In vivo evaluation of sunitinib-loaded DC Beads."
 Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
 September 15-19, 2012, Lisbon (Portugal)
14. P.E. BIZE, O. JORDAN, O. DORMOND, R. DURAN, E. DOELKER, T. DE BAERE, A. DENYS
 "In vivo evaluation of sunitinib-eluting beads in the rabbit VX2 tumor model."
 Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
 September 15-19, 2012, Lisbon (Portugal)
15. O. JORDAN, K. FUCHS, N. BOULENS, P.E. BIZE, E. DOELKER, A. DENYS
 "In vitro characterization of sunitinib loaded DC Beads."
 Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
 September 15-19, 2012, Lisbon (Portugal)

4. THESIS PRESENTED

4.1. INTRA-MUROS THESIS

1. Hansson Annasara
Polymeric controlled release systems for RGD peptides delivery in skin repair.
 University of Geneva-**2012**-
 Supervisor: Prof. G. Borchard
 Co-Supervisor: Dr. O. Jordan
2. Vacher Gaelle
Oral thin films (OTF) for virosomal vaccines.
 University of Geneva-**2012**-thesis n° 4515
 Supervisor: Prof. G. Borchard
 Co-Supervisor: Prof. R. Gurny

LIFE SCIENCE MASS SPECTROMETRY



PROFESSOR

HOPFGARTNER Gérard

MER

VARESIO Emmanuel

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	9
1.2 BOOKS OR BOOKS CHAPTERS	2
2.1 POSTERS PRESENTATIONS	6
3.1 CONGRESSES & SYMPOSIA	11
4.1 THESIS PRESENTED	2

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

TRAC	6.87
Anal.Chem.	5.85
J.Chromatogr. A	4.53
Anal.Bioanal. Chem.	3.77
J.Am.Soc.Mass Spectrom.	4.00
J.Mass Spectrom.	3.26
J.Chromatogr.B	2.88
Rapid Commun.Mass Spectrom.	2.79
Int.J.Mass Spectrom.	2.54
Eur.J.Mass Spectrom.	1.10

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. M. WAGNER, E. VARESIO, G. HOPFGARTNER, A Novel Tube-based Format for Dried Blood Spots Integrating Sample Collection and Sample Preparation, CHIMIA International Journal for Chemistry, 66(1):65, **2012** 1.21
2. E. VARESIO, JCY LE BLANC, G. HOPFGARTNER, Real-time 2D separation by LC x differential ion mobility hyphenated to mass spectrometry, Analytical and Bioanalytical Chemistry, 402(8):2555-64, **2012** 3.77
3. D. TONOLI, E. VARESIO, G. HOPFGARTNER, Quantification of acetaminophen and two of its metabolites in human plasma by ultra-high performance liquid chromatography-low and high resolution tandem mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci., 904:42-50. Epub 2012/08/08, **2012** 2.88
4. D. TONOLI, E. VARESIO, G. HOPFGARTNER, Liquid Chromatography High-resolution Mass Spectrometric QUAL/QUAN Approaches for Drug Metabolism and Metabolomics, Chimia (Aarau), 66(4):218-22. Epub 2012/05/23, **2012** 1.21
5. LESUR, E. VARESIO, B. DOMON, G. HOPFGARTNER, Peptides Quantification by Liquid Chromatography with Matrix-Assisted Laser Desorption/Ionization and Selected Reaction Monitoring Detection. J Proteome Res., 11(10):4972-82. Epub 2012/08/18, **2012** 5.11
6. G. HOPFGARTNER, E. VARESIO, The Life Sciences Mass Spectrometry Research Unit, Chimia, 66(5):335, **2012** 1.21

7. G. HOPFGARTNER, D. TONOLI, E. VAREGIO, High-resolution mass spectrometry for integrated qualitative and quantitative analysis of pharmaceuticals in biological matrices, *Analytical and Bioanalytical Chemistry*, 402(8):2587-96, **2012** 3.77
8. P. DITTRICH, D. GUNTHER, G. HOPFGARTNER, R. ZENOBI, Analytical science in Switzerland and ANAKON 2011, *Analytical and Bioanalytical Chemistry*, 402(8):2483-4, **2012** (Editorial for Special Issue) 3.77
9. T. BRUDERER, E. VAREGIO, S. WINTER, G. HOPFGARTNER, In silico prediction for the investigation of comedication interferences in quantitative LC-MS detection in the SRM mode. *Bioanalysis*, 4(15):1907-17, **2012** 3.22

1.2 BOOKS OR BOOKS CHAPTERS

1. G. HOPFGARTNER, E. VAREGIO, *Tandem Mass Spectrometry Hyphenated with HPLC and UHPLC for Targeted Metabolomic. In Metabolomics in Practice: Successful Strategies to Generate and Analyze Metabolic Data* Michael Lämmerhofer (Editor), W. W. E., Ed. Wiley: 2012; p 21.
2. G. HOPFGARTNER, *Overview of the Various Types of Mass Spectrometers that are Used in Drug Discovery and Drug Development* Spectrometry for Drug Discovery and Drug Development, (Editor), W. A. K., Ed. Wiley: 2012; p 1.

2. PRESENTATIONS

2.1 POSTERS PRESENTATIONS

1. T. PORTA, E. VAREGIO, G. HOPFGARTNER, *Direct analysis of tissue sections by liquid extraction surface analysis – differential ion mobility mass spectrometry*, 1st Ourense Conference on Imaging Mass Spectrometry, Ourense, Spain, September 2012
2. T. PORTA, T. KRAEMER, E. VAREGIO, G. HOPFGARTNER, *QUAL/QUAN Analysis of Drugs and Metabolites from Tissue sections by Liquid Extraction Surface Analysis - Differential Ion Mobility Mass Spectrometry*, 60th ASMS conference on Mass Spectrometry and Allied topics at the Conventional Center of Vancouver, BC, Canada, 2012
3. S. CUDRE, S. LEFAUCHEUR, V. SLAVEYKOVA, E. VAREGIO, G. HOPFGARTNER, *Evaluation of cellular disruption techniques to study metabolites in unicellular algae by LC-MS* JFSM-Journées françaises de spectrométrie de masse, Orléans, France, 17-20 septembre 2012
4. A. BILBAO, Y. ZHANG, D. BOTTINELLI, B. AIGHANEM, F. NIKITIN, J. LUBAN, C. STRAMBIO DE CASTILLIA, E. VAREGIO, G. HOPFGARTNER, M. MUELLER, F. LISACEK *Comparing and validating protein expression in multiple experimental conditions of antiviral immune response using clustering techniques on label-free LC-MS/MS data* ECCB'12 (11th European Conference on Computational Biology) September 9th-12th 2012, Basel, Switzerland
5. A. BILBAO, Y. ZHANG, D. BOTTINELLI, B. ALGHANEM, F. NIKITIN, M. MUELLER, F. LISACEK, J. LUBAN, C. STRAMBIO DE CASTILLIA, E. VAREGIO, G. HOPFGARTNER *Comparing and validating protein expression in multiple experimental conditions of antiviral immune response using clustering techniques on label-free LC-MS/MS data* IMSC2012 (19th International Mass Spectrometry Conference) September 15th-21st 2012, Kyoto, Japan
6. T. SAJIC *Alternative liquid chromatography tandem mass spectrometry approaches for proteome analysis of complete adipose tissue* 60th ASMS Conference on Mass Spectrometry and Allied Topics, Vancouver, CA, 2012

3. ORAL PRESENTATIONS

3.1 CONGRESSES & SYMPOSIA

1. T. PORTA, E. VARELIO, G. HOPFGARTNER, Assessing the relevance of Surface Sampling based on Liquid Extraction coupled to Differential Ion Mobility for Quantitative Mass Spectrometry Imaging,
29èmes Journées Françaises de Spectrométrie de Masse, Orléans, France, September, 2012
2. T. PORTA, E. VARELIO, G. HOPFGARTNER, *Direct QUAL/QUAN analysis of isomers in tissue sections by Liquid Extraction Surface Sampling hyphenated to Differential Ion Mobility – Tandem Mass Spectrometry*,
PhD day of the School of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland, June, 2012
3. A.BILBAO, *Bioinformatics tools for qualitative and quantitative analysis of antiviral response using mass spectrometry*,
Presentation at the SIB PhD Training Network Retreat 2012, March 5th-6th 2012, Bern, Switzerland
4. T. SAJIC, *New analytical approaches in proteome analysis of mouse adipose tissue*
1th Annual Symposium of PHYME, Faculty of Medicine, University of Geneva, Geneva, 2012
5. T. SAJIC, *Alternative liquid chromatography tandem mass spectrometry approaches for proteome analysis of complete adipose tissue*
7th PhD DAY of the School of Pharmacy Geneva – Lausanne (EPGL) part of the PhD program in Pharmaceutical Sciences (University of Geneva) Brocher Foundation, Hermance, 2012
6. T. SAJIC, *Anti-inflammatory signals at the crossroad of obesity and hepatosteatosis: results from proteomic studies of liver and adipose tissue*
Graduate Schools Infection & Immunity and Biology & Medicine, PhD Day, Faculty of Medicine, University of Geneva, Geneva, 2012
7. G. HOPFGARTNER, K. ABBHINANDAN, E. VARELIO, *Novel data acquisition and mining strategies based on fast separations and high resolution mass spectrometry for the simultaneous analysis of xenobiotic and endogenous metabolites*
Novartis Innovation Days, Basel, Switzerland, October 11, 2012
8. G. HOPFGARTNER, E. VARELIO, *The Impact of High Resolution and Ion Mobility Mass Spectrometry for the Analysis of Complex Samples by Liquid Chromatography - Mass Spectrometry*
38th International Symposium on High-Performance Liquid Phase Separations and Related Techniques, Anaheim, CA, USA, 16-21 June 2012
9. G. HOPFGARTNER, E. VARELIO, *Challenges in (Un)-Supervised LC-MS/(MS) - Based Metabolomics*
Shimadzu Lunch Seminar at IMSC 2012, Kyoto, Japan, 18 September 2012
10. G. HOPFGARTNER, A. LESUR, T. PORTA, E. VARELIO, *Quantification in MALDI-MSI: What can we learn from MALDI-SRM/MS?*
OurCon 2012, Ourense Conference on Imaging Mass Spectrometry, Ourense, Spain, 3rd - 5th September 2012
11. G. HOPFGARTNER, *Alternative Sample Preparation based on Dried Blood Spots for Bioanalysis and High Resolution LC-MS/(MS) for Drug Metabolism and Metabolomics*
Bristol Myers-Squibb, Seminar, Princeton, NJ, USA, October 21, 2012

4. THESIS PRESENTED

4.1 THESIS INTRA-MUROS

1. Antoine LESUR
Novel Analytical Strategies for the Quantitative Analysis of Proteins by Mass Spectrometry
University of Geneva, 28 September 2012
2. David TONOLI
Qualitative and Quantitative Determination of Drugs, Metabolites and their Adducts to Proteins in Biological Matrices by Liquid Chromatography Hyphenated to Low and High Resolution Mass Spectrometry
University of Geneva, 29 October 2012

PHARMACEUTICAL ANALYTICAL CHEMISTRY



PROFESSORS

RUDAZ Serge

VEUTHEY Jean-Luc (*vice-chancellor since January 2011*)

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	22
1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)	5
1.3 BOOKS OR BOOKS CHAPTERS	5
2.1 POSTERS PRESENTATIONS	27
3.1 CONGRESSES & SYMPOSIA	35
3.2 CONTINUING EDUCATION & OPEN TOT THE PUBLIC LECTURES	22
4.1 THESIS PRESENTED (INTRA-MUROS)	1

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

Trac-Trend Anal Chem	6.27
Anal Chem	5.85
Anal Chim Acta	4.55
J Chromatogr A	4.53
Analyst	4.23
J Am Soc Mass Spectro	4.00
Talanta	3.79
Anal Bioanal Chem	3.77
Electrophoresis	3.30
J. Mass Spectrom	3.26

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. J. RUTA, D. ZURLINO, C. GRIVEL, S. HEINISCH, J.-L. VEUTHEY, D. GUILLARME. 4.53
Evaluation of columns packed with shell particles with compounds of pharmaceutical interest. *Journal of Chromatography A*, **1228**, 221-231, (2012)
2. M. RODRIGUEZ-ALLER, B. KAUFMANN, D. GUILLARME, C. STELLA, P. FURRER, S. 4.40
RUDAZ, I. EL ZAOUI, F. VALAMANESH, C. DI TOMMASO, F. BEHAR-COHEN, J.-L. VEUTHEY, R. GURNY. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease. *European Journal of Pharmaceutics and Biopharmaceutics*, **80**, 544-552 (2012)
3. J. RUTA, J. BOCCARD, D. CABOOTER, S. RUDAZ, G. DESMET, J.-L. VEUTHEY, D. 2.97
GUILLARME. Method development for pharmaceuticals: some solutions for tuning selectivity in reversed phase and hydrophilic interaction liquid chromatography. *Journal of Pharmaceutical and Biomedical Analysis*. **63**, 95-105, (2012)

4. S. NUSSBAUMER, L. GEISER, F. SADEGHIPOUR, D. HOCHSTRASSER, P. BONNABRY, J.-L. VEUTHEY, S. FLEURY-SOUVERAIN. Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces. *Anal Bioanal Chemistry*. **402**, 2499-2509, (2012) 3.77
5. G. BONVIN, J.-L. VEUTHEY, S. RUDAZ, J. SCHAPPLER. Evaluation of a sheathless nanospray interface based on a porous tip sprayer for CE-ESI-MS coupling. *Electrophoresis*. **33**, 552-562, (2012) 3.30
6. I. KOHLER, J. SCHAPPLER, T. SIERRO, S. RUDAZ. Dispersive liquid-liquid microextraction combined with capillary electrophoresis and time-of-flight mass spectrometry for urine analysis. *Journal of Pharmaceutical and Biomedical Analysis*. **73**, 82-89, (2012) 2.97
7. S. FEKETE, R. BERKY, J. FEKETE, J.-L. VEUTHEY, D. GUILLARME. Evaluation of a new wide pore core-shell material (Aeris™ WIDEPOR) and comparison with other existing stationary phases for the analysis of intact proteins. *Journal of Chromatography A*, **1236**, 177-188, (2012) 4.53
8. D. GUILLARME, J. SCHAPPLER, J. BOCCARD, J.-L. VEUTHEY, S. RUDAZ. New insights in pharmaceutical analysis. *Chimia*, **66**, 330-334, (2012) 1.14
9. K. VUIGNIER, J.-L. VEUTHEY, P.-A. CARRUPT, J. SCHAPPLER. Characterization of drug-protein interaction by capillary electrophoresis hyphenated to mass spectrometry. *Electrophoresis*, **33**, 1-10, (2012) 3.30
10. S. FEKETE, R. BERKY, J. FEKETE, J.-L. VEUTHEY, D. GUILLARME. Evaluation of recent very efficient wide-pore stationary phases for the reversed-phase separation of proteins. *Journal of Chromatography A*, **1252**, 90-103, (2012) 4.53
11. S. FEKETE, J.-L. VEUTHEY, D. GUILLARME. New trends in reversed-phase liquid chromatographic separation of therapeutic peptides and proteins: Theory and applications. *Journal of Pharmaceutical and Biomedical Analysis*. **69**, 9-27, (2012) 2.96
12. A. GRAND-GUILLAUME-PERRENOUD, J. BOCCARD, J.-L. VEUTHEY, D. GUILLARME. Analysis of basic compounds by supercritical fluid chromatography: Attempts to improve peak shape and maintain mass spectrometry compatibility. *Journal of Chromatography A*, **1262**, 205-213, (2012) 4.53
13. S. HERZIG, E. RAEMY, S. MONTESSUIT, J.-L. VEUTHEY, N. ZAMBONI, B. WESTERMANN, E. R. S. KUNJI, J.-C. MARTINOU. Identification and Functional Expression of the Mitochondrial Pyruvate Carrier. *Science*, **337**, 93-96, 1-10, (2012) 31.20
14. A. GRAND-GUILLAUME-PERRENOUD, J.-L. VEUTHEY, D. GUILLARME. Comparison of ultra-high performance supercritical fluid chromatography and ultra-high performance liquid chromatography for the analysis of pharmaceutical compounds. *Journal of Chromatography A*, **1266**, 158-167, (2012) 4.53
15. S. FEKETE, S. RUDAZ, J.-L. VEUTHEY, D. GUILLARME. Impact of mobile phase temperature on recovery and stability of monoclonal antibodies using recent reversed phase stationary phases. *Journal of Separation Science*, **35**, 3113-3123, (2012) 2.73
16. S. FEKETE, J.-L. VEUTHEY, D.V. MCCALLEY, D. GUILLARME. The effect of pressure and mobile phase velocity on the retention properties of small analytes and large biomolecules in ultra-high-pressure liquid chromatography. *Journal of Chromatography A*. **1270**, 127-138, (2012) 4.53
17. S. FEKETE, S. RUDAZ, J. FEKETE, D. GUILLARME. Analysis of recombinant monoclonal antibodies by RPLC: toward a generic method development approach. *Journal of Pharmaceutical and Biomedical Analysis*, **70**, 158-168, (2012) 2.97
18. E. TYTECA, A. LIEKEN, D. CLICQ, A. FANIGLIULO, B. DEBRUS, S. RUDAZ, D. GUILLARME, G. DESMET. Predictive Elution Window Stretching and Shifting as a Generic Search Strategy for Automated Method Development for Liquid Chromatography. *Analytical Chemistry*, **84**, 7823-7830, (2012) 5.85
19. P. J. EUGSTER, D. BIASS, D. GUILLARME, P. FAVREAU, R. STOCKLIN, J.-L. WOLFENDER. Peak capacity optimisation for high resolution peptide profiling in complex mixtures by liquid chromatography coupled to time-of-flight mass spectrometry: Application to the *Conus consors* cone snail venom. *Journal of Chromatography A*, **1259**, 187-189, (2012) 4.53

- 20.. G. BONVIN, J. SCHAPPLER, S. RUDAZ. Capillary electrophoresis-electrospray ionization-mass spectrometry interfaces: Fundamental concepts and technical developments. *Journal of Chromatography A*, 1267, 17-31, (2012) 4.53
21. S. FEKETE, D. GUILLARME. Reversed-Phase liquid. Chromatography for the analysis of therapeutic proteins and recombinant monoclonal antibodies. *LC-GC Europe*, 25, 540-550, (2012) 0.49
22. I. KOHLER, J. SCHAPPLER, S. RUDAZ. Microextraction techniques combined with capillary electrophoresis in bioanalysis. *Anal Bioanal Chemistry*, 405, 125-141, (2012) 3.77

1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)

1. I. KOHLER, J. SCHAPPLER, T. SIERRO, S. RUDAZ. Microextraction liquide-liquide dispersive combinée à l'électrophorèse capillaire et la spectrométrie de masse pour l'analyse de l'urine, *CJ Mag* **04** (2012).
2. I. KOHLER, J. SCHAPPLER, S. RUDAZ, H.P. ZIMMERMANN, C. WENZ. Compatibility of Agilent Jet Stream thermal gradient focusing technology with CE-MS. *Technical Overview* (2012)
3. G. ROZING, J. SCHAPPLER, S. RUDAZ. Electrophoresis special issue dedicated to the 27th International Symposium on MicroScale Bioseparations and Analyses, *Electrophoresis*, **33**, 3265-3266, Editorial (2012)
4. S. RUDAZ. Les multiples clés de la réussite in Special issue "Metabolomique et biomarqueurs". *Spectra Analysis*, **284**, Editorial (2012)
5. J. BOCCARD, F. BADOUD, E. GRATA, S. OUERTANI, M. HANAFI, G. MAZEROLLES, P. LANTERO, J.-L. VEUTHEY, M. SAUGY, S. RUDAZ. Analyse métabolomique dans l'urine par UHPLC-QTOF-MS^E: profilage des stéroïdes appliqué au dépistage anti-dopage. *Spectra Analyse*, **284**, 48-54 (2012)

1.3 BOOKS OR BOOKS CHAPTERS

1. B. DEBRUS, E. ROZET, PH. HUBERT, J.-L. VEUTHEY, S. RUDAZ, D. GUILLARME. Method transfer between conventional HPLC and UHPLC. UHPLC in Life Sciences. D. Guillaume, J.-L. Veuthey (eds), Royal Society of Chemistry, **2012**, 67-101, chapter 3.
2. F. BADOUD, M. SAUGY, J.-L. VEUTHEY. Ultra-high Pressure Liquid Chromatography coupled to Mass Spectrometry in Doping Control Analysis. UHPLC in Life Sciences. D. Guillaume, J.-L. Veuthey (eds), Royal Society of Chemistry, **2012**, 283-317, chapter 10.
3. S. FEKETE, J. FEKETE. Comparison of the performance of totally porous and core-shell particles, Basic of UHPLC and Application in Life Science, D. Guillaume, J.-L. Veuthey (eds), Royal Society of Chemistry, **2012**.
4. D. GUILLARME, J.-L. VEUTHEY. UHPLC in Life Science. D. Guillaume, J.-L. Veuthey (eds), Royal Society of Chemistry, **2012**, 466 pages.
5. G. MARTI, M. ERB, S. RUDAZ, T. TURLINGS, J.-L. WOLFENDER. Search for low-molecular-weight biomarkers in plant tissues and seeds using metabolomics: tools, strategies and applications. In Seed Development: OMICS Technologies toward Improvement of Seed Quality and Crop Yield. Agrawal, Ganesh K., Rakwak, Randeep (Eds.) Springer Verlag, Heidelberg, Germany, **2012**, ISBN 978-94-007-4749-4

1. PPRESENTATIONS

2.1 POSTERS PRESENTATIONS

1. K. VUIGNIER, D. GUILLARME, J.L. VEUTHEY, P.A. CARRUPT, J. SCHAPPLER
Critical evaluation and comparison of capillary electrophoresis, liquid chromatography, and surface plasmon resonance to study drug-plasma protein interactions.
MSB 2012 – Geneva, Switzerland, 12-15 February 2012
2. K. VUIGNIER, J.-L. VEUTHEY, P.-A. CARRUPT, J. SCHAPPLER
Characterization of drug-protein interactions by capillary electrophoresis hyphenated to mass spectrometry
MSB 2012 – Geneva, Switzerland, 12-15 February 2012

3. M. RODRIGUEZ-ALLER, D. GUILLARME, R. NICOLI, S. RUDAZ, J.-L. VEUTHEY, R. GURNY
Analytical Challenges for in vivo Investigations on a Rodent Ocular Model: Quantification of Cyclosporine A
MSB 2012 – Geneva, Switzerland, 12-15 February 2012
4. I. KOHLER, J. SCHAPPLER, M. AUGSBURGER, J.-L. VEUTHEY, S. RUDAZ
Capillary electrophoresis combined with time-of-flight mass spectrometry for the analysis of carbohydrate-deficient transferrin.
MSB 2012 – Geneva, Switzerland, 12-15 February 2012.
5. I. KOHLER, J. SCHAPPLER, S. RUDAZ, M. GREINER, H.-P. ZIMMERMANN, C. WENZ
A New Sprayer for Coupling Capillary Electrophoresis with Thermal Gradient Focusing ESI-MS Technology,
MSB 2012 – Geneva, Switzerland, 12-15 February 2012
6. I. KOHLER, J. SCHAPPLER, T. SIERRO, J.-L. VEUTHEY, S. RUDAZ
Dispersive liquid-liquid microextraction combined with capillary electrophoresis and time-of-flight mass spectrometry for urine analysis,
MSB 2012 – Geneva, Switzerland, 12-15 February 2012
7. L. BERTOLETTI, J. SCHAPPLER, S. RUDAZ, R. COLOMBO, E. DE LORENZI
Optimisation of CE-ESI-MS platform for intact protein analysis: conformational studies on beta2-microglobulin
MSB 2012 – Geneva, Switzerland, 12-15 February 2012
8. G. BONVIN, J.-L. VEUTHEY, S. RUDAZ, J. SCHAPPLER
Insuline ionization profiles in CE-ESI-MS
MSB 2012 – Geneva, Switzerland, 12-15 February 2012
9. G. BONVIN, J.-L. VEUTHEY, S. RUDAZ, J. SCHAPPLER
• *Evaluation of a sheathless nanospray interface based on a porous tip for CE-MS coupling*
MSB 2012 – Geneva, Switzerland, 12-15 February 2012
10. M. RODRIGUEZ-ALLER, J.-L. VEUTHEY, R. GURNY
*Formulation of poorly water-soluble drugs for ophthalmic use*How to improve animal studies in experimental biology,
Rigi Workshop, Rigi Kilm, Switzerland, January 22-24, 2012
11. I. KOHLER, J. SCHAPPLER, S. RUDAZ, R. SCHOENING, J. JASAK, G. ROSS, C. WENZ, M. GRENIER.
Compatibility of Agilent Jet Stream thermal gradient focusing technology with CE/MS tested with labile polar compound.
ASMS 2012, Vancouver, Canada, May 20-24, 2012
12. M. RODRIGUEZ-ALLER, D. GUILLARME, S. RUDAZ, J.-L. VEUTHEY, R. GURNY
A Novel Water-soluble Cyclosporine A Prodrug for Ophthalmic Application.
39th annual meeting of the Controlled Release Society, Quebec City, Canada, July 15-18, 2012
13. S. BIERI, Y. JANIN, B. DEBRUS, S. RUDAZ, P.J. MARRIOTT, A. BUGEY
Enantioselective GCxGC-TOFMS for the detection of adulterated fruit spirits with synthetic aroma.
36th International Symposium on Capillary Chromatography (ISCC) Riva del Garda, Italy, May 27-June 1, 2012
14. S. FEKETE, J.-L. VEUTHEY, D. GUILLARME
A novel water-soluble Cyclosporine A prodrug for ophthalmic application
Controlled release society (CRS 2012) – Quebec, Canada, June 2012
15. S. FEKETE, J.-L. VEUTHEY, D. GUILLARME
Possibility of modern RP-HPLC for the analysis of recombinant monoclonal antibodies
International Symposium on Chromatography (ISC'12) – Torun, Poland, September 9-13, 2012
16. A. GRAND-GUILLAUME-PERRENOUD, J.-L. VEUTHEY, D. GUILLARME
Generic approach development for basic drugs analysis on new waters Acquity UPC2
International Symposium on Chromatography (ISC'12) – Torun, Poland, September 9-13, 2012
17. S. FEKETE, J.-L. VEUTHEY, D. GUILLARME
The effect of ultra high-pressure on the retention properties in RP-HPLC: from small to very large analytes (biomolecules)
International Symposium on Chromatography (ISC'12) – Torun, Poland, September 9-13, 2012

18. A. PERIAT, B. DEBRUS, J.-L. VEUTHEY, S. RUDAZ, D. GUILLARME
Systematic method development in HILIC: which parameters are the most relevant for tuning selectivity and retention ?
International Symposium on Chromatography (ISC'12) – Torun, Poland, September 9-13, 2012
19. S. CHALLAL, E.F. QUEIROZ, D. GUILLARME, J.-L. WOLFENDER
Method transfer from HPLC to Middle Pressure Liquid Chromatography (MPLC) for efficient large scale isolation of natural products
Meeting DAC – Zurich, Switzerland, September 2012
20. S. CHALLAL, E.F. QUEIROZ, D. GUILLARME, J.-L. WOLFENDER
Rational isolation strategy of plant biomarkers at the mg scale based on chromatography modeling, MPLC-ELSD and fast UHPLC-TOF-MS monitoring
Metabomeeting – Manchester, UK, September 25-27, 2012
21. I. KOHLER, J. SCHAPPLER, M. AUGSBURGER, J.L. VEUTHEY, S. RUDAZ
Capillary electrophoresis combined with time-of-flight mass spectrometry for the analysis of carbohydrate-deficient transferrin
Pharmaday - Berne, Switzerland, August 29, 2012
22. I. KOHLER, J. SCHAPPLER, M. GREINER, S. RUDAZ
On-line sample preconcentration prior to CE-ESI-MS/MS: quantitation of drugs of abuse in bioanalysis
ITP 2012 – Baltimore, USA, September 20 – October 3, 2012
23. F. MEHL, G. MARTI, J. BOCCARD, B. DEBRUS, P. MERLE, E. DELORT, L. BAROUX, L. WUNSCH, H. SOMMER, J.-L. WOLFENDER, S. RUDAZ
Classification of lemon essential oils and selection of biomarkers by a multiblocks analysis of UHPLC-TOF-MS, NMR and NIR data using multiple factor analysis
Fall Meeting 2012 – Zurich, Switzerland, September 13, 2012
24. A. AZZOLINI, S. BERTRAND, A. NIEVERGELT, J. BOCCARD, S. RUDAZ, M. CUENDET, J.-L. WOLFENDER
Integrative approach in natural product research: at-line coupling of micro fractionation with NMR, C-MS and bioassays
Fall Meeting 2012 – Zurich, Switzerland, September 13, 2012
25. S. RUDAZ, J. BOCCARD, F. BADOUD, N. BAUME, M. SAUGY
From targeted analysis to steroidomics
Metabomeeting 2012 – Manchester, UK, September 25-27, 2012
26. F. JEANNERET, J. BOCCARD, F. BADOUD, O. SORG, J.-H. SAURAT, D. HOCHSTRASSER, S. RUDAZ
Biomarkers of Dioxin Exposure in Human Urine: a Metabolomic Study of the Poisoning of Victor Yushchenko
Metabomeeting – Manchester, UK, September 25-27, 2012
27. K. VUIGNIER, D. GUILLARME, J.-L. VEUTHEY, P.-A. CARRUPT, J. SCHAPPLER
Critical evaluation and comparison of capillary electrophoresis, liquid chromatography, and surface plasmon resonance to study drug-plasma protein interactions
22nd International Symposium on Medicinal Chemistry (ISMC 2012) – Berlin, Germany, September 2012

3. ORAL PRESENTATIONS

3.1 CONGRESSES & SYMPOSIA

1. B. DEBRUS, D. GUILLARME, S. FEKETE, S. RUDAZ
Quality-by-design-compliant automated method development in liquid chromatography
Club Lyonnais de chromatographie – Lyon, France, January 2012
2. J.-L. VEUTHEY, D. GUILLARME
New finding in high speed, high temperature and high pressure chromatography
Norske symposium – Oslo, Norway, January 2012
3. S. FEKETE, J.-L. VEUTHEY, D. GUILLARME
Reversed phase separation of proteins : optimization of selective and kinetic efficiency
HTC-12 – Bruges, Belgium, February 2012

4. D. GUILLARME
HPLC vs UHPLC : a systematic comparison of both approaches
Live webcast LG-GC North America, February 2012
5. S. FEKETE, J. RUTA, A. STAUB, J.-L. VEUTHEY, D. GUILLARME
High resolution separations of peptides and proteins with sub-2 μ m and shell particles
Pittcon congress – Orlando, USA, March 2012
6. A. GRAND-GUILLAUME-PERRENOUD, J.-L. VEUTHEY, D. GUILLARME
Critical evaluation of new generation of SFC instrument (Waters Acquity UPC²) and dedicated stationary phases : application to drugs analysis
International Symposium on Chromatography (ISC'12) - Torun, Poland, September 2012
7. P.-J. EUGSTER, D. BIASS, D. GUILLARME, P. FAVREAU, R. STOCKLIN, J.-L. WOLFENDER
Maximising resolution for UHPLC-TOF-MS metabolite profiling of complex natural samples – application to small and large molecules
Meeting DAC – Zurich, Switzerland, September 2012
8. D. GUILLARME,
UHPLC-MS/ state-of-the-art and pharmaceutical applications
School of mass spectrometry – Srni, Czech Republic, September 2012
9. B. DEBRUS, A. PERIAT, S. FEKETE, A. GRAND-GUILLAUME-PERRENOUD, S. RUDAZ, D. GUILLARME
Method development Olympics at the University of Geneva
Conference on small molecules – COSMOS, Thode Island, USA, September 2012
10. D. GUILLARME
Les récentes évolutions de la chromatographie liquide rapide
ccCTA annual meeting - Les Diablerets, Switzerland, September 13, 2012
11. A. GRAND-GUILLAUME-PERRENOUD
Supercritical Fluid Chromatography and sub-2 μ m particles : towards new frontiers in pharmaceutical analysis
ccCTA annual meeting - Les Diablerets, Switzerland, September 13, 2012
12. A. GRAND-GUILLAUME-PERRENOUD
Critical evaluation of SFC using columns packed with sub-2 μ m particles and its application to pharmaceutical compounds
SFC 2012 – Bruxelles, Belgique, October 3-5, 2012
13. A. GRAND-GUILLAUME-PERRENOUD, J.-L. VEUTHEY, D. GUILLARME
Evaluation of ultra-high performance SFC and dedicated sub-2 μ m particles for drugs analysis
Applica 2012 – Basel, Switzerland, October 16, 2012
14. D. GUILLARME
Fast liquid chromatography and its application
Applica 2012 – Basel, Switzerland, October 16, 2012
15. D. GUILLARME
UPC² for the pharmaceutical industry
Live webcast LC-GC North America, November 2012
16. A. GRAND-GUILLAUME-PERRENOUD
Sub-2 μ m particles and supercritical fluid chromatography : towards new frontiers in pharmaceutical analysis
Afsep Club de chromatographie – Toulouse, France, November 15, 2012
17. I. KOHLER, J. SCHAPPLER, T. SIERRO, J.-L. VEUTHEY, S. RUDAZ
Combination of liquid-based microextraction technique with capillary electrophoresis and mass spectrometry for toxicological analysis
MSB 2012 – Genève, Switzerland, February 12-15, 2012
18. K. VUIGNIER, J.-L. VEUTHEY, P.-A. CARRUPT, J. SCHAPPLER
Capillary electrophoresis hyphenated to mass spectrometry as an efficient tool for drug-protein interactions characterization
MSB 2012 – Geneva, Switzerland, 12-15 February 2012
19. E. DE LORENZI, L. BERTOLETTI, S. RUDAZ, L. REGAZZONI, G. ALDINI, F. ABALLE, R. COLOMBO, J. SCHAPPLER
Beta2-microglobulin and amyloidosis : separation and characterization of protein folding conformers
MSB 2012 – Geneva, Switzerland, 12-15 February 2012

20. I. KOHLER, J. SCHAPPLER, M. AUGSBURGER, S. RUDAZ
Intact protein analysis by capillary electrophoresis: investigations of MS compatible capillary coatings for carbohydrate-deficient transferrin analysis
CE-Forum 2012 – Aalen, Germany – September 24-25, 2012
21. G. BONVIN, S. RUDAZ, J. SCHAPPLER
CE-esi-ms interfaces: effect on protein ionization profiles
19th International Symposium on Capillary Electroseparation Techniques (ITP 2012) – Baltimore, USA, October 2012
22. I. KOHLER, J. SCHAPPLER, M. GREINER, S. RUDAZ
Sensitivity improvement in CE-MS with Agilent Jet Stream technology for bioanalysis
ITP 2012 – Baltimore, USA, September 30 – October 3, 2012
23. I. KOHLER, J. SCHAPPLER, M. AUGSBURGER, S. RUDAZ
Investigations of MS compatible capillary coatings for intact protein analysis by CE-MS
ITP 2012 – Baltimore, USA, September 30 – October 3, 2012
24. I. KOHLER, J. SCHAPPLER, M. AUGSBURGER, S. RUDAZ
Capillary electrophoresis in bioanalysis: application to transferrin in chronic alcohol intake
GPEN 2012 – Melbourne, Australia, November 28 – December 1, 2012
25. J. SCHAPPLER, S. RUDAZ
Capillary electrophoresis-mass spectrometry. The interface features and issues
Biomedical Proteomic Research Group Seminar (BPRG) – Geneva, Switzerland, November 2012
26. A.-L. GASSNER, S. RUDAZ, J. SCHAPPLER
Contribution of capillary zone electrophoresis to the analysis of monoclonal antibody drugs
Meeting of the Society for BioChromatography and Nanoseparations (SBCN 2012)
27. S. RUDAZ
Comment conceptualiser la multi-dimensionnalité en sciences séparatives
Club Lyonnais de Chromatographie Liquide – Lyon, France, May 10, 2012
28. S. RUDAZ
When New Chromatographic Tools Bring Robustness and insurance of Quality
Executive Ultra Performance Chromatography Forum – Saint-Paul-de-Vence, France, June 2012
29. D. GUILLARME
Critical evaluation of Waters UPC2 system and pharmaceutical applications
Executive Ultra Performance Chromatography Forum – St Paul de Vence, France, June 2012
30. S. RUDAZ
Chromatographies, retour vers le futur
Journées scientifiques, Centre de Compétence en Chimie et Toxicologie Analytiques – Les Diablerets, Switzerland September 13-14, 2012
31. S. RUDAZ
CE-MS: from small to high molecular weight molecules
7ème Rencontres Club Utilisateurs Spectrométrie de masse, Pierre Fabre – Saint-Julien, France, October 25, 2012
32. J. BROSEUS, B. DEBRUS, O. DELEMONT, S. RUDAZ, P. ESSEIVA
Study of common database feeding with results coming from different analytical methods in the framework of illicit drugs chemical profiling
Chimiométrie 2012 – Marseille, France, December 5-6, 2012
33. F. MEHL, G. MARTI, J. BOCCARD, B. DEBRUS, P. MERLE, E. DELORT, L. BAROUX, V. RAYMON, M.I. VELAZCO, H. SOMMER, J.-L. WOLFENDER, S. RUDAZ
Differentiation of lemon essential oil based on volatile and non-volatile fractions with various analytical techniques: a metabolomic approach
Chimiométrie 2012 – Marseille, France, December 5-6, 2012
34. M. HANAFI, S. OUERTANI, J. BOCCARD, G. MAZEROLLES, S. RUDAZ
Optimality properties of Nway PLS and its relation to PARAFAC
Chimiométrie 2012 – Marseille, France, December 5-6, 2012
35. G. BONVIN
Effect of CE-ESI-MS interfaces on human insulin ionization profile
Journée scientifique du Club Jeune - Paris, France, October 25.2012

3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES

1. L. GEISER
Rapid and cost-effective analytical strategies to evaluate CYP-related metabolism and drug-drug interactions of new chemical entities
Summer School on Pharmaceutical Analysis 2012 – Rimini, Italy, June 10-13, 2012
2. S. RUDAZ
UPLC-TOF-MS fingerprinting at data mining
Metabolomics workshop, Leiden University - Leiden, Netherland, april 23-27, 2012
3. S. RUDAZ
Capillary Electrophoresis and stereoselective separations
University Cheikh Anta Diop – Dakar, Sénégal, March 29-30, 2012
4. S. RUDAZ
Introduction on plant metabolomics, Fast Analysis in LC, Basics in Data Treatment
Université de Neuchâtel – Neuchâtel, Switzerland, January 26-27, 2012
5. S. RUDAZ
A short insight into Design of Experiment (DOE) approaches
In Master en Sciences Criminelles (2h) – Université de Lausanne, Switzerland
6. S. RUDAZ
Quantitative aspects in Method Validation
Société Firmenich (7h) – Pavillon Ansermet, Genève Switzerland, June 1st, 2012
7. S. RUDAZ
Analytical Method Validation
In Master en Sciences Analytiques (16h) Université de Lyon – Lyon, France
8. S. RUDAZ
Validation des méthodes analytiques II (Formation sur logiciels)
Cours de formation du Centre de Compétence en Chimie et Toxicologie Analytique (CCCTA) (7h) - Geneva, Switzerland, March 23, 2012
9. S. RUDAZ
Validation des méthodes analytiques, Généralités et Protocoles de Validation
Cours de formation du Centre de Compétence en Chimie et Toxicologie Analytique (CCCTA) (7h) - Geneva, Switzerland, March 22, 2012
10. D. GUILLARME
Les nouvelles tendances HPLC: comment améliorer sa productivité au laboratoire ?
Cours de formation du Centre de Compétence en Chimie et Toxicologie Analytique (CCCTA) (14h) - Geneva, Switzerland, March 2012
11. D. GUILLARME
Training Waters on SFC and UPC²
Université de Genève, Genève, Switzerland, April 2012
12. J.-L. VEUTHEY, D. GUILLARME
Recent evolution of separation techniques
Nestlé research center – Lausanne, Switzerland, April 2012
13. B. DEBRUS, D. GUILLARME, S. RUDAZ
Quality-By-Design compliant automated development of robust LC methods with Fusion
AETM - User meeting Waters – Barcelona, Spain, May 2012
14. M. RODRIGUEZ-ALLER, D. GUILLARME, S. RUDAZ, J.-L. VEUTHEY, R. GURNY
A Novel Water-soluble Cyclosporine A Prodrug for Ophthalmic Application
PhD Day – Geneva, Switzerland, June 15, 2012
15. D. GUILLARME
Evaluation of SFC and UPC² for the analysis of pharmaceutical compounds
User meeting Waters – St Quentin en Yvelines, France, June 2012
16. D. GUILLARME
Les nouvelles tendances de la chromatographie liquide
IDECOS course (2 days) – Nice, France, June 2012
17. D. GUILLARME
La chromatographie en phase liquide: les bases, les nouvelles tendances et le développement de méthodes - GSK (2 days) – Les Ulis, France, June 2012

18. S. RUDAZ
New insights in pharmaceutical analysis, from metabolism to metabolomics
Scientific Meeting, Agilent – Waldbronn, Germany, November 30, 2012
19. J. SCHAPPLER
New insights in pharmaceutical analysis, from sample preparation to separation with capillary electrophoresis - Scientific Meeting, Agilent – Waldbronn, Germany, November 30, 2012
20. D. GUILLARME
Comparison of Acquity UPC2 vs. RP-LC (UPLC)
Seminar of UPC2 organized by Waters - Geneva, Switzerland, September 2012
21. D. GUILLARME
Evaluation of Waters UPC2 system and columns: application to compounds of pharmaceutical interest - User meeting Waters - Bruxelles, Belgium, October 2012
22. J.-L. VEUTHEY
Hyphenation of capillary electrophoresis and ultra high pressure liquid chromatography with mass spectrometry - 7th MS PharmaDay, Roma, Italia, October 2012

4. THESIS PRESENTED


4.1 INTRA-MUROS THESIS

1. KARINE VUIGNIER
Analytical strategy to characterize drug-protein interactions: from high throughput to in-depth analysis
Directeur: Pierre-Alain Carrupt, Co-directeur: Jean-Luc Veuthey,
Université de Genève, Thèse N° 4489

4.2 JURE DE THESE

1. F. BEEN – Mid-term qualification for PhD. thesis
Refining sewage epidemiology for the monitoring of illicit drug consumption: investigating the added value of wastewater analyses in relation to conventional analysis
Scientific direction: Prof. P. Esseiva, Université de Lausanne, Switzerland
S. RUDAZ – member of Jury
2. P. ANRES – PhD thesis
Développement de nouvelles méthodologies de préconcentration électrocinétique in-situ en électrophorèse capillaire pour l'analyse de trace
Scientific direction : Prof. P. Gareil, Université Pierre et Marie Curie, Paris, France
S. RUDAZ – member of Jury
3. K. KIPPER – PhD thesis
Fluoroalcohols as Components of LC-ESI-MS Eluents: Usage and Applications
Scientific direction: Prof. K. Herodes, University of Tartu, Estonia
S. RUDAZ – Opponent - member of Jury

PHARMACEUTICAL BIOCHEMISTRY



PROFESSOR

SCAPOZZA Leonardo

MER

KALIA Yogeshvar

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	9
1.2 SCIENTIFIC PUBLICATIONS EXTRA-MUROS (WITH IMPACT FACTOR)	9
1.3 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)	1
1.4 BOOKS OR BOOKS CHAPTERS	1
2.1 POSTERS PRESENTATIONS	23
3.1 CONGRESSES & SYMPOSIA	15
3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES	2
4.1 THESIS PRESENTED (INTRA-MUROS)	1

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

Cancer Res.	7.86
J. Biol. Chem.	4.77
J. Med. Chem.	5.25
Cancer Gene Ther.	2.80
Proteins	3.39
Biochemistry-US	3.42
Protein Sci.	2.80
J. Chem. Inf. Model	4.68
Protein Expres. Purif.	1.59
J. Mol. Model	1.80
Adv. Drug Deliv. Rev.	11.50
J. Control. Rel.	5.73
Mol. Pharmaceut.	5.78
Pharm. Res.	4.10
AAPS J.	5.09
Expert Opin. Drug Del.	4.90
Eur. J. Pharm. Biopharm.	4.27
Int. J. Pharm.	3.35
J. Pharm. Sci.	3.06
Eur. J. Pharm. Sci.	3.21

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. B.C. GOODALE, J. K. LA DU, W. H. **BISSON**, D. B. JANSZEN, K. M. WATERS, R. L. TANGUAY. *Ahr2 Mutant Reveals Functional Diversity of Aryl Hydrocarbon Receptors in Zebrafish*. PLoS One 7, no. 1: e29346, **2012**. 4.09
2. S. SENGUPTA, W. H. **BISSON**, L. K. MATHEW, S. K. KOLLURI, R. L. TANGUAY. *Alternate Glucocorticoid Receptor Ligand Binding Structures Influence Outcomes in an in Vivo Tissue Regeneration Model*. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 156(2): 121-9, **2012**. 2.62

3. A.O. KASIMOVA, G. M. PAVAN, A. DANANI, K. MONDON, A. CRISTIANI, L. **SCAPOZZA**, R. GURNY, M. MOLLER. *Validation of a Novel Molecular Dynamics Simulation Approach for Lipophilic Drug Incorporation into Polymer Micelles*. J. Phys. Chem. B. 116 (14): 4338-45, **2012**. 3.70
4. Y.N. KALIA, R. PEROZZO, L. **SCAPOZZA**. *The Pharmaceutical Biochemistry Group: Where Pharmaceutical Chemistry Meets Biology and Drug Delivery*. Chimia, 66: 313-319, **2012**. 1.21
5. T. GRATIERI, B. WAGNER, D. R. KALARIA, B. ERNST AND Y. N. **KALIA**. *Development and validation of a hpa-e-pad method for the quantification of cgp69669a, a sialyl lewis^x mimetic, in skin permeation studies*. Biomed. chromatogr. **2012**, 26(4): 507-511. 1.97
6. T. GRATIERI, B. WAGNER, D. R. KALARIA, B. ERNST AND Y. N. **KALIA**. *Transdermal delivery of CGP69669A, a sialyl Lewis^x mimetic, across intact porcine and human skins*. Exp. Dermatol. **2012**, 21(3): 226-228. 3.54
7. S. LOVERA, L. SUTTO, R. BOUBEVA, L. **SCAPOZZA**, N. DOLKER, F. L. GERVASIO. *The Different Flexibility of C-Src and C-Abl Kinases Regulates the Accessibility of a Druggable Inactive Conformation*. J. Am. Chem. Soc. 134(5): 2496-9, **2012**. 9.91
8. R. WEISS, M. HESSENBERGER, S. KITZMÜLLER, D. BACH, E. WEINBERGER, W. D. KRAUTGARTNER, C. HAUSER-KRONBERGER, B. MALISSEN, C. BOEHLER, Y. N. **KALIA**, J. THALHAMER, S. SCHEIBLHOFFER. *Transcutaneous vaccination via laser microporation*. J. Control. Release, **2012**; 162(2): 391-399. 6.50
9. D. R. KALARIA, P. PATEL, V. PATRAVALE AND Y. N. **KALIA**. *Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro*. Int J Pharm. **2012**; 438: 202-208. 3.35

1.2 SCIENTIFIC PUBLICATIONS EXTRA-MUROS (WITHOUT IMPACT FACTOR)

1. M. BOI, A. STATHIS, E. ZUCCA, G. INGHIRAMI, F. BERTONI. *Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells*. Cancer Sci. 103(8): 1397-404, **2012**. 3.33
2. W.H. **BISSON**. *Drug Repurposing in Chemical Genomics: Can We Learn from the Past to Improve the Future?* Curr. Top. Med. Chem. 12 (17): 1883-1888, **2012**. 4.17
3. MALEK, A., L. E. NUNEZ, M. MAGISTRI, L. BRAMBILLA, S. JOVIC, G. M. CARBONE, F. MORIS, C. V. CATAPANO. *Modulation of the Activity of Sp Transcription Factors by Mithramycin Analogues as a New Strategy for Treatment of Metastatic Prostate Cancer*. PLoS One 7, no. 4: e35130, **2012**. 4.09
4. BABBIO, F., C. PISTORE, L. CURTI, I. CASTIGLIONI, P. **KUNDERFRANCO**, L. BRINO, P. OUDET, R. SEILER, G. N. THALMAN, E. ROGGERO, M. SARTI, S. PINTON, M. MELLO-GRAND, G. CHIORINO, C. V. CATAPANO, G. M. CARBONE, I. M. BONAPACE. *The Sra Protein Uhrf1 Promotes Epigenetic Crosstalks and Is Involved in Prostate Cancer Progression*. Oncogene 31 (46): 4878-87, **2012**. 6.37
5. G.A. CHIRIANO, A. DE SIMONE, F. MANCINI, D. I. PEREZ, A. CAVALLI, M. L. BOLOGNESI, G. LEGNAME, A. MARTINEZ, V. ANDRISANO, P. CARLONI, M. ROBERTI. *"A Small Chemical Library of 2-Aminoimidazole Derivatives as Bace-1 Inhibitors: Structure-Based Design, Synthesis, and Biological Evaluation."* Eur. J. Med. Chem. 48: 206-13, **2012**. 3.35
6. A. GIROLAMI, P. SCARPARO, E. BONAMIGO, L. SANTAROSSA, A. CRISTIANI, S. MORO, A. M. LOMBARDI. *A Cluster of Factor Xi-Deficient Patients Due to a New Mutation (Ile 436 Lys) in Northeastern Italy*. Eur. J. Haematol. 88 (3): 229-36, **2012**. 2.61
7. N. LONGONI, P. **KUNDERFRANCO**, S. PELLINI, D. ALBINO, M. MELLO-GRAND, S. PINTON, G. D'AMBROSIO, M. SARTI, F. SESSA, G. CHIORINO, C. V. CATAPANO, G. M. CARBONE. *Aberrant Expression of the Neuronal-Specific Protein Dcdc2 Promotes Malignant Phenotypes and Is Associated with Prostate Cancer Progression*. Oncogene, doi:10.1038/onc.2012.245, **2012**. 6.37

8. D. ALBINO, N. LONGONI, L. CURTI, M. MELLO-GRAND, S. PINTON, G. CIVENNI, G. THALMANN, G. D'AMBROSIO, M. SARTI, F. SESSA, G. CHIORINO, C. V. CATAPANO, G. M. CARBONE. *Ese3/Ehf Controls Epithelial Cell Differentiation and Its Loss Leads to Prostate Tumors with Mesenchymal and Stem-Like Features*. Cancer Res. 72(11): 2889-900, **2012**. 7.86
9. M. MIAN, M. **SCANDURRA**, E. CHIGRINOVA, Y. SHEN, G. INGHIRAMI, T. C. GREINER, W. C. CHAN, J. M. VOSE, M. TESTONI, A. CHIAPPELLA, L. BALDINI, M. PONZONI, A. J. FERRERI, S. FRANCESCHETTI, G. GAIDANO, S. MONTES-MORENO, M. A. PIRIS, F. FACCHETTI, A. TUCCI, J. F. NOMDEDEU, T. LAZURE, S. UCCELLA, M. G. TIBILETTI, E. ZUCCA, I. KWEE, F. BERTONI. *Clinical and Molecular Characterization of Diffuse Large B-Cell Lymphomas with 13q14.3 Deletion*. Ann. Oncol. 23 (3): 729-35, **2012**. 6.43

1.3 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)

1. M. LAPTEVA, I. ALBERTI, Y. CHEN, T. GRATIERI, D. R. KALARIA AND Y. N. **KALIA**. *Redefining the limits of transdermal drug delivery: New technologies for the non- and minimally-invasive delivery of peptides and proteins into the skin*. APV Drug Delivery Newsletter, **2012**; 2: 4-11.

1.4 BOOKS CHAPTERS

1. W.H. **BISSON**, *Editorial: Computational Chemogenomics in Drug Design and Discovery*. Curr. Top. Med. Chem., 12: 1867-1868, **2012**.

2. PRESENTATIONS

2.1. SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)

1. P. GRAVEN, M. TAMBALO, L. **SCAPOZZA**, R. PEROZZO. *Alteration of adenylate energy charge in Trypanosoma brucei: Towards the understanding of growth inhibition induced by 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]-morpholin*. Fall Meeting of the Swiss Chemical Society, 13 September, **2012**, ETH Zurich (Switzerland).
2. P. GRAVEN, M. TAMBALO, L. **SCAPOZZA**, R. PEROZZO. *Is growth inhibition in Trypanosoma brucei induced by 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine due to an alteration of the adenylate energy charge?* Swiss Pharma Science Day, 29 August, **2012**, Bern (Switzerland).
3. L. SLEPIKAS, W. BISSON, R. PEROZZO, E. TARASEVICIUS, L. **SCAPOZZA**. *Ex Novo Rhodanine Derivatives Targeting InhA*. Swiss Pharma Science Day, 29 August, **2012**, Bern (Switzerland).
4. L. LAUCIELLO, S. AHMED, B. DERRER, B. KAPPES, T. WANG, R. TUTEJA, W. SEEBACHER, L. **SCAPOZZA**, R. PEROZZO. *From Compound to Target: Chemical proteomics and in silico screening identify HSP90 and CDPK2 as putative targets in Plasmodium falciparum*. Swiss Pharma Science Day, 29 August, **2012**, Bern (Switzerland).
5. L. LAUCIELLO, S. AHMED, B. DERRER, B. KAPPES, T. WANG, R. TUTEJA, W. SEEBACHER, L. **SCAPOZZA**, R. PEROZZO. *Chemical proteomics and in silico screening team up against Plasmodium falciparum*. 8th Annual BioMalPar I EVIMalaR Conference, 14-16 May, **2012**, EMBL Heidelberg (Germany).
6. L. LAUCIELLO, S. AHMED, B. DERRER, B. KAPPES, L. **SCAPOZZA**, R. PEROZZO. *Chemical proteomics and in silico screening team up against Plasmodium falciparum*. USGEB, 6-7 February, **2012**, Lausanne (Switzerland).
7. L. PERNOT, I. NOVACOVIC, R. PEROZZO, S. RAIC-MALIC, L. **SCAPOZZA**. *Structural insight of a N-methyl thymine with a dihydroxyisobutenyl unit as a new PET tracer for HSV1-TK-based gene therapy*. USGEB, 6-7 February, **2012**, Lausanne (Switzerland).
8. P. GRAVEN, M. TAMBALO, L. **SCAPOZZA**, R. PEROZZO. *Analysis of purine nucleosides/nucleotides in Trypanosoma brucei by means of ion-pair reversed-phase HPLC/UV and bioluminescence assay*. USGEB, 6-7 February, **2012**, Lausanne (Switzerland).
9. S. DUBEY, R. PEROZZO, L. **SCAPOZZA**, Y.N. KALIA. *Effect of protein-protein interactions on the transdermal iontophoretic delivery of Interferon β -1b and a poly-Arg Interferon β -1b analogue*. USGEB, 6-7 February, **2012**, Lausanne (Switzerland).

10. P. GRAVEN, M. MOSIMANN, P. MAESER, L. **SCAPOZZA**, R. PEROZZO. *Analysis of the Effect of Compound 1 on Purine Nucleotide/Nucleoside Concentrations in Trypanosoma brucei Using an Ion-Pair HPLC/UV Assay*. 29th Swiss Trypanosomatid Meeting, 25-27 January, **2012**, Classic Hotel, Leysin (Switzerland).
11. S. DUBEY, R. PEROZZO, L. **SCAPOZZA**, Y. N. KALIA. *Effect of protein-protein interactions on the transdermal iontophoretic delivery of interferon beta-1b and a poly-arg interferon beta-1b analogue*. USGEB Annual Meeting – Molecular Recognition: When Biology Meets Chemistry. February 6-7, **2012**, Lausanne (Switzerland).
12. P. A. PATEL, S. C. PATIL, D. R. KALARIA, Y. N. **KALIA**, V. B. PATRAVALE. *Feasibility of transdermal delivery of lipid based nanocarriers of huperzine-a for treatment of alzheimer disease*. 9th International Conference and Workshop on Biological Barriers – in vitro and in silico tools for drug delivery and nanosafety research. February 29 - March 9, **2012**, Saarland University, Saarbrücken (Germany).
13. T. GRATIERI, G. M. GELFUSO, J. G. DE SOUZA, R. F. V. LOPEZ, Y. N. **KALIA**. *Topical iontophoresis for fast locally enhanced drug delivery to the muscle*. Perspectives in Percutaneous Penetration: 13th International Conference, April 11-14, **2012**, La Grande Motte (France).
14. T. GRATIERI, B. WAGNER, D. R. KALARIA, B. ERNST, Y. N. **KALIA**. *Iontophoretic delivery of CGP69669A – potential therapeutic agent for the treatment of psoriasis*. Perspectives in Percutaneous Penetration: 13th International Conference, April 11-14, **2012**, La Grande Motte (France).
15. I. ALBERTI, J. CARDIA, K. BULOCK, L. LIBERTINE, C. BÖHLER, Y.N. **KALIA**. *Visualizing needle-less siRNA delivery into ex vivo skin using confocal biphoton imaging*. 7th Workshop on Advanced Multiphoton and Fluorescence Lifetime Imaging Techniques (FLIM 2012). June 25-26, **2012**, Saarland University, Saarbrücken (Germany).
16. M. LAPTEVA, K. MONDON, M. MÖLLER, R. GURNY, Y. N. **KALIA**. *Smart micellar systems for targeted cutaneous drug delivery*. 39th Annual Meeting & Exposition of the Controlled Release Society. July 15-18, **2012**, Quebec City (Canada).
17. M. LAPTEVA, K. MONDON, M. MÖLLER, R. GURNY, Y. N. **KALIA**. *Targeted cutaneous drug delivery using polymeric micelles*. Swiss Pharma Science Day. August 29, **2012**, Bern (Switzerland).
18. M. LAPTEVA, K. MONDON, M. MÖLLER, R. GURNY, Y. N. **KALIA**. *Targeted cutaneous drug delivery using polymeric micelles*. XXVIIIèmes GTRV Scientific Meeting. December 3-5, **2012**, Chilly Mazarin (France).
19. S. KADERLI, R. GURNY, L. **SCAPOZZA**, M. MÖLLER, *Osteoarthritis viscosupplementation therapy: Novel hyaluronic acid based hydrogels*. Rigi-Workshop, January 22nd-24th **2012**, Lucerne, (Switzerland) and USGEB 2012, February 6th and 7th **2012**, Lausanne (Switzerland).
20. S. KADERLI, R. GURNY, L. **SCAPOZZA**, A.L. ROUGEMONT, J.P. GILBERTO, B. H. WALPOTH and O. JORDAN, *Novel biocompatible Hyaluronic acid-chitosan hybrid hydrogel for osteoarthritis therapy*. PharmaScience Day, August 29th **2012**, Bern (Switzerland).
21. S. KADERLI, R. GURNY, L. **SCAPOZZA**, M. MÖLLER, *Novel hyaluronic acid-antioxidant conjugates for osteoarthritis therapy*. Swiss Chemical Society Fall meeting 2012, September 13th **2012**, Zurich (Switzerland).
22. J. NAYAK, A. KRANJC PIETRUCCHI, L. **SCAPOZZA**. *How Chronic myeloid leukaemia inhibitors and Abl partner protein Crkl influence the open conformation of Abl*. USGEB, 6-7 February, **2012**, Lausanne (Switzerland).
23. A. MONACO, O. MICHELIN, J. PRIOR, R. OSMAN, L. **SCAPOZZA**, Y. SEIMBILLE. *Positron Emission Tomography (PET) imaging of $\alpha\beta3$ integrin expression with a 18F-labeled cyclic-[RGDFK] peptide*. USGEB, 6-7 February, **2012**, Lausanne (Switzerland).

3. ORAL PRESENTATIONS

3.1 CONGRESSES & SYMPOSIA

1. R. PEROZZO. *Crystal Structures of T. b. rhodesiense Adenosine Kinase Complexed with Inhibitor and Activator: Implications for Catalysis and Hyperactivation*. Paper presentation in the framework of the award ceremony for the Phoenix Pharmazie-Wissenschaftspreis 2012, Hotel Radisson Blu, 25 October, **2012**, Berlin (Germany).
2. P. GRAVEN. *Alteration of adenylate energy charge in Trypanosoma brucei: Towards the understanding of growth inhibition induced by 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]-morpholin*. PhD Day, 15 June, **2012**, Fondation Brocher Hermance, Geneva (Switzerland).
3. W.H. BISSON. *Future of Drug Repurposing: Old Drugs, New Opportunities*. USGEB, 6-7 February, **2012**, Lausanne (Switzerland).
4. L. SCAPOZZA. *Chimica farmaceutica quo vadis? La ricerca di nuovi medicament*. Pharmactuel, 5. March, **2012**, Manno (Switzerland).
5. L. SCAPOZZA. *Pharmaceutical Chemistry: QUO VADIS? Molecular recognition: Where Chemistry, Biology and Formulation meet*. Debiopharm, 25. May, **2012**, Martigny (Switzerland).
6. L. SCAPOZZA. *Molecular recognition: when chemistry meets biology and drug delivery*. Yeditepe University, 17. October, **2012**, Istanbul (Turkey)
7. M. VEURINK, L. ASMUS, B. KAUFMANN, M. MÖLLER, E. MENDRINOS, C.J. POURNARAS, R. GURNY. *Investigation of a sustained release injectable for treatment of posterior segment eye diseases*. Swiss Galenic Meeting, January 26, **2012**, Zürich (Switzerland).
8. M. VEURINK, L. ASMUS, B. KAUFMANN, M. MÖLLER, G. MANGIORIS, C.J. POURNARAS, R. GURNY. *Targeting the retinal vasculature: ex vivo and in vivo sustained release of vasodilators from injectable polymers*. PhD day, June 6, **2012**, Hermance (Switzerland).
9. M. VEURINK, L. ASMUS, M. MÖLLER, B. KAUFMANN, G. MANGIORIS, M. HENNIG, A. HEILIGENHAUS, C.J. POURNARAS, R. GURNY. *Novel injectable polymer systems for intraocular sustained release of vasodilators*. International Pharmaceutical Technology Symposium, Sept 10-12, **2012**, Antalya (Turkey).
10. Y.N. KALIA. *Intra- and transepidermal drug delivery: State of the art*. 31ème Congrès de la Société Francophone des Lasers Médicaux, January 19-22, **2012**, Les Arcs, Bourg Saint Maurice (France).
11. Y. N. KALIA. *Fractional laser ablation for percutaneous delivery of small molecules, peptides and proteins*. 9th International Conference and Workshop on Biological Barriers – in vitro and in silico tools for drug delivery and nanosafety research, February 29 - March 9, **2012**, Saarland University, Saarbrücken (Germany).
12. Y. N. KALIA. *Transdermal delivery systems: their contribution to cosmetology*. 3rd Swiss International Congress in Anti-Aging and Aesthetic Medicine and Surgery, April 19-21, **2012**, Geneva (Switzerland).
13. Y. N. KALIA. *Administration d'actifs intra- et transépidermique: Etat de l'art et l'avenir ?* 33e Congrès national de médecine esthétique et de chirurgie dermatologique & 11e Congrès de la société française de dermatologie chirurgicale et esthétique. Palais des Congrès, Septembre 14-15, **2012**, Paris (France).
14. Y. N. KALIA. *Techniques for the controlled cutaneous delivery of small molecules, peptides and proteins*. Face 2 f@ce 2012: Facial Aesthetics & Cosmetic Events – Anti-Aging Medicine & Facial Plastic Surgery, November 2-3, **2012**, Cannes (France).
15. A. GARCIA-LOPEZ. *Targeting RNA toxicity in Myotonic Dystrophy*. 7th International Conference on Unstable Microsatellites and Human Disease. 2012, Ottrott (France).

3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES

1. Iontophoresis – Delivering charged molecules across biological membranes. Cours 4^{ème} année – Pharmacie Galénique, UV Industrie, Université Claude Bernard Lyon 1, March 29, **2012**, Lyon (France).
2. Iontophoresis – Delivering charged molecules across biological membranes. Advanced Delivery Strategies for Pharmceutics and Cosmeceutics (European Lifelong Learning Program / Erasmus Intensive Program), Université Claude Bernard Lyon 1, October 8 – November 7, **2012**, Lyon (France).

4. THESIS PRESENTED

4.1. INTRA-MUROS THESIS

1. Dhaval KALARIA
Transdermal Iontophoresis for the Controlled Delivery of Therapeutic Agents to Treat Neurodegenerative Diseases.
University of Geneva – **2012**– thesis n° 4480
Supervisor: Prof. Leonardo SCAPOZZA
Co-supervisor: Dr. Yogeshvar KALIA

PHARMACEUTICAL TECHNOLOGIES



PROFESSOR

ALLEMANN Eric

MER

DELIE SALMON Florence
LANGE Norbert

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	17
1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)	1
2.1 POSTERS PRESENTATIONS	6
3.1 CONGRESSES & SYMPOSIA	5
3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES	7
4.1 THESIS PRESENTED (INTRA-MUROS)	2

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

Biomaterials	7.40
Journal of Controlled Release	6.49
Nanomedicine	5.05
Bioconjugate chemistry	4.93
Arthritis research & therapy	4.44
European Journal of Pharmaceutics and Biopharmaceutics	4.26
Pharmaceutical research	4.09
International Journal of Pharmaceutics	3.35
European Journal of Pharmaceutical Sciences	3.21
Ultrasound in medicine and biology	2.29

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. B. PETIT, E. GAUD, D. COLEVRET, M. ARDITI, F. YAN, F. TRANQUART, E. ALLEMANN. *In vitro sonothrombolysis of human blood clots with BR38 microbubbles*, Ultrasound in medicine & biology 38, (7) 1222-33(2012) 2.29
2. J. PRADAL, O. JORDAN, E. ALLEMANN. *Intra-articular drug delivery for arthritis diseases: the value of extended release and targeting strategies*. J. Drug Delivery Science and Technology, 22(5), 409-419 (2012) 0.67
3. F. DELIE, E. ALLEMANN, M. COHEN. *Nanocarriers for ovarian cancer active drug targeting*. Drug Delivery Science and Technology 22(5), 421-426 (2012) 0.67
4. B. PETIT, F. TRANQUART, E. ALLEMANN. *Microbubbles and ultrasound-mediated thrombolysis: a review of recent in vitro studies*. Drug Delivery Science and Technology, 22(5), 381-392 (2012) 0.67
5. N. STRANSKY-HEILKRON, S. HUMBERT-MEHIER, E. ALLEMANN. *Combination treatments of tumors with thermoablation, Principles and review of preclinical studies*. Drug Delivery Science and Technology, 22(5), 435-446 (2012) 0.67
6. E. ALLEMANN, F. DELIE, N. LANGE. *Pharmaceutical technology at the service of targeted drug delivery*. Chimia, 66, 308-312 (2012) 1.21

7. N. STRANSKY-HEILKRON, S. HUMBERT-MEHIER, E. ALLEMANN. *The Impact of the Salting-Out technique on the preparation of colloidal particulate system for pharmaceutical applications*. J. Drug Delivery Science and Technology, 6, 236-249 (2012) 0.67
8. D. GABRIEL, N. LANGE, V. CHOBAS-PECLAZ M.F. ZULUAGA, R. GURNY, H. VAN DEN BERGH, N. BUSSO. *Thrombin-sensitive dual fluorescence imaging and therapeutic agent for detection and treatment of synovial inflammation in murine rheumatoid arthritis*. J Control Release, 163, 178-186 (2012) 6.49
9. G. HEUCK, N. LANGE. *Matrix mediated fluorescence enhancement – why nano-particles and PPIX make a friendly couple*. J Porphyr Phthalocya, 16, 878-884 (2012) 1.40
10. N. SEKKAT, H. VAN DEN BERGH, T. NYOKONG, N. LANGE. *Like a Bolt from the Blue: Phthalocyanines in Biomedical Optics*. Molecules, 17, 98-144 (2012) 2.38
11. M.F. ZULAGA, D. GABRIEL, N. LANGE. *Enhanced prostate cancer targeting by modified protease sensitive photosensitizer prodrugs*. Mol Pharm, 9, 1570-1579 (2012) 4.78
12. C. EENSCHOOTEN, A. VACCARO, F. DELIE, F. GUILLAUMIEA, K. TOMMERAAS, G.M. KONTOGEORGIS, K. SCHWACH-ABDELLAOUI, M. BORKOVEC, R. GURNY. *Novel self-associative and multiphasic nanostructured soft carriers based on amphiphilic hyaluronic acid derivatives*. Carbohydrate Polymers, 87(1), 444-451 (2012) 3.98
13. F. DELIE, P. PETIGNAT, M.COHEN. *GRP78 protein expression in ovarian cancer patients and perspectives for a drug targeting approach*. J. Oncol, 1-5 (2012) 2.19
14. N. SEKKAT, H. VAN DEN BERGH, T. NYOKONG, N. LANGE. *Anti-KDEL-coated nanoparticles: promising therapeutic target for ovarian cancer?*. Biochimie, 94(11), 2391-2397(2012) 3.29
15. M. RODRIGUEZ-ALLER, B. KAUFMANN, D. GUILLARME, C. STELLA, P. FURRER, S. RUDAZ, I. EL ZAOUI, JL. VEUTHEY, R. GURNY. *In vivo characterization of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease*. European Journal Pharm. Biopharm, 80, 544-552 (2012) 4.40
16. C. DI TOMMASO, F. VALAMANESH, F. MILLER, P. FURRER, M. RODRIGUEZ-ALLER, F. BEHAR-COHEN, R. GURNY, M. MOELLER. *A novel cyclosporine a aqueous formulation for dry eye treatment: In vitro and in vivo evaluation*. Investigative Ophthalmology and Visual Science, 53(4), 2292-2299(2012) 3.59
17. N. MENDOZA-MUNOZ, D. QUINTANAR-GURRERO, E. ALLEMANN. *The impact of the salting-out technique on the preparation of colloidal particulate system for pharmaceutical applications*. Recent Patents on Drug Delivery & Formulation, 6, 236-249 (2012) 1.27

1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)

1. F. DELIE. *Les nanomédicaments pour le traitement des affections cérébrales*. Belgishe-Luxemburgische Business Club in der Schweiz, 43-47 (2012)

2. PPRESENTATIONS

2.1 POSTERS PRESENTATIONS

1. A.PELCZARSKA, S. MARTEL, F.DELIE, P.-A. CARRUPT, U. DOMANSKA
"Polymeric nanoparticles in enhancing drug solubility". 14th International Union of Pure and Applied Chemistry Conference on Polymers and Organic Chemistry, January 6-9, 2012, Doha (Qatar)
2. A.BABIC, S. LAMPRIANOU, H. GLOMBIK, HP JURETSCHKE, P. MEDA, N. LANGE
"Imaging pancreatic beta cells using Glibenclamide-Dendrimer Conjugates." World molecular imaging meeting, September, 2012, Dublin (Ireland)

3. J. PRADAL, O. JORDAN, C. GABAY, E. DOELKER, J.M. WALDBURGER, E. ALLEMANN
"In vitro and in vivo studies of two P38 Mapk inhibitors: Formulation of particles for the long term intra-articular treatment of osteoarthritis". 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 2012, Istanbul (Turkey)
4. B. PETIT, E. GAUD, D. COLEVRET, M. ARDITI, F. YAN, F. TRANQUART, E. ALLEMANN
"In vitro sonothrombolysis of human blood clots with microbubbles." 8th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 2012, Istanbul (Turkey)
5. N. STRANSKY-HEILKRON, S. LUGBULL, S. MOUTON, E. HILTBRAND, Y. MARTIN, S. HUMBERT-MEHIER, E. ALLEMANN
"Controlled water steam injection: ex vivo optimization of parameters for the ablation of liver lesions". 39th International Symposium on Controlled Release of Bioactive Materials, 2012, Québec (Canada)
6. C. XAYAPHOUMMINE, A.-S. CHAUVIN, E. ALLEMANN
"Synthesis of a Novel Amphiphilic Chelating Molecule for Magnetic Resonance Imaging" Swiss Pharma Science Day, 2012, Bern (Switzerland)

3 ORAL PRESENTATIONS

3.1 CONGRESSES AND SYMPOSIA

1. E. ALLEMANN
Ultrasound bubbles for diagnostics and therapy.
COST TD1004 action meeting, 2012, Torino (Italy)
2. N. LANGE
The Dark Side of Biophotonics.
7th ICPP Meeting , July, 2012, Jeju (South Korea)
3. N. LANGE
The Use of Ultrafast Quenching Phenomena in Biomedical Optics.
35th ASP Meeting, June, 2012, Montreal (Canada)
4. P. FURRER
European Pharmacopoeia Perspective on functionality-related characteristics.
APV – IPEC 2012 , November 27, Berlin (Germany)
5. B. PETIT, F. YAN, E. GAUD, F. COLEVRET, M. ARDITI, F. TRANQUART, E. ALLEMANN
Microbubbles for ischemic stroke treatment: in vitro sonotrombolysis.
27^e Journées Scientifiques du GTRV, 2012, Paris (France)

3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES

1. P. FURRER
Cours de formation continue à l'intention des pharmaciens romands: Déviance ou deviation dans les bonnes pratiques de fabrication à l'officine.
PharmaGenève, October 16, 2012, Geneva (Switzerland)
2. P. FURRER
Cours de formation continue à l'intention des pharmaciens suisses: cinétique et galénique passent pas l'estomac.
pharmActuel Symposium, November 18, 2012, Bern (Switzerland)
3. E. ALLEMANN
New drug delivery systems and energy activated carriers.
Continuing education GSK, Novartis, UCB and Vifor, 2012, Fribourg (Switzerland)
4. E. ALLEMANN
Microbubbles, new fragile formulations for imaging and new therapeutic modalities.
Continuing education GSK, Novartis, UCB and Vifor 2012, Fribourg (Switzerland)
5. P. FURRER
Cours de master en pharmacie et master en pharmacie industrielle MIP (Drug Delivery and Drug Targeting): Ophtalmic devices/dermopharmacy
EPFZ, December 4th , 2012, Zürich (Switzerland)


6. P. FURRER
Préparation de crèmes hydrophiles.
Stage Boussole, March 1st 2012, Geneva (Switzerland)
7. P. FURRER
Préparation de crèmes hydrophiles.
Journée "Futur en tous genres", November 8 - 2012, Geneva (Switzerland)

4. THESIS PRESENTED

4.1 INTRA-MUROS THESIS (*SUPERVISED BY PROF. HONORARY R. GURNY)

1. LUTZ ASMUS*
Injectable sustained-release formulations based on polyesters from small molecule solutions to protein delivery to the eye,
thèse n° 4403, 2012
2. GESINE HEUCK
New strategies for the induction of endogenous porphyrins in eukaryotic and prokaryotic cells,
thèse n°4415, 2012

PHARMACOCHEMISTRY



PROFESSOR

CARRUPT Pierre-Alain

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	12
1.2 BOOKS OR BOOKS CHAPTERS	3
2.1 POSTERS PRESENTATIONS	12
3.1 CONGRESSES & SYMPOSIA	10
4.1 THESIS PRESENTED	3

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

Anal.Chem.	5.85
J.Med.Chem.	5.24
Pharm.Res.	4.09
Eur.J.Med.Chem	3.34
Eur.J.Pharm.Biopharm.	4.26
J.Pharm.Sc.	3.21
Bioorgan.Med.Chem.	2.92
Bioorg.Med.Chem.Lett.	2.55
Eur.J.Pharm.Sc.	3.21
Helv.Chim.Acta.	1.47

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. B. ROLANDO, A. FILIERI, K. CHEGAEV, L. LAZZAROTO, M. GIORGIS, C. DE NARDI, R. FRUTTERO, P.A. CARRUPT, A. GASCO. A. *Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs*. Bioorg. Med. Chem., 2012, 20: 841-850. doi.org/10.1016/j.bmc.2011.11.065 2.92
2. R. HO, A. VIOLETTE, D. CRESSEND, P. RAHARIVELOMANANA, P.A. CARRUPT, K. HOSTETTMANN. *Antioxidant potential and radical scavenging effects of flavonoids from the leaves of Psidium cattleianum grown*. Nat. Prod. Res., **2012**, 26: 274-277. doi.org/10.1080/14786419.2011.585610 1.24
3. B. LEFEBVRE, D. KLAUS-HEISEN, A. PIETRASZEWSKA-BOGIEL, C. HERVÉ, S. CAMUT, M.C. AURIAC, V. GASCIOLLI, A. NURISSO, T.W.J. GADELLA, J. CULLIMORE. *Role of N-glycosylation sites and CXC motifs in trafficking of Medicago trunculata Nod Factor Perception protein to the plasma membrane*. J. Biol. Chem., **2012**, 287: 10812-10823. doi.org/10.1074/jbc.M111.281634 4.77
4. C.S. FUNARI, P.J. EUGSTER, S. MARTEL, P.A. CARRUPT, J.L. WOLFENDER, D.H.S. SILVA. *High resolution Ultra High Pressure Liquid Chromatography Time-of-Flight Mass Spectrometry dereplication strategy for the metabolite profiling of Brazilian Lippia species*, J. Chrom. A, **2012**, 1259: 167-178. doi.org/10.1016/j.chroma.2012.03.069 3.21

5. C. MUELLER, M.A.H. CAPELLE, E. SEYREK, S. MARTEL, P.A. CARRUPT, T. ARVINTE, G. BORCHARD. Noncovalent PEGylation: different effects of dansyl-,L-tryptophan-, phenylbutylamino-, benzyl- and cholesteryl-PEGs on the Aggregation of Salmon Calcitonin and Lysozyme. *J. Pharm. Sci.*, 2012, 101: 1995-2008. doi.org/10.1002/jps.23110 4.67
6. A. NURISSO, J. BRAVO, P.A. CARRUPT, A. DAINA. *Molecular docking using the Molecular Lipophilicity Potential as hydrophobic descriptor: impact on GOLD docking performance.* *J. Chem. Inf. Mod.*, 2012, 52: 1319-1327. doi.org/10.1021/ci200515g 1.21
7. A. NURISSO, C. SIMOES-PIRES, S. MARTEL, D. CRESSEND, A. GUILLLOT, P.A. CARRUPT. *How to increase safety and efficacy of compounds against neurodegeneration? A multifunctional approach.* *Chimia*, 2012, 66: 286-290. <http://dx.doi.org/10.2533/chimia.2012.286> 1.21
8. G. BORCHARD, P.A. CARUPT. *The School of Pharmacy Geneva-Lausanne (EPGL)-The First Ten Years.* *Chimia*, 2012, 66: 286-290. <http://dx.doi.org/10.2533/chimia.2012.280> 1.21
9. K. VUIGNIER, J.L. VEUTHEY, P.A. CARRUPT, J. SCHAPPLER. *Characterization of drug-protein interactions by capillary electrophoresis hyphenated to mass spectrometry.* *Electrophoresis*, 2012, 33: 3306-3315. Doi.org/10.1002/elps.201200116 3.3
10. B. BARD, P.A. CARRUPT, S. MARTEL. *Determination of Alkane/Water partition coefficients of Polar Compounds using Hydrophilic Interaction Chromatography.* *J. Chrom. A*, 2012, 1260: 164-168. doi.org/10.1016/j.chroma.2012.08.094 4.53
11. E. CHABROL, A. NURISSO, A. DAINA, E. VASSAL-STERMANN, M. THEPAUT, E. GIRARD, R.R. VIVÈS, F. FIESCHI. *Glycosaminoglycans Are Interactants of Langerin: Comparison with gp120 Highlights an Unexpected Calcium-Independent Binding Mode.* *PLoS ONE*, 2012, 7(11): e50722. Doi.org/10.1371/journal.pone.0050722 4.09
12. L. SACCONNAY, MPB. SOARES, D. SMIRLIS, EF. QUEIROZ, JL. WOLFENDER, PA. CARRUPT, A. NURISSO. *Toward a novel high-throughput screening assay based on PAMPA-GIT to detect potential interaction with P-Glycoprotein.* *Chimia*, 2012, 66: 346. 1.21

1.2 BOOKS OR BOOKS CHAPTERS

1. A. NURISSO, A. DAINA, R.C. WALKER. *A Practical Introduction to Molecular Dynamics Simulations.* Editors: A.J.W. Orry, R. Abagyan, Springer Verlag, Methods Mol. Biol.; 857, 2012; pp 137-173.
2. A.T. ZIZZARI, P.A. CARRUPT, S. MARTEL. *UHPLC for the Determination of Physicochemical Parameters in Drug Discovery.* Editors: D.Guillarme, J.L. Veuthey, RSC Publishing, UHPL in Life Sciences, 2012; pp 211-236.
3. N. SAPAY, A. NURISSO, A. IMBERTY. *Simulation of Carbohydrates. From Molecular Docking to Dynamics in Water.* Editors: L. Monticelli, E. Salonen, Springer Verlag, Methods Mol. Biol. 934, 2012, pp 1469-1486.

2. PPRESENTATION

2.1 POSTERS PRESENTATIONS

1. K. VUIGNIER, JL. VEUTHEY, PA. CARRUPT, J. SCHAPPLER. *Characterization of drug-protein interactions by capillary electrophoresis hyphenated to mass spectrometry.* MSB 2012, 12-15 February, 2012, Geneva (Switzerland).
2. K. VUIGNIER, D. GUILLARME, JL. VEUTHEY, PA. CARRUPT, J. SCHAPPLER. *Critical evaluation and comparison of capillary eletrophoresis, liquid chromatography, and surface plasmon resonance to study drug-plasma protein interactions.* MSB 2012, 12-15 February, 2012, Geneva (Switzerland).
3. S. ROMAND, JL. VEUTHEY, S. MARTEL, PA. CARRUPT. *The capillary isoelectric focusing: a novel approach for the fast determination of pKa values of small compounds.* MSB 2012, 12-15 February, 2012, Geneva (Switzerland).

4. C. PASSELEU LE BOURDONNEC, S. CHALLAL, P. CELINE, J. BOCCARD, S. RUDAZ, JL. WOLFENDER, PA. CARRUPT, S. MARTEL. *Evaluation of BBB permeation with PAMPA thanks to a new artificial membrane.*
Swiss Pharma Day, 29 August, **2012**, Bern (Switzerland).
5. L. SACCONNAY, MPB. SOARES, D. SMIRLIS, EF. QUEIROZ, JL. WOLFENDER, PA. CARRUPT, A. NURISSO. *NAD dependant deacetylases as promising biotargets to fight against Chagas disease and Leishmaniasis.*
Swiss Chemical Fall Meeting, 13 September, **2012**, Zurich (Switzerland).
6. A. BUJARD, S. MARTEL, PA. CARRUPT. *Toward a novel high-throughput screening assay based on PAMPA-GIT to detect potential interaction with P-Glycoprotein.*
ISMC 2012, 2-6 September, **2012**, Berlin (Germany).
7. S. ROMAND, JL. VEUTHEY, PA. CARRUPT, S. MARTEL. *The capillary isoelectric focusing: a novel approach for the fast determination of pKa values of monofunctional compounds and pharmaceutical compounds.*
ISMC 2012, 2-6 September, **2012**, Berlin (Germany).
8. L. SACCONNAY, MPB. SOARES, D. SMIRLIS, EF. QUEIROZ, JL. WOLFENDER, PA. CARRUPT, A. NURISSO. *Towards the conception of novel antiparasitic compounds: in silico studies on NAD+-dependent deacetylases.*
ISMC 2012, 2-6 September, **2012**, Berlin (Germany).
9. L. RYCKEWAERT, C. DOS SANTOS PASSOS, C. SIMOES PIRES, A. HENRIQUES, PA. CARRUPT. *Alkaloids from Psychotria as HDAC inhibitors: a multifunctional approach against neurodegeneration.*
ISMC 2012, 2-6 September, **2012**, Berlin (Germany).
10. N. OBERHAUSER, PA. CARRUPT, A. NURISSO. *MLP-tools: a software package to apply the molecular lipophilicity potential in PyMOL.*
ISMC 2012, 2-6 September, **2012**, Berlin (Germany).
11. A. NURISSO, C. SIMOES PIRES, D. CRESSEND, PA. CARRUPT. *Antioxidants interacting with HDACs: a multifunctional approach against neurodegeneration.*
ISMC 2012, 2-6 September, **2012**, Berlin (Germany).
12. A. NURISSO, C. SIMOES PIRES, D. CRESSEND, PA. CARRUPT. *Détermination de pKa par focalization isoélectrique capillaire (cIEF).*
V^{ème} journées scientifiques du Club Jeunes de l'AfSep, 25 October, **2012**, Lyon (France).

3. ORAL PRESENTATIONS

3.1 CONGRESSES & SYMPOSIA

1. A. NURISSO. *In silico studies of the human Tyrosinase: structure and interactions.*
ANR, 15 May, **2012**, Archamps (France).
2. A. NURISSO. *Drugs acting on the dopaminergic system.*
Université San Pablo CEU, 25 April, **2012**, Madrid (Espagne).
3. A. NURISSO. *Homology modeling and molecular dynamics in drug design.*
Université San Pablo CEU, 26 April, **2012**, Madrid (Espagne).
4. A. NURISSO. *Search for active molecules to fight against neurodegeneration.*
Université San Pablo CEU, 27 April, **2012**, Madrid (Espagne).
5. S. ROMAND. *Homology modeling and molecular dynamics in drug design.*
V^{ème} journées scientifiques du Club Jeunes de l'AfSep, 25 October, **2012**, Lyon (France).
6. C. LE BOURDONNEC PASSELEU. *Development of a novel PAMPA method for the prediction of passive permeation through the BBB-Application to phytoextracts.*
PhD Day, 15 June, **2012**, Geneva (Switzerland).
7. K. VUIGNIER. *Capillary electrophoresis hyphenated to mass spectrometry as an efficient tool for drug-protein interactions characterization.*
MSB, 14 February, **2012**, Geneva (Switzerland).
8. C. AVELLO SIMOES PIRES. *Epigenetic targets for aging related diseases: the role of HDACs.*
2e Journées Scientifiques du Médicament, 15 June **2012**, University Joseph Fourier, Grenoble (France).

9. P.A. CARRUPT. *Bioaccumulation et perméation cutanée: modèles physicochimiques récents*. Firmenich, 28 August **2012**, Geneva (Switzerland).
10. P.A. CARRUPT. *Identification of multifunctional compounds acting on symptomatic and/or epigenetic targets in neurogenerative diseases*. Università di Chieti, 10 July **2012**, Università di Chieti, Chieti, (Italy).

4. THESIS PRESENTED

4.1. INTRA-MUROS THESIS

1. Elisabeth FAVRE
In silico studies of tyrosinases: structures and interactions.
University of Geneva –**2012**
Supervisor : Prof. Pierre-Alain CARRUPT
2. Karine VUIGNIER
Analytical strategy to characterize drug-protein interactions: from high throughput to in-depth analysis.
University of Geneva –**2012**
Supervisor : Prof. Pierre-Alain CARRUPT
3. Cristina POMILIO (Tesi di Laurea)
Liposomal formulations of antiparkinson agents: study of passive diffusion using a PAMPA-BBB model
University of Chieti –**2012**
Supervisor : Prof. Pierre-Alain CARRUPT

PHARMACOGNOSY



PROFESSOR

CUENDET Muriel

MER

CHRISTEN Philippe

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	6
2.1 POSTERS PRESENTATIONS	4
3.1 CONGRESSES & SYMPOSIA	5
3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES	1
3.3 RADIO/TELEVISION INTERVENTION	1

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

Cancer Res.	7.85
Clin. Cancer Res.	7.74
J. Biol. Chem.	4.77
Cancer Prev. Res.	4.90
Phytochemistry	3.35
J. Nat. Prod.	3.12
J. Agr. Food Chem.	2.82
Phytochem. Analysis	2.63
Planta Med.	2.15
Helv. Chim. Acta	1.47

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. S.M. AL-MASSARANI, S. BERTRAND, A. NIEVERGELT, A.M. EL-SHAFEE, T.A. AL-HOWIRINY, N.M. AL-MUSAYEIB, M. CUENDET, J.-L. WOLFENDER. *Acylation of pregnane glycosides from Caralluma sinica*. *Phytochemistry*, 79, 129-140. **2012**. 3.35
2. G. BAYIHA BA NJOCK, T.A. BARTHOLOMEUSZ, M. FOROOZANDEH, D.E. PEGNYEMB, P. CHRISTEN, D. JEANNERAT. *NASCA-HMBC, a new NMR methodology for the resolution of severely overlapping signals. Application to the study of agathisflavone*. *Phytochemical analysis* 23, 126-130. **2012**. 2.63
3. P. CHRISTEN, M. CUENDET. *Plants as a source of therapeutic and health products*. *Chimia*, 66 (5), 320-323. **2012**. 1.21
4. R. HO, A. NIEVERGELT, C. SIMOES PIRES, M. CUENDET. *Histone deacetylases as cancer chemoprevention targets for natural products*. *Natural Products Chemistry*, 38. **2012**. 3.12
5. C. MATHON, M. DURET, M. KOHLER, P. EDDER, S. BIERI, P. CHRISTEN. *Multi-targeted screening of botanicals in food supplements by liquid chromatography with tandem mass spectrometry*. *Food Chemistry*, 138 (1), 709-717. **2012**. 3.65
6. M. PEREZ-FEHRMANN, V. KESTERNICH, F. VERDUGO, P. CHRISTEN, C. BESNARD. *2-(4-Bromophenyl)-N-[3-(1H-imidazol-1-yl)propyl]quinazolin-4-amine*. *Acta Crystallographica E* 68, o2249. **2012**. 0.34

2. PRESENTATIONS

2.1 POSTERS PRESENTATIONS

1. C. SIMOES-PIRES, L. GALLEY, P.-A. CARRUPT, M. CUENDET. *Natural products as inhibitors of purine nucleoside phosphorylase, a target against Plasmodium spp.*
International Congress on Natural Products Research, 28 July-1 August, **2012**, New-York (USA).
2. I. CESARI, M. HOERLE, E. FERREIRA-QUEIROZ, G. BRUSOTTI, G. CACCIALANZA, P. MOUNDIPA, J.-L. WOLFENDER, M. CUENDET. *Anti-inflammatory compounds isolated from Diospyros bipindensis Gürke.*
International Congress on Natural Products Research, 28 July-1 August, **2012**, New-York (USA).
3. A. AZZOLLINI, S. BERTRAND, A. NIEVERGELT, J. BOCCARD, S. RUDAZ, M. CUENDET, J.-L. WOLFENDER. *Integrative approach in natural product research: at-line coupling of micro-fractionation with NMR, LC-MS and bioassays.*
Swiss Chemical Society, 13 September, **2012**, Zurich (Switzerland).
4. A. HAOUALA, C. SIMOES-PIRES, J. DEGLON, K. NDJOKO, M. IAKOVLEV, J. HOURIET, J. FALQUET, B. GRAZ, C. STAUB, M. CUENDET, P. CHRISTEN. *In vitro and in vivo metabolite identification of Argemone mexicana L.*
Metabommeting, 25-27 September, **2012**, Manchester (UK).

3. ORAL PRESENTATIONS

3.1 CONGRESSES & SYMPOSIA

1. M. CUENDET. *Targets for Natural Chemopreventive Agents.*
Nestlé Research Center, 16 March, **2012**, Lausanne (Switzerland).
2. B. GRAZ, J. FALQUET, A. HAOUALA, C. SIMOES-PIRES, K. NDJOKO, P. CHRISTEN, M. CUENDET, M. WILLCOX, D. DIALLO. *Reverse Pharmacology of Medicinal Plants: Good Luck or Efficient Method?*
International Congress on Natural Products Research, 28 July-1 August, **2012**, New-York (USA).
3. A. HAOUALA, C. SIMOES-PIRES, J. DEGLON, K. NDJOKO, M. IAKOVLEV, J. HOURIET, J. FALQUET, B. GRAZ, C. STAUB, M. CUENDET, P. CHRISTEN. *In vitro and in vivo metabolite identification of Argemone mexicana L.*
27th Seminar in Pharmaceutical Sciences, 3-7 September, **2012**, Zermatt (Switzerland).
4. M. CUENDET. *Natural Products as Chemopreventive Agents.*
Polytechnical School, 6 November, **2012**, Zurich (Switzerland).
5. O. MUÑOZ, B. AEDO, V. ALVAREZ, V. IBACACHE, P. CHRISTEN. *Estudios químicos de Adesmia boronioides DC, planta de uso medicinal del cono sur de America.*
7th International Symposium on Chemistry of Natural Products and its applications, 5-8 November, **2012**, Talca (Chile).


3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES

1. M. CUENDET. *Préparations phytothérapeutiques pour la dépression, la détente et le sommeil : état de la recherche sur les composées responsables de l'activité et études cliniques.*
Presented for the « Formation continue des pharmaciens », PharmaGenève, 29 May, **2012**, Geneva (Switzerland).

3.3 RADIO/TELEVISION INTERVENTION

- Nouvelles plantes contre les maladies graves. CQFD, Radio Suisse Romande. September 18th, 2012.

PHARMACOLOGY



PROFESSOR

RUEGG Urs T.

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	4
1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)	1
1.3 BOOKS OR BOOKS CHAPTERS	1
2.1 POSTERS PRESENTATIONS	3
3.1 CONGRESSES & SYMPOSIA	5
3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES	1

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

Journal of Biological Chemistry	5.85
FASEB Journal	7.06
Journal of Cell Science	6.54
Cell Calcium	4.90
Journal of General Physiology	4.40
Am. Journal of Physiology	3.90
Journal of Physiology	4.20
Biochemical Journal	4.20
J. Pineal Res.	5.06
Mol. Ther.	5.97

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. J. REUTENAU-PATTE, F.X. BOITTIN, O. PATTHEY-VUADENS, U.T. RUEGG, O.M. DORCHIES. *Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and Epac-dependent pathways*. Am. J. Pathol. (2012), 180(2):749-762 5.22
2. Y. NAKAE, O.M. DORCHIES, P.J. STOWARD, B.F. ZIMMERMANN, C. RITTER, U.T. RUEGG. *Quantitative evaluation of the beneficial effects in the mdx mouse of epigallocatechin gallate, an antioxidant polyphenol from green tea*. Histochem. Cell Biol. (2012), 137(6):811-27 2.59
3. N. ZANOUE, O. SCHAKMAN, P. LOUIS, U.T. RUEGG, A. DIETRICH, L. BIRNBAUMER, P. GAILLY. *TRPC1 ion channel modulates phosphatidylinositol 3-kinase/Akt pathway during myoblast differentiation and muscle regeneration*. J. Biol. Chem. (2012), 287(18):14524-34. 4.77
4. M ABSI , H GHAREEB , A KHALIL , UT RUEGG . *The effect of levofloxacin and moxifloxacin on cardiovascular functions of rats with streptozotocin-induced diabetes*. Diab Vasc Dis Res. 10, 65-71 (2012). 2.11

1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)

1. CP MPAMHANGA, JL SHARMAN, AJ HARMAR & THE NC-IUPHAR TEAM. *How to use the IUPHAR receptor database to navigate pharmacological data*. Methods Mol Biol. 897, 15-29 (2012).

1.3 BOOKS CHAPTERS

1. U.T. RUEGG, G. SHAPOVALOV, K. JACOBSON, J. REUTENAUER-PATTE, H.M. ISMAIL, O.M. DORCHIES, P. AVDONIN, *Store-operated channels and Ca²⁺ handling in muscular dystrophy. In: Store-operated Ca²⁺ entry (SOCE) pathways: Emerging signaling concepts in human (Patho) physiology.* Eds. Groschner K, Graier W Romanin C, Springer Verlag (**2012**).

2. PRESENTATIONS

2.1 POSTERS PRESENTATIONS

1. O.M. DORCHIES, J. REUTENAUER-PATTE, X. MONTET, O. PATTHEY-VUADENS, U.T. RUEGG
"Long-term administration of green tea polyphenols and pentoxifylline to mdx^{5Cv} dystrophic mice : differential effects on leg muscle function and kyphosis"
9th Swiss Meeting on Muscle Research, November 25-27, **2012**, Magglingen (Suisse)
2. O.M. DORCHIES, J. REUTENAUER-PATTE, H.M. ISMAIL, U.T. RUEGG
"Effects of the selective estrogen receptor modulators tamoxifen and raloxifene and the pure anti-estrogen fulvestrant on muscle function of the mdx5Cv dystrophic mouse"
9th Swiss Meeting on Muscle Research, November 25-27, **2012**, Magglingen (Suisse)
3. H.M. ISMAIL, V. DUFOUR, O.M. DORCHIES and U.T. RUEGG
"SOC, SAC, iPLA₂ and NOX involvement in the abnormal calcium handling and muscle contraction in isolated fast and slow muscles from mdx mice"
9th Swiss Meeting on Muscle Research, November 25-27, **2012**, Magglingen (Suisse).

3. ORAL PRESENTATIONS

3.1 CONGRESSES & SYMPOSIA

1. H.M. ISMAIL
Investigation of NOX inhibition in mdx dystrophic mice
9th Swiss Meeting on Muscle Research, November 25-27, **2012**, Magglingen (Suisse)
2. U.T. RUEGG
A Brief Portrait of IUPHAR, 7è Congrès de la Société Française de Physiologie, Pharmacologie et de Thérapeutique, April 6, 2012, Dijon (France)
3. U.T. RUEGG
Calcium link in DMD/mdx pathogenesis and how to counteract it by pharmacological means
Washington Childrens Hospital, April 27, **2012**, Washington, D.C.,(USA)
4. U.T. RUEGG
Proposal for clinical investigation of tamoxifen in DMD boys based on results in dystrophic mice
April 28, **2012**, Arlington, VA 22209,(USA)
5. U.T. RUEGG
Thoughts about the past, the present & the future of our lab
Symposium "Of channels, bicycles and other – mostly public - transporters, June 08, **2012**, Geneva (Suisse)

3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES

Co-organizer of « Formation continue pour Pharmaciens » at Lausanne & Geneva Universities

PHYTOCHEMISTRY AND BIOACTIVE NATURAL PRODUCTS



PROFESSOR

WOLFENDER Jean-Luc

MER

Emerson FEIRRERA-QUEIROS

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	13
1.2 BOOKS OR BOOKS CHAPTERS	4
2.1 POSTERS PRESENTATIONS	24
3.1 CONGRESSES & SYMPOSIA	31
3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES	5
4.1 RADIO/TV/MEDIA INTERVENTIONS	3

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

Anal.Chem.	5.85
J.Biol.Chem.	4.77
J.Chromatogr. A	4.53
Phytochemistry	3.35
J.Nat.Prod	3.12
J.Chromatogr. B	2.88
J.Agr.Food Chem.	2.82
Phytochem.Anal.	2.63
Planta Med.	2.15
Helv.Chim.Acta	1.47

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. S. M. AL-MASSARANI, S. BERTRAND, A. NIEVERGELT, A. M. EL-SHAFEE, T. A. AL-HOWIRINY, N. M. AL-MUSAYEIB, M. CUENDET, J.-L. WOLFENDER. *Acylated pregnane glycosides from Carallum sinaica*. *Phytochemistry*, 79: 129-140, **2012**. 3.35
2. B. BILOA MESSI, K. NDJOKO IOSET, B. HERTLEIN-AMSLINGER, A. M. LANNANG, A. E. NKENGFAK, J.-L. WOLFENDER, K. HOSTETTMANN, G. BRINGMANN. *Preussianone, a New Flavanone-Chromone Biflavonoid from Garcinia preussii Engl*. *Molecules*, 17: 6114-6125, **2012**. 2.38
3. I. CALDERON ANGELA, HODEL, J.-L. WOLFENDER, P. GUPTA MAHABIR, CORREA, K. HOSTETTMANN
LC-DAD-MS based metabolite profiling of three species of *Justicia* (Acanthaceae)
Nat. Prod. Res., DOI:10.1080/14786419.14782012.14738207, **2012**. 1.0
4. S. CHALLAL, N. BOHNI, O. E. BUENAFE, C. V. ESGUERRA, P. A. M. DE WITTE, J.-L. WOLFENDER, A. D. CRAWFORD. *Zebrafish Bioassay-guided Microfractionation for the Rapid in vivo Identification of Pharmacologically Active Natural Products*. *Chimia*, 66: 229-232, **2012**. 1.21

5. M. F. ELSEBAI, M. NAZIR, S. KEHRAUS, E. EGEREVA, K. NDJOKO IOSET, L. MARCOURT, D. JEANNERAT, M. GÜTSCHOW, J.-L. WOLFENDER, G. M. KÖNIG. Polyketide Skeletons from the Marine Alga-Derived Fungus *Coniothyrium cereale*. *Eur. J. Org. Chem.*, 31: 6197-6203, 2012. 3.32
6. P. J. EUGSTER, D. BIASS, D. GUILLARME, P. FAVREAU, R. STÖCKLIN, J.-L. WOLFENDER. *Peak capacity optimisation for high resolution peptide profiling in complex mixtures by Liquid Chromatography coupled to Time-of-Flight Mass Spectrometry: Application to the Conus consors cone snail venom*. *J. Chromatogr. A*, 1259: 187-199, 2012. 4.53
7. C. S. FUNARI, P. J. EUGSTER, S. MARTEL, P.-A. CARRUPT, J.-L. WOLFENDER, D. H. S. SILVA. *High resolution ultra high pressure liquid chromatography-time-of-flight mass spectrometry dereplication strategy for the metabolite profiling of Brazilian Lippia species*. *J. Chromatogr. A*, 1259: 167-178, 2012. 4.53
8. C. A. M. ROBERT, N. VEYRAT, G. GLAUSER, G. MARTI, G. R. DOYEN, N. VILLARD, M. D. P. GAILLARD, T. G. KÖLLNER, D. GIRON, M. BODY, B. A. BABST, R. A. FERRIERI, T. C. J. TURLINGS, M. ERB. *A specialist root herbivore exploits defensive metabolites to locate nutritious tissues* - *Ecol. Lett.*, 15: 55-64, 2012. 17.55
9. O. SCHUMPP, N. BRUDERHOFER, M. MONOD, J.-L. WOLFENDER, K. GINDRO. *Ultraviolet Induction of antifungal activity in plants*. *Mycoses*, 55: 507-513, 2012. 2.24
10. O. SCHUMPP, V. BERGER, E. REMOLIF, B. MESSERLI, M. MONOD, J.-L. WOLFENDER, K. GINDRO. *Nouvelles propriétés antifongiques de plantes exposées aux UV*. *Agrarforschung Schweiz*, 3: 464-469, 2012. 0.13
11. J. VERRIER, M. PRONINA, C. PETER, O. BONTEMS, M. FRATTI, K. SALAMIN, S. SCHÜRCH, K. GINDRO, J.-L. WOLFENDER, K. HARSHMAN, M. MONOD. *Identification of Infectious Agents in Onychomycoses by PCR-Terminal Restriction Fragment Length Polymorphism*. *J. Clin. Microbiol.*, 50: 553-561, 2012. 4.15
12. J.-L. WOLFENDER, E. F. QUEIROZ. *New Approaches for Studying the Chemical Diversity of Natural Resources and the Bioactivity of their Constituents*. *Chimia*, 66: 324-329, 2012. 1.21
13. J.-L. WOLFENDER, S. RUDAZ, Y. H. CHOI, H. K. KIM. *Plant Metabolomics: From Holistic Data to Relevant Biomarkers*. *Curr. Med. Chem.*, 20: 1056-1090, 2012. 4.85

1.2 BOOKS OR BOOK CHAPTERS

1. P. J. EUGSTER, J.-L. WOLFENDER. *UHPLC in Natural Products Analysis*. In: *UHPLC in Life Sciences*, Eds. Cambridge, UK, pp. 354-386, 2012.
2. K. GINDRO, V. ALONSO-VILLAVARDE, O. VIRET, J.-L. SPRING, G. MARTI, J.-L. WOLFENDER, R. PEZET. *Stilbenes: Biomarkers of Grapevine Resistance to Disease of High Relevance for Agronomy, Oenology and Human Health*. In: *Plant Defence: Biological Control*, Eds. Netherlands, pp. 25-54, 2012.
3. G. MARTI, M. ERB, S. RUDAZ, T. TURLINGS, J.-L. WOLFENDER. *Search for Low-Molecular-Weight Biomarkers in Plant Tissues and Seeds Using Metabolomics: Tools, Strategies, and Applications*. In: *Seed Development: OMICS Technologies toward Improvement of Seed Quality and Crop Yield*, Eds. pp. 305-341, 2012.
4. E. F. QUEIROZ, K. HOSTETTMANN, J.-L. WOLFENDER. *Modern Approaches in the Search for New Active Compounds from Crude Extracts of Natural Sources*. In: *Plant Bioactives and Drug Discovery: Principles, Practice, and Perspectives*, Eds. John Wiley & Sons, Inc., Hoboken, NJ, USA, pp. 43-80, 2012.

2. PRESENTATIONS

2.1 POSTERS PRESENTATIONS

1. A. AZZOLLINI, S. BERTRAND, A. NIVERGELT, J. BOCCARD, S. RUDAZ, M. CUENDET, J.-L. WOLFENDER. *Integrative approach in natural product research: at-line coupling of micro-fractionation with NMR, LC-MS and bioassays*. Fall Meeting of the Swiss Chemical Society 2012, 13 September, 2012, ETH Zurich (Switzerland).

2. A. AZZOLLINI, S. BERTRAND, O. SCHUMPP, N. BOHNI, M. MONOD, K. GINDRO, J.-L. WOLFENDER. *MS-based metabolomic strategy for the screening of new induced metabolites in miniaturized fungal co-cultures*. Metabomeeting, 27 September, **2012**, Manchester (United Kingdom).
3. S. BERTRAND, A. AZZOLLINI, O. SCHUMPP, N. BOHNI, M. MONOD, K. GINDRO, J.-L. WOLFENDER. *Miniaturization of fungal co-culture for the screening of new bioactive induced metabolites by MS-based metabolomics*. Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).
4. N. BOHNI, O. SCHUMPP, S. BERTRAND, K. GINDRO, M. MONOD, J.-L. WOLFENDER. *Hohenbuehelia reniformis extract is active against human pathogenic Fusarium sp.* Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).
5. I. CESARI, M. HOERLE, E. F. QUEIROZ, G. BRUSOTTI, G. CACCIALANZA, J. L. WOLFENDER, M. CUENDET. *Anti-inflammatory compounds isolated from Diospyros bipindensis*. ICNPR 2012, International Congress on Natural Product Research, 30 July, **2012**, New York (USA).
6. I. CESARI, E. F. QUEIROZ, G. BRUSOTTI, Q. FAVRE-GODAL, G. CACCIALANZA, P. MOUNDIPA, J.-L. WOLFENDER. *Efficient identification of antifungal compounds from the stem bark of Diospyros bipindensis Gürke*. Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).
7. S. CHALLAL, E. F. QUEIROZ, B. DEBRUS, D. GUILLARME, J.-L. WOLFENDER. *Rational isolation strategy of plant biomarkers at the mg scale based on chromatography modelling, MPLC-ELSD and fast UHPLC-TOF-MS monitoring*. Metabomeeting, 27 September, **2012**, Manchester (United Kingdom).
8. S. CHALLAL, E. F. QUEIROZ, D. GUILLARME, J.-L. WOLFENDER. *Method transfer from HPLC to Middle Pressure Liquid Chromatography (MPLC) for efficient large scale isolation of natural products*. Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).
9. A. CHAUVIN, D. CALDELARI, J.-L. WOLFENDER, E. E. FARMER. *Identifying enzymes necessary for jasmonate production less than 40s after wounding*. 8th Tri-National Arabidopsis Meeting, 12-15 September, **2012**, Lausanne (Switzerland).
10. P. EUGSTER, R. KNOCHENMUSS, J.-L. WOLFENDER. *Ion mobility spectrometry applied to complex plant extract profiling: possibilities, limitations and outlook*. Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).
11. P. J. EUGSTER, R. KNOCHENMUSS, J. L. WOLFENDER. *Ion mobility spectrometry in metabolite profiling of complex plant extracts*. ICNPR 2012, International Congress on Natural Product Research, 30 July, **2012**, New York (USA).
12. Q. FAVRE-GODAL, E. F. QUEIROZ, D. SANGLARD, J.-L. WOLFENDER. *Detection of antifungal compounds using LC microfractionation and bioautography with a hypersusceptible strain of C. albicans*. ICNPR 2012, International Congress on Natural Product Research, 30 July, **2012**, New York (USA).
13. Q. FAVRE-GODAL, E. F. QUEIROZ, D. SANGLARD, J.-L. WOLFENDER. *HPLC-microfractionation and bioautography with a hypersusceptible strain of C. albicans for an efficient detection of antifungal natural products in complex crude plant extracts*. Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).
14. A. LANDREAU, S. BERTRAND, C. SIMOES-PIRES, L. MARCOURT, T. D. BACH, M. LITAUDON, D. GUILLET, P. RICHOMME, P. A. CARRUPT, J.-L. WOLFENDER. *Normal phase HPLC profiling of the acetylcholinesterase activity in apolar plant extracts*. ICNPR 2012, International Congress on Natural Product Research, 30 July, **2012**, New York (USA).
15. A. MACHADO, N. RAMALHETE, R. SERRANO, J.-L. WOLFENDER, E. T. GOMES, O. SILVA. *Hypericum foliosum leaf - Chromatographic fingerprint of a promising antidepressant medicinal plant*. ICNPR 2012, International Congress on Natural Product Research, 30 July, **2012**, New York (USA).
16. G. MARTI, V. ZUFFEREY, K. GINDRO, O. VIRET, J.-L. WOLFENDER. *A comprehensive metabolomic study of wine from the Vaud Switzerland vineyard*. ICNPR 2012, International Congress on Natural Product Research, 30 July, **2012**, New York (USA).
17. G. MARTI, V. ZUFFEREY, K. GINDRO, O. VIRET, J.-L. WOLFENDER. *Effect of nitrogen supply during grape-growing on wine composition unraveled by a metabolomic approach*. Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).

18. F. MEHL, G. MARTI, J. BOCCARD, L. MARCOURT, B. DEBRUS, P. MERLE, E. DELORT, L. BAROUX, H. SOMMER, J.-L. WOLFENDER, S. RUDAZ. *Classification of lemon essential oils and selection of biomarkers by a multiblock analysis of UHPLC-TOF-MS, NMR and MIR data using multiple factor analysis.*
Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).
19. F. MEHL, E. F. QUEIROZ, S. BERTRAND, M. PETERS, Q. FAVRE-GODAL, J.-L. WOLFENDER. *Enhancement of chemodiversity in crude plant extracts by generic chemical transformations.*
Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).
20. C. PETIT, S. BERTRAND, L. MARCOURT, R. HO, M. MONOD, J.-L. WOLFENDER. *High resolution antifungal HPLC profiling for the early identification of compounds in plants from French Polynesia.*
ICNPR 2012, International Congress on Natural Product Research, 30 July, **2012**, New York (USA).
21. C. PETIT, S. BERTRAND, L. MARCOURT, R. HO, M. MONOD, J.-L. WOLFENDER. *High resolution HPLC biological profiling for the rapid identification of antifungal compounds in plants from French Polynesia.*
Swiss Pharma Science Day, 29 August, **2012**, Bern (Switzerland).
22. C. PETIT, S. BERTRAND, L. MARCOURT, R. HO, M. MONOD, J.-L. WOLFENDER. *High resolution HPLC biological profiling for the rapid identification of antifungal compounds in plants from French Polynesia.*
Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).
23. L. SACCONNAY, M. B. P. SOARES, D. SMIRLIS, E. F. QUEIROZ, J.-L. WOLFENDER, P. CARRUPT, A. NURISSE. *NAD⁺ dependant deacetylases as promising biotargets to fight against Chagas disease and Leishmaniasis.*
Fall Meeting of the Swiss Chemical Society 2012, 13 September, **2012**, ETH Zurich (Switzerland).
24. A. STEFANO, M. HALABALAKI, S. BERTRAND, J. BOCCARD, S. KOSTIDIS, S. RUDAZ, H. SCHAEFER, M. SPRAUL, E. MIKROS, J. L. WOLFENDER (2012). *NMR- and UHPLC-MS-based metabolomics for the discrimination of different resistant Vitis vinifera L. cultivar woods.*
12th Eurasia Conference on Chemical Sciences (EuAsC2S-12), 16 April **2012**, Corfu (Greece).

3. ORAL PRESENTATIONS

3.1 CONGRESSES & SYMPOSIA

1. S. BERTRAND, A. AZZOLLINI, O. SCHUMPP, N. BOHNI, M. MONOD, K. GINDRO, J.-L. WOLFENDER. *Fungal co-culture as a new source of bioactive induced metabolites: A MS-based metabolomic study.*
ICNPR 2012, International Congress on Natural Product Research, 30 July, **2012**, New York (USA).
2. S. BERTRAND, A. AZZOLLINI, O. SCHUMPP, N. BOHNI, M. MONOD, K. GINDRO, J.-L. WOLFENDER. *LC-MS Metabolomic: Examples of Fungal Interactions.*
UFR de Sciences pharmaceutiques et ingénierie de la santé, Université d'Angers, 13 February, **2012**, Angers (France).
3. I. CESARI, G. BRUSOTTI, M. HOERLÉ, E. F. QUEIROZ, M. CUENDET, J.-L. WOLFENDER, G. CACCIALANZA. *Diospyros bipindensis (Gürke): Bioguided Study of Stem Bark Extracts with Anti-Inflammatory Properties.*
NPCF6 Symposium, Nuove Prospettive in Chimica Farmaceutica, 15-17 April, **2012**, Riccione (Italy).
4. S. CHALLAL, E. F. QUEIROZ, B. DEBRUS, D. GUILLARME, O. E. BUENAFE, A. HARVEY, CV. ESGUERRA, P. A. M. DE WITTE, J.-L. WOLFENDER, A. D. CRAWFORD. *Rational strategy for the isolation of CNS bioactive compounds from Solanum torvum based on MPLC-ELSD and fast UHPLC-TOF-MS monitoring.*
27ème Séminaire en Sciences Pharmaceutiques-Drugs from Nature: Discovery to Clinic, 3-7 September, **2012**, Zermatt (Switzerland).
5. P. J. EUGSTER. *Maximising resolution for UHPLC-TOF-MS metabolite profiling of complex natural samples-application to small and large molecules.*
7th PhD Day of the School of Pharmaceutical Sciences Geneva-Lausanne (EPGL), 15 June, **2012**, Hermance (Switzerland).

6. P. J. EUGSTER, D. BIASS, D. GUILLARME, P. FAVREAU, R. STÖCKLIN, J.-L. WOLFENDER. *Maximising resolution for UHPLC-TOF-MS metabolite profiling of complex natural samples-application to small and large molecules.*
Fall Meeting of the Swiss Chemical Society (SCS), 13 September, **2012**, Zurich (Switzerland).
7. Q. FAVRE-GODAL, E. F. QUEIROZ, D. SANGULARD, J.-L. WOLFENDER. *Detection of antifungal compounds using LC-microfractionation and bioautography with a hypersusceptible strain of C. albicans.*
27ème Séminaire en Sciences Pharmaceutiques-Drugs from Nature: Discovery to Clinic, 3-7 September, **2012**, Zermatt (Switzerland).
8. G. GLAUSER, B. ROCHAT, N. VEYRAT, E. GRATA, T. TURLINGS, J.-L. WOLFENDER. *Quadrupole time-of-flight versus single stage Orbitrap for LC-MS-based plant metabolomics: the response of plants to wounding as a model for evaluation.*
30th SGMS Annual Meeting, 1-2 November, **2012**, Beatenberg (Switzerland).
9. M. HALABALAKI, S. BERTRAND, A. STEFANO, J. BOCCARD, S. KOSTIDIS, S. RUDAZ, E. GIKAS, A. L. SKALTSOUNIS, K. GINDRO, J.-L. WOLFENDER. *NMR- and UHPLC-MS correlation for identification of biomarkers from woods of Vitis Vinifera cultivar resistant to pathogens.*
ICNPR 2012, International Congress on Natural Product Research, 30 July, **2012**, New York (USA).
10. G. MARTI, M. ERB, J. BOCCARD, G. GLAUSER, G. R. DOYEN, N. VILLARD, T. TURLINGS, S. RUDAZ, J.-L. WOLFENDER. *Metabolomics reveals herbivore-induced metabolites of resistance and susceptibility in maize.*
Natural Products and Biocontrol, 19 - 21 September, **2012**, Perpignan (France).
11. F. MEHL, G. MARTI, J. BOCCARD, B. DEBRUS, P. MERLE, E. DELORT, L. BAROUX, V. RAYMO, M. I. VELAZCO, H. SOMMER, J.-L. WOLFENDER, S. RUDAZ. *Differentiation of lemon essential oil based on volatile and oxygen heterocyclic fractions with various analytical techniques: a metabolomic approach.*
Congrès Chimométrie 2012, 5-6 December, **2012**, Villeneuve d'Ascq, Polytech'Lille (France).
12. E.F. QUEIROZ. *Supply of natural products from sustainable sources and efficient strategies for their isolation.*
Phytochemistry: Mini-symposium, 16 March, **2012**, Nestlé Research Center, Lausanne (Switzerland).
13. E.F. QUEIROZ. *Modern approaches in the search for new active compounds from higher plants.*
Conference at Pavia University, Dipartimento di Scienze del Farmaco, 22 March, **2012**, Pavia (Italy).
14. E.F. QUEIROZ. *Modern approaches in the search for new active compounds from higher plants.*
Conference at McMaster University, department of Biology, 13 April, **2012**, Hamilton (Canada).
15. E.F. QUEIROZ. *Brazilian Biodiversity as a source of new herbal drug* (open conference).
3° Congresso Iberoamericano de Fitoterapia, 1-5 Mai, **2012**, Foz do Iguaçu (Brazil).
16. E.F. QUEIROZ. *Open Innovation Networks: Success stories of drug development in Brazil.*
Open-Ended Meeting with Member States in the Framework of the Development Agenda Project on Open Collaborative Projects and IPBased Models. Wipo meeting, 18 June, **2012**, Geneva (Switzerland).
17. O. SCHUMPP, S. BERTRAND, N. BOHNI, J.-L. WOLFENDER, K. GINDRO. *Search for bioactive stress-induced compounds in fungal co-cultures.*
British Mycological Society BMS2012, Fungal Interactions, 3-6 September, **2012**, University of Alicante, Alicante (Spain).
18. J.-L. WOLFENDER. *Metabolomic strategies for the search of original stress induced biomarkers in plants and fungi.*
Geneva Plant Seminars, 22 February, **2012**, University of Geneva (Switzerland).
19. J.-L. WOLFENDER. *Profiling natural extracts: current challenges for the early identification of biomarkers and bioactive compounds.*
Phytochemistry: Mini-symposium, 16 March, **2012**, Nestlé Research Center, Lausanne (Switzerland).
20. J.-L. WOLFENDER. *Nouvelles approches pour le profilage à haute résolution d'extraits naturels: Identification de biomarqueurs et de composés bioactifs à l'échelle du microgramme.*
CNRS-ICSN Seminar, 3 April, **2012**, Gif-Sur-Yvette (France).

21. J.-L. WOLFENDER. *Recent advances in the profiling of crude plant extracts: dereplication and metabolomics*.
Programa de Pós-Graduação em Química, 17 April, **2012**, Fortaleza Bahia (Brazil).
22. J.-L. WOLFENDER. *Latest technological advances in Pharmacognosy: evolution or revolution*.
VIII Brazilian Symposium on Pharmacognosy, 19 April, **2012**, Ilhéus Bahia (Brazil).
23. J.-L. WOLFENDER, O. SCHUMPP. *Metabolomic and mycological approaches for the search of bioactive stress induced compounds in fungal co-cultures*.
Novartis Seminar, 3 May, **2012**, Basle (Switzerland).
24. J.-L. WOLFENDER. *Chromatography and hyphenation for natural products analysis and dereplication: How far are we now?*
8th International Symposium on Chromatography of Natural Products (ISCNP), 18 May, **2012**, Lublin (Poland).
25. J.-L. WOLFENDER. *Hyphenation of HPLC with MS and NMR for natural product identification: current status and future perspectives*.
AGROCOS symposium "Enabling Technologies in Natural Product-based Lead Discovery", 28 June, **2012**, University of Geneva (Switzerland).
26. J.-L. WOLFENDER. *Advances in Chromatography: Efficient profiling of crude extracts and isolation of natural products*.
ICNPR 2012, International Congress on Natural Product Research, 30 July, **2012**, New York (USA).
27. J.-L. WOLFENDER. *Bridging sensitive MS-based metabolomics and targeted microNMR methods for biomarker discovery*.
Natural Products Research Lecture Series, 20 September, **2012**, Copenhagen (Denmark).
28. J.-L. WOLFENDER, S. BERTRAND, N. BOHNI, O. SCHUMPP, K. GINDRO. *Combination of MS-based metabolomics and microNMR for studying fungal interactions and induction of bioactive natural products*.
Metabomeeting, 27 September, **2012**, Manchester (United Kingdom).
29. J.-L. WOLFENDER. *Strategies for a rapid and rational early identification of potential bioactive natural products in complex extracts*.
2nd International Conference and Workshop Plant – the source of research material, 18 October, **2012**, Lublin (Poland).
30. J.-L. WOLFENDER. *Nouvelles méthodologies analytiques pour la découverte de produits bioactifs naturels*.
Conférence Hygia LVMH, Académie Nationale de Pharmacie, 7 November, **2012**, Paris (France).
31. J.-L. WOLFENDER. *Metabolomics for studying stress response phenomena*.
Holistic Analytical Technologies for BioMedical, Food and Plant Science, 11 November, **2012**, Athens (Greece).

3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES

1. M. CUENDET, J.-L. WOLFENDER. *Drugs from Nature: from Discovery to Clinic*.
27ème Séminaire de 3ème Cycle en Science Pharmaceutique, 3 - 7 September, **2012**, Zermatt (Switzerland).
2. A. L. SKALTSOUNIS, M. HALABALAKI, J.-L. WOLFENDER. *Exploring Chemical Biodiversity with Innovative Approaches for Fighting Chagas and Leishmaniasis*.
Workshop Chembiofight (FP7-PEOPLE-IRSES /IAPP- EUROPEAN GRANT), VIII Brazilian Symposium on Pharmacognosy, 20 April, **2012**, Ilhéus Bahia (Brazil).
3. J.-L. WOLFENDER. *Confirmatory analysis and de novo structural identification*.
Workshop Plants and Metabolomics 2012, 25 April, **2012**, University of Leiden, Leiden (Netherlands).
4. J.-L. WOLFENDER, A. EDISON, S. RUDAZ. *Metabolomics Workshop at the University of Florida*.
University of Florida, 4-7 June, **2012**, Gainesville (USA).
5. J.-L. WOLFENDER, S. RUDAZ. *Workshop: Introduction to plant metabolomics*.
Interuniversity Doctoral Program in Organismal Biology, 25-26 January, **2012**, University of Neuchâtel (Switzerland).

4. RADIO/TELEVISION/MEDIA INTERVENTION

1. J.-L. WOLFENDER, A. BURKHARDT. Un cocktail toxique. Magazine Horizons, Fonds National Suisse de la Recherche Scientifique, 24, **2012**.
2. J.-L. WOLFENDER. Le pouvoir caché des plantes stressées. Magazine Campus, Université de Genève, 109, 18-19, **2012**.
3. J.-L. WOLFENDER, K. GINDRO. Emission Radio 'Impatience' RTS: « Les vertus des plantes stressées » 20 mars **2012**. <http://www.rts.ch/la-1ere/programmes/impatience/3831960-impatience-du-20-03-2012.html>

CLINICAL PHARMACY



PROFESSOR

CSAJKA Chantal

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	8
1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)	2
1.3 BOOKS OR BOOKS CHAPTERS	2
2.1 POSTERS PRESENTATIONS	8
3.1 CONGRESSES & SYMPOSIA	3
3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES	4

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

Clinical Pharmacology and Therapeutics.	6.43
British Journal of Clinical Pharmacy	3.76
Antimicrobial Agents and Chemotherapy	4.84
Clinical Pharmacokinetics	5.39
Pharmacogenetics and Genomics	5.77
Clinical Infectious Diseases	9.15
Journal of clinical Pharmacology	2.91

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. A. HAOUALA, N.WIDMER, M. MONTEMURRO, S. LEYVRAZ, T. BUCLIN, C.B.EAP, L.A. DECOSTERD, C. CSAJKA.
Prediction of free imatinib concentrations based on total plasma levels in GIST patients. Br J Clin Pharmacol. (2012) Aug 15. [Epub ahead of print] 3.76
2. Pascual. A*, **Csajka C***, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O.
Challenging recommended oral and intravenous voriconazole doses: a population pharmacokinetics analysis of efficacy and safety in adult patients with invasive fungal infections. Clinical Infectious Diseases (2012) Aug;55(3):381-90. 9.15
3. Guidi M, Arab-Alameddine M, Rotger M, Aouri M, Telenti A, Decosterd LA, Buclin T, **Csajka C.** *Dosage optimization through population pharmacokinetics and simulation: the example of nevirapine in HIV positive patients.* Chemia 2012;66(5):291-5. 0.52
4. Siccardi, M, Almond, L, Schipani, A, **Csajka, C.** Marzolini, C, Edwards D, Khoo, S,Owen, A, Back D. *Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation model.* Clinical Pharmacology and Therapeutics 2012 Mars 91(1):S104-S104. 6.43
5. Arab-Alameddine M*, Fayet-Mello A*, Lubomirov R, Neely M, di Iulio J, Owen A, Boffito M, Cavassini M, Günthard HE, Rentsch K, Buclin T, Aouri M, Telenti A, Decosterd LA, Rotger M, **Csajka C;** the Swiss HIV Cohort Study. *Population Pharmacokinetic Analysis and Pharmacogenetics of Raltegravir In HIV-positive and Healthy Individuals.* Antimicrob Agents Chemother. 2012 Jun;56(6):2959-66. 4.84

6. Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, **Csajka C**, Buclin T. Therapeutic drug monitoring of imatinib: bayesian and alternative methods to predict trough levels. *Clin Pharmacokinet*. 2012 Mar 1;51(3):187-2012 5.39
7. Glass T, Rotger M, Decosterd LA, Telenti A, **Csajka C**, Bucher HC, Günthard H, Nicca, D, Hirschel B, Bernasconi H, Wanderer G, Battegay M, Marzolini C, and the Swiss HIV Cohort Study. Determinants of virological suppression in HIV-infected patients on antiretroviral therapy with self-reported poor adherence. *PLoS One*. 2012;7(1):e29186. Epub 2012 Jan 3. 4.40
8. Panchaud A, **Csajka C**, Merlob P, Schaefer C, Berlin M, De Santis M, Vial T, Ieri A, Malm H, Eleftheriou G, Stahl B, Rouso P, Winterfeld U, Rothuizen LE, Buclin T. Pregnancy Outcome Following Exposure to Topical Retinoids: A Multicenter Prospective Study. *J Clin Pharmacol*. 2012 Dec;52(12):1844-51 2.91

1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)

1. Panchaud A, Berger G, **Csajka C**, Bugnon O. Médicaments, grossesse et allaitement. Toutes les sources d'information ne sont pas fiables! *Journal Suisse de Pharmacie* 2012 n°1.
2. Panchaud A, Verdun FR, **Csajka C**. Un examen radiologique est-il toujours à risqué pour l'enfant à naître? *Journal Suisse de Pharmacie* 2012 n°17.

1.3 BOOK CHAPTERS

1. Guignard B, **Csajka C**, Beney J, Bugon O, Bonnabry P. La Pharmacie Clinique en Suisse Romande, (invited chapter, in press) 2012.
2. Decosterd LA, Dahmane E, Neeman M, Buclin T, **Csajka C**, Haouala A, Widmer N. Therapeutic Drug Monitoring of the anticancer targeted therapy: Tyrosine kinase inhibitors and selective oestrogen receptor modulators: a clinical pharmacology laboratory perspective. In: *Liquid Chromatography-Mass Spectrometry in Drug Bioanalysis*, Editors Alan Xu and Timothy L. Madden. Publisher: Springer Verlag (invited chapter, in press) 2012.

2. PRESENTATIONS

2.1 POSTERS PRESENTATIONS

1. GUIDI M, VANDENBERGHE F, CHOONG E, BUCLIN T, EAP CB, **CSAJKA C**. Population Pharmacokinetics Of Risperidone And 9-Hydroxy-Risperidone In Psychiatric Patients. 21th Meeting Of Page (Population Approach Group In Europe) Venice, June 2012.
2. ARAB-ALAMEDDINE M, BUCLIN T, GUIDI M, WIDMER N, DECOSTERD LA, **CSAJKA C**. PRAGMATIC APPROACH FOR INTERPRETING ANTIRETROVIRAL DRUG CONCENTRATIONS BASED ON A SYSTEMATIC REVIEW OF POPULATION PHARMACOKINETIC STUDIES. 21TH MEETING OF PAGE (POPULATION APPROACH GROUP IN EUROPE) VENICE, JUNE 2012.
3. Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. A therapeutic drug monitoring software benchmark: A systematic evaluation of available computer tools. 21th Meeting of PAGE (Population Approach Group in Europe) Venice, June 2012.
4. Livio F, Guidi M, Wahl P, Gautier E, Prod'Hom G, Buclin T, Csajka C. Vancomycin exposure from active calcium sulfate bone filler. Congrès annuel de la Société Suisse de Pharmacologie et Toxicologie cliniques, Basel May 2012.
5. Gotta V, Bouchet S, Widmer N, Mahon F-X, Molimard M, Buclin T, Csajka C. Population pharmacokinetics (Pop-PK) in chronic myeloid leukemia (CML) patients: observations under field-conditions. Congrès annuel de la Société Suisse de Pharmacologie et Toxicologie cliniques, Basel May 2012.
6. Rothuizen L, Joray N, Mello A, Cairoli A, Cavassini M, Csajka C, Buclin T. Antiretroviral treatment and chemotherapy: dose adaptation of antineoplastic agents in HIV patients treated for lymphoma. Congrès annuel de la Société Suisse de Pharmacologie et Toxicologie cliniques, Basel May 2012
7. E. Dahmane, K. Zaman, M. Galmiche, L. Perey, A. Bodmer, S. Leyvraz, C.Eap, L.Decosterd, T. Buclin, C.Csajka. The influence of CYP2D6 genetic polymorphism on tamoxifen and its active metabolite exposure in breast cancer patients: preliminary results from a prospective, open-label trial. In: the Annual Meeting of the Population Approach Group in Europe (PAGE). 2012.

8. K. Zaman, E. Dahmane, L. Perey, A. Bodmer, S. Anchisi, A. Wolfer, M. Galmiche, A. Stravodimou, T. Buclin, C. Eap, L. Decosterd, C. Csajka and S. Leyvraz. Tamoxifen dose escalation based on endoxifen level: a prospective trial with genotyping, phenotyping and pharmacokinetics over 4 months. In: The 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). 2012

3. ORAL PRESENTATIONS

3.1 CONGRESSES & SYMPOSIA

1. S. CRETOL-WAVRE, N. ANSERMOT, C. CSAJKA, CB EAP. Genetics of methadone pharmacokinetics and cardiotoxicity: an update. 10th European Congress of the European Opiate Addiction Treatment Association, Barcelona May 25-27 2012.
2. E. DAHMANE, K. ZAMAN, M. GALMICHE, L. PEREY, A. BODMER, S. LEYVRAZ, C.EAP, L.DECOSTERD, T. BUCLIN, C.CSAJKA. Impact of tamoxifen dose on tamoxifen and its active metabolites exposure in breast cancer patients: preliminary results from a prospective, open-label trial. In: 80^{ème} Assemblée Annuelle de la Société Suisse de Médecine Interne Générale Congress Center, Bâle. 2012.
3. V. GOTTA, C. CSAJKA, N. WIDMER, T BUCLIN, M MOLIMARD. Possible predictors for cytogenetic response in chronic myeloid leukemia (CML) patients observed under field-conditions. 80^{ème} rencontre annuelle de la Société Suisse de Médecine Interne, Basel, May 2012.

3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES

1. A. Panchaud, C. Csajka. La pharmacocinétique et son rôle en Clinique. Colloque HESV sages-femmes, CHUV, September 2012.
2. A. Panchaud, C. Csajka. Antidépresseurs, grossesse et allaitement- Colloque Pharmacie- Pharmacologie Clinique, CHUV, November 2012
3. C. Csajka. Fiche clinique Voriconazole. Colloque TDM Pharmacologie Clinique, CHUV, May 2012
4. C. CSAJKA, A. TELENTI. "Pharmacology and Pharmacogenetics". Doctoral School UNIL July 2012.

COMMUNITY PHARMACY



PROFESSOR

BUGNON Olivier

SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	3
SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)	15
PUBLICATIONS EXTRAMUROS	2
BOOKS OR BOOKS CHAPTERS	8
POSTERS PRESENTATIONS	6
CONGRESSES & SYMPOSIA	25
CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES	34
THESIS PRESENTED (EXTRA-MUROS)	1

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD OF PHARMACY PRACTICE (WITH IMPACT FACTOR 2011)

American Journal of Health System Pharmacy	1.96
Annals of Pharmacotherapy	2.12
Disease Management and Health Outcomes	0.36
International Journal of Pharmacy Practice	PR*
Journal of Clinical Pharmacy and Therapeutics	1.57
Journal of Managed Care Pharmacy	2.25
Patient Education and Counselling	2.30
Pharmacy Practice (www.pharmacypractice.org)	PR*
Pharmacy World and Sciences	1.21
Revue Médicale Suisse	PR*

*PR=peer reviewed

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. O. BUGNON, D. HUGENTOBLE-HAMPAÏ, J. BERGER, M-P. SCHNEIDER 1.212
New Roles for Community Pharmacists in Modern Health Care Systems: A Challenge for Pharmacy Education and Research.
CHIMIA (2012 February); 66: No. 5, 304-307.
2. I. KRUMMENACHER, M. CAVASSINI, O. BUGNON, M-P. SCHNEIDER 1.215
Characteristics of HIV patients referred to a medication adherence program in Switzerland.
Int J Clin Pharm 2012, 34: 426-431.
3. G. GRAS, M.-P. SCHNEIDER, M. CAVASSINI, F. LUCHT, M. LOILIER, R. VERDON, L. BERNARD, J.-J. PARIENTI 4.425
Patterns of Adherence to Raltegravir-Based Regimens and the Risk of Virological Failure Among HIV-Infected Patients: The RALTECAPS Cohort Study.
JAIDS 2012, 61 : 265 -269

1.2 SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR)

1. O. BUGNON
Cybersanté : support et non-substitut de la promotion individualisée de l'adhésion thérapeutique.
Rev Med Suisse 2012; 8 : 209.
2. O. BUGNON, S. DI GIOVANNI, M. BUCHMANN
The pharmacist's perspective to advance person- and people-centered care.
The International Journal of Person Centered Medicine Vol 2 Issue 1 pp 129-134.
3. O. BUGNON, I. ANGUISH, M. EGGENBERGER, E. MICHIELAN, I. BURG, C. REPOUND
Incitations à la performance - financement et monitoring innovants de l'assistance pharmaceutique des EMS fribourgeois. Care Management (2012) ; 5 (Nr. 5/6) : 1-5.
4. O. BUGNON, M. BUCHMANN
Pharmacie d'officine et médecine interne générale à la croisée des mêmes chemins : des opportunités à saisir.
Rev Med Suisse 2012; 8 : 2287-91.
5. O. BUGNON, S. JOTTERAND, A. NIQUILLE CHARRIERE, M. RUGGLI, L. HERZIG
Cercles de qualité médecins-pharmaciens, pour une responsabilité partagée de la liberté de prescription.
Rev Med Suisse (2012); 8 : 1042-8.
6. P. PAPIN, J. BERGER, O. BUGNON
Interaction entre l'aspirine et les AINS. Comment éviter la diminution possible de l'effet cardioprotecteur ?
Interaktion zwischen Acetylsalicylsäure und NSAR. Wie verhindert man eine mögliche Abnahme des kardioprotektiven Effekts?
pharmaJournal (2012); Nr. 15/7.2012.
7. M. SCHÜTZ, J. BERGER, O. BUGNON
Urée et acide salicylique. Quelles concentrations prescrire pour le pied du diabétique ?
Harnstoff und Salicylsäure. Verschreibung beim diabetischen Fuss : in welcher Konzentration ?
pharmaJournal (2012); Nr. 20/10.2012.
8. J. BERGER, N. GENRE, A. ALATRI, O. BUGNON
Quelle attitude adopter en cas d'utilisation concomitante d'acénocoumarol et de paracétamol ?
Verhalten bei gleichzeitiger Einnahme von Acenocoumarol und Paracetamol ?
pharmaJournal (2012); Nr. 22/11.2012.
9. M-P. SCHNEIDER, N. GENRE, M. REYMERMIER, O. BUGNON, D. MORADPOUR
Hépatite C. Avancées thérapeutiques.
Hépatitis C. Therapeutische Fortschritte.
pharmaJournal (2012); Nr 24/11.2012. pharmaJournal (2012); Nr 25/12.2012.
10. FONDATION POUR LA SECURITE DES PATIENTS ET EXPERTS EXTERNES (DONT J. BERGER)
Intoxication au méthotrexate : éviter les surdosages par voie orale !
Methotrexat-Intoxikation : vermeiden von oralen Überdosierungen !
Intossicazione da metotrexato : evitare sovradosaggi per via orale ! Quick-Alert® (2012) ; Nr. 28/05.12.2012.
11. O. BUGNON, H. BALMER
Optimiser les collaborations médecins-pharmaciens-soignants pour la prise médicamenteuse. La cybersanté pour un soutien individualisé.
Clinicum Romandie (1/2012); Le numéro 1 pour la gestion de l'hôpital.
12. S. BEN AMARA, M. SCHUETZ, M.-C. HOFNER, O. BUGNON
Implication du pharmacien d'officine romand dans la prévention de la violence domestique.
Collaboration avec la Dr Marie-Claude Hofner, Responsable de la recherche et de la formation, Unité de Médecine des Violences (UMV) du Centre Universitaire Romand de Médecine Légale (2012). Travail personnel de recherche, Maîtrise en Pharmacie. L'encadrement du travail a bénéficié du soutien financier de la Société vaudoise de Pharmacie.

13. O. MICHEL, A. GUERTSCH, M. CAVASSINI, O. BUGNON, MP SCHNEIDER
Evaluation de l'adhésion thérapeutique aux traitements antirétroviraux pendant la grossesse et le postpartum.
Collaboration avec le Dr Matthias Cavassini, directeur médical de la consultation ambulatoire du service des maladies infectieuses du CHUV et responsable des consultations VIH-SIDA hospitalières du CHUV (2012). Travail personnel de recherche, Maîtrise en Pharmacie.
14. J. ISELY, MP SCHNEIDER, R. MOSIMANN, O. BUGNON, S. DU PASQUIER *Commande illégale de médicaments par Internet, enquête exploratoire en Suisse.*
Collaboration avec Swissmedic (Ruth Mosimann) (2012). Travail personnel de recherche, Maîtrise en Pharmacie. L'encadrement du travail a bénéficié du soutien financier de la Société vaudoise de Pharmacie.
15. A. NIQUILLE CHARRIERE, M. RUGGLI, M. BUCHMANN, D. JORDAN, O. BUGNON
Impact des cercles de qualité médecins-pharmaciens pour la prescription médicamenteuse entre 1999 et 2010.
Die Auswirkungen der Qualitätszirkel Ärzte-Apotheker auf die Medikamentenverschreibungen von 1999 bis 2010.
PrimaryCare (2012); 12 (2) : 27-28.

1.3 PUBLICATIONS EXTRAMUROS

1. I. ANGUISH, J.-F. LOCCA, O. BUGNON
Etude comparative 2010-2011 : Résultat de l'assistance pharmaceutique dans les EMS fribourgeois.
Rapport à l'intention des partenaires à la Convention cantonale (Association fribourgeoise des institutions pour personnes âgées, santésuisse et la Société des pharmaciens du canton de Fribourg), 14 septembre 2012.
2. M.-J. ZEUKENG, J.-F. LOCCA, O. BUGNON
Assistance pharmaceutique et Cercles de Qualité dans les établissements médico-sociaux (EMS) du Canton de Vaud: état des lieux du programme cantonal et présentation de résultats préliminaires 2009-2011.
Rapport à l'intention du Comité de pilotage du projet, dirigé par le Service de la santé publique du Canton de Vaud, 29 novembre 2012.

1.4 BOOKS OR BOOKS CHAPTERS

1. J. BERGER, N. GENRE, A. ALATRI
Potentialisation de l'effet anticoagulant du Sintrom[®] par le Dafalgan[®] : quelle attitude adopter en pratique ?
News médicaments de la Pharmacie de la Policlinique Médicale Universitaire, Lausanne (Janvier 2012) [Intranet].
2. J. DE MOOIJ, J. BERGER
Vitamine D3 – mise à jour 2012 – Quelles spécialités prescrire en tenant compte des recommandations actuelles ?
News médicaments de la Pharmacie de la Policlinique Médicale Universitaire, Lausanne (Février 2012) [Intranet].
3. J. CELIO, J. BERGER
Targin[®] (oxycodone/naloxone) – Recommandations d'emploi – mise à jour 2012.
News médicaments de la Pharmacie de la Policlinique Médicale Universitaire, Lausanne (Mars 2012) [Intranet].
4. M.-J. BARBALAT, J. BERGER
Interaction entre contraceptifs et antibiotiques – mise à jour 2012.
News médicaments de la Pharmacie de la Policlinique Médicale Universitaire, Lausanne (Juillet 2012) [Intranet].
5. A. PANCHAUD, J. BERGER, O. BUGNON
Médicaments, grossesse et allaitement.
Babyguide – Le manuel officiel suisse : Grossesse, naissance et les trois premières années de l'enfant, Ed. BabyGuide, Le Mont-sur-Lausanne (Décembre 2012).

6. J. BERGER, O. BUGNON
Du bon usage des médicaments en pédiatrie.
Babyguide – Le manuel officiel suisse : Grossesse, naissance et les trois premières années de l'enfant, Ed. BabyGuide, Le Mont-sur-Lausanne (Décembre 2012).
7. V. PAVON, O. BUGNON
Voyager durant la grossesse, avec des bébés ou des petits enfants.
Babyguide – Le manuel officiel suisse : Grossesse, naissance et les trois premières années de l'enfant, Ed. BabyGuide, Le Mont-sur-Lausanne (Décembre 2012).
8. B. GUIGNARD, C. CSAJKA, J. BENEY, O. BUGNON, P. BONNABRY
Pharmacie clinique en Suisse romande.
Dans : Pharmacie clinique et thérapeutique. J. Calop, S. Limat, C. Fernandez et G. Aulagner. Elsevier Masson, 4^{ème} Edition (2012) ; Chap. 65 : 1277-1290

2. PRESENTATIONS

2.1 POSTERS PRESENTATIONS

- A. SCHNEIDER, S. DI GIOVANNI, O. BUGNON, P. HALFON
1. *Prescription patterns and appropriateness of non-steroidal anti-inflammatory drugs (NSAIDs) among Swiss adults in ambulatory care.*
Poster presented at the Swiss Family Docs Conference, Lausanne 30-31.08.2012.
- M-J. ZEUKENG, J-F. LOCCA, D. MAURI, S. DI GIOVANNI, C. ROSSIER, A-S. FONTANNAZ, F. BEFFA, O. BUGNON
2. *Antiepileptic and antiparkinsonian drugs use for the elderly living in nursing home: first report from a collaborative pharmaceutical service in a Swiss canton.*
Poster presented at the International Pharmaceutical Federation (FIP) World Centennial Congress of Pharmacy and Pharmaceutical Sciences, Amsterdam 3-8.10.2012.
- A. GERTSCH, M. CAVASSINI, I. LOCATELLI, O. BUGNON, M-P. SCHNEIDER
3. *Emtricitabine, efavirenz, tenofovir: switching from a 2-pill to a one-pill regimen may affect subjects's perceptions and routine.*
Poster presented at the Annual Symposium of ESPACOMP (European Society for Patient Adherence, COMPLIance and Persistence), Gand 26-27.10.2012.
- S. DI GIOVANNI, M-J. ZEUKENG, P. BALLABENI, I. ANGUISH, J-F. LOCCA, O. BUGNON
4. *Polypharmacy as predictor of drug cost, length of hospital stay and mortality rate in nursing homes: a retrospective analysis of pharmacy medication records.*
Poster presented at the 41st ESCP Symposium on Clinical Pharmacy- Personalised and safe therapy, Barcelona 29-31.10.2012.
- S. DU PASQUIER, J. ISELY, R. MOSIMANN, M-P. SCHNEIDER, O. BUGNON
5. *Ordering Medical Product from the Internet: an exploratory study with French speaking Swiss residents about practice and opinions.*
Poster presented at the 41st ESCP Symposium on Clinical Pharmacy- Personalised and safe therapy, Barcelona 29-31.10.2012.
- O. MICHEL, A. GERTSCH, I. LOCATELLI, M. CAVASSINI, M. RICKENBACH, O. BUGNON, M-P. SCHNEIDER
6. *A dynamic assessment of medication-taking behavior during pregnancy and postpartum: should cART adherence be reinforced during postpartum?*
Poster presented at the 11th International Congress on Drug Therapy in HIV Infection, Glasgow 11-15.11.2012.

3. ORAL PRESENTATIONS

3.1 CONGRESSES & SYMPOSIA

- O. BUGNON
1. *Adhésion thérapeutique et rôle de la Cybersanté : pour qui, pourquoi ?*
Congrès Médical du Praticien, Quadrimed « La médecine au-delà des sentiers battus », Crans-Montana, 26-29.01.2012.

2. O. BUGNON
Soins intégrés et médicaments : nouvelles pistes thérapeutiques.
Hôpital du Valais (RSV), Centre Valaisan de Pneumologie, Crans-Montana, 14.3.2012.
3. O. BUGNON
La cybersanté au service du soutien individualisé de la prise des médicaments / Elektronische Kontrollsysteme zur Medikamenteneinnahme.
Trenstage Gesundheit Luzern, Die Patientengeneration der Zukunft - Le patient de demain, Luzern, 21-22.03.2012.
4. J. BERGER, O. BUGNON
Prévention, causes et conséquences des chutes : médicaments et chutes.
Colloque multidisciplinaire valaisan. GPS Groupement interprofessionnel des professions de la santé. Sion, 26.04.2012.
5. O. BUGNON (as representative of the International Pharmaceutical Federation (FIP))
Policy Statements from Collaborating Major Medical and Health Organizations. Special Session.
5th Geneva Conference on Person-centered Medicine, « *Chronic Diseases: Person- and People-centered Perspectives* », Geneva, 2.05.2012.
6. O. BUGNON
On the way of implementing Integrated Health Services Delivery Networks (IHSDNs) : Medication adherence case report.
World Health Professions Alliance (WHPA) Leadership Forum, Geneva, 20.05.2012.
7. M.J. ZEUKENG, member of the symposium committee and chairman
PhD Day 2012.
School of pharmaceutical sciences, University of Geneva and University of Lausanne, Fondation Brocher, Hermance (Geneva), 15.6.2012.
8. J. BERGER, O. BUGNON
Mesures de contrainte en situation d'extrême urgence et... contraintes médicamenteuses.
Symposium de La Lignière. 21.06.2012.
9. M.-P. SCHNEIDER
La place du pharmacien d'officine du 21^{ème} siècle dans la promotion de l'adhésion thérapeutique.
Symposium pharmcare, Bruxelles, 15.09.2012
10. O. BUGNON
Compliance, observance, adhésion, coaching de patients... Au-delà des mots utilisés, une contribution du pharmacien à développer.
Table ronde sur l'adhésion thérapeutique. Journée pharmaceutique internationale de Casablanca. 22.09.2012.
11. I. ANGUISH
Nine Years of remuneration for performance of collaborative pharmaceutical care service in Swiss nursing homes.
FIP Centennial Congress of Pharmacy and Pharmaceutical Sciences, Amsterdam, 05.10.2012.
12. O. BUGNON
Innovative collaborative practice and payment for performance.
Forum for Policy makers – Trends in community pharmacy. FIP Centennial Congress of Pharmacy and Pharmaceutical Sciences, Amsterdam, 05.10.2012.
13. O. BUGNON
10-year performance-based remuneration for one standardized collaborative pharmacy service in Swiss nursing homes.
Forum for innovators – Business and financial aspect of implementing and integrating pharmaceutical services. FIP Centennial Congress of Pharmacy and Pharmaceutical Sciences, Amsterdam, 08.10.2012.
14. O. BUGNON
Défis de la collaboration interdisciplinaire autour de l'usage responsable des médicaments.
Colloques de Médecine, Aula de l'Hôpital, Sion, 10.10.2012.
15. O. BUGNON
Mesa redonda. Experiencia suiza con la implantacion de servicios cognitivos.
XVIII Congreso Nacional Farmaceutico, Santander, 25.10.2012.

16. M.P. SCHNEIDER, member of the scientific committee, of the best poster committee
15th Annual meeting of ESPACOMP (European Society for Patient Adherence, COMPLIance and Persistence. Ghent (Belgium), 26-27.10.2012.
17. M. DE BRUIN, M.P. SCHNEIDER, G. KOK, D. SCHAAFSMA, G.J. PETERS
Workshop : « Designing interventions for treatment initiation, execution and persistence (an intervention mapping approach) ».
15th Annual meeting of ESPACOMP (European Society for Patient Adherence, COMPLIance and Persistence. Ghent (Belgium), 26-27.10.2012.
18. O. BUGNON
Zusammenarbeit zwischen Ärzten, Apothekern und Pflegepersonal - Die Qualitätszirkel Arzt-Apotheker : ein Vertrauensbasis für die nächste gemeinsamen Schritte.
Veranstaltung der Qualitätszirkel Arzt-Apotheker der Region Aarau und Brugg, Aarau, 5.11.2012.
19. O. BUGNON, A. NIQUILLE
Workshop : « Collaboration interprofessionnelle : quelles pistes concrètes et comment les mettre en œuvre au niveau local et/ou cantonal ».
1^{er} Forum de la Société vaudoise de Pharmacie (SVPh): "La place des pharmaciens dans le future système de santé vaudois", Paudex, 9.11.2012.
20. J. BERGER
Le triage à l'officine... passe par l'estomac.
Symposium annuel pharmActuel, formation continue FPH, Berne, 13.11.12
21. O. BUGNON, member of the symposium committee and chairman
Littératie et Web 2.0 : chances et défis pour la santé.
Symposium scientifique des 125 ans de la Policlinique Médicale Universitaire (PMU) de Lausanne, Lausanne, 14.11.2012.
22. M.-J. ZEUKENG, O. BUGNON
Assistance pharmaceutique (Cercles de Qualité) dans les établissements médico-sociaux : état des lieux du programme cantonal et présentation de quelques résultats préliminaires 2009-2011.
FORUM Cercles de Qualité en EMS, CHUV, Lausanne, 29.11.2012.
23. O. BUGNON
1. *Introduction to the Swiss Health care system.*
2. *Introduction to Quality circles physicians-pharmacists in primary care.*
3. *10-year performance-based remuneration for one standardized collaborative pharmacy service in Swiss nursing homes.*
Symposium organisé pour une délégation de la Société des pharmaciens du Japon venue visiter la Pharmacie de la PMU et ses activités de recherche, Lausanne, 10.12.2012.
24. M. P. SCHNEIDER
Medication adherence program.
Symposium organisé pour une délégation de la Société des pharmaciens du Japon venue visiter la Pharmacie de la PMU et ses activités de recherche, Lausanne, 11.12.2012.
25. O. BUGNON
New perspectives for community pharmacists in modern health care systems.
Symposium organisé pour une délégation de la Société des pharmaciens du Japon venue visiter la Pharmacie de la PMU et ses activités de recherche, Lausanne, 12.12.2012.

3.2 CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES

1. I. ANGUISH, O. BUGNON
Présentation des statistiques 2009-2010 de la consommation des médicaments dans les EMS fribourgeois.
Formation continue à l'intention des pharmaciens responsables des EMS fribourgeois, Fribourg, 16.01.2012.
2. O. BUGNON, A. NIQUILLE, C. ROSSIER
Optimiser le profil de prescriptions des antiagrégants et anticoagulants (IT 06.03).
Cercle de qualité médecins-pharmaciens de Lausanne, Paudex, 15.02.2012.
3. J. BERGER
Visite interdisciplinaire à domicile, cas du couple M.
Colloque des Chefs de Clinique du Service de Gériatrie, Policlinique Médicale Universitaire, Lausanne, 28.02.12.

4. O. BUGNON
Entretiens de polymédication (PMC), une nouvelle prestation à mettre en place.
Séminaire CAP, formation continue FPH, Cully, 13.3.2012.
5. O. BUGNON
1. *Bilan des résultats du cercle 2009-2010 : suite de l'analyse et fixation d'objectifs.*
2. *Retour sur quelques avis récents de pharmacovigilance.*
3. *Optimiser le profil de prescriptions des antiagrégants et anticoagulants.*
Cercle de qualité médecins-pharmaciens d'Yvonand-Echallens, Yvonand, 29.03.2012.
6. I. ANGUISH, J. BERGER
Formation continue FPH en ligne pour pharmaciens : « Médicaments et conduite automobile ».
CAP et Pharmacie de la PMU, avril 2012.
7. J. BERGER, O. BUGNON
Visite interdisciplinaire à domicile (présentation d'un cas) : circuit du médicament... et de l'information!
APROMAD, CUTR Sylvana, Epalinges, 03.04.12.
8. N. GENRE, M.P. SCHNEIDER
A propos des hépatites et de leurs traitements.
Séminaire pharmActuel, formation continue FPH, 03.04.12.
9. J. BERGER
Analyse de la médication (Medication review) d'un patient de la Consultation générale de la PMU – Mme J. (1942).
Colloque de la Consultation Générale, Policlinique Médicale Universitaire, Lausanne, 11.04.12.
10. O. BUGNON
Les prestations pharmaceutiques face aux forces du marché ?
Conférence lors des Symposia Pharmacie on top 2012 sur le thème « Retrouver un nouveau souffle : l'exemple de ceux qui ont réussi. », tenue à 2 reprises : Montreux (26.04.2012), Lausanne-Bussigny (27.04.2012). Organisateur : MEPHA Pharma SA avec le soutien de SISpha SA.
11. O. BUGNON
1. *Les entretiens motivationnels, éléments clés des prestations de la pharmacie d'officine moderne.*
2. *Entretiens de polymédications (PMC) : éléments clés et check-liste cardiovasculaire.*
Conférence lors du Symposium Pharmacie on top 2012 sur le thème « Formation continue en communication - Premiers pas en entretien motivationnel », tenue à Lugano (03.05.2012).
Organisateur : MEPHA Pharma SA avec le soutien de SISpha SA.
12. O. BUGNON, A. NIQUILLE, C. ROSSIER
1. *Optimiser le profil de prescriptions des antiépileptiques.*
2. *Nouveautés à propos de la bonne prescription des IPP (IT 04.99), des analgésiques (IT 01.01) et des AINS et apparentés (IT 07.10).*
3. *Informations interprofessionnelles à propos des entretiens de polymédication (PMC) et des programmes SISCare.*
Cercle de qualité médecins-pharmaciens de Lausanne, Paudex, 09.05.2012.
13. K. BOUFERRACHE, J. BERGER
Douleurs et affections dentaires : cas pratiques de validations d'ordonnances.
Séminaire pharmActuel, formation continue FPH, 15.05.12
14. O. BUGNON
La valorisation des actes pharmaceutiques, leur standardisation. L'expérience suisse. La rémunération.
Formation universitaire postgraduée, Diplôme Universitaire de pharmacie clinique, Université de Grenoble, Grenoble, 21.05.2012.
15. I. ANGUISH, J. BERGER, L. NICOLET, J. CELIO, J. DE MOOIJ
Formation continue FPH en ligne pour pharmaciens : « Méthotrexate : indications, manipulations et interactions ».
CAP et Pharmacie de la PMU, juin 2012.
16. J. BERGER
Analyse de la médication (Medication review) d'un patient de la Consultation générale de la PMU – Mme Z. (1943).
Colloque de la Consultation Générale, Policlinique Médicale Universitaire, Lausanne, 06.06.12.

17. O. BUGNON, J. BERGER
 1. *Les médicaments dans le système de santé et sources d'informations.*
 2. *De la molécule de médicament au patient.*
 3. *A propos des antidépresseurs.*
 4. *A propos des somnifères et des tranquillisants.*
 5. *A propos des neuroleptiques.*
 6. *Contraception.*
 7. *Traitements de la douleur : antalgiques et myorelaxants.*
 8. *Anticancéreux dans le traitement du cancer du sein.*
 Formation continue pour ostéopathes et physiothérapeutes, Montreux, 04.07.12.
18. I. ANGUISH, J. BERGER, L. NICOLET, J. CELIO, J. DE MOOIJ

Formation continue FPH en ligne pour pharmaciens : « Cas de validations d'ordonnances ».
CAP et Pharmacie de la PMU, septembre 2012.
19. M.-P. SCHNEIDER

L'entretien motivationnel et les collaborations interdisciplinaires pour soutenir l'adhésion thérapeutique des patients ambulatoires.
Soirée de formation continue organisée par la Société valaisanne de pharmacie et les médecins oncologues valaisans, Sierre, 06.09.2012.
20. O. BUGNON, J. BERGER

Gestion des interactions pharmaceutiques en pratique officinale.
Conférence pharmActuel, formation continue FPH, Lausanne, 11.09.2012.
21. O. BUGNON, A. NIQUILLE, C. ROSSIER
 1. *Bilan des résultats du cercle 2010-2011 : première analyse et fixation d'objectifs.*
 2. *Optimiser le profil de prescriptions des antidiabétiques (IT 07.06).*
 Cercle de qualité médecins-pharmaciens de Lausanne, Paudex, 19.09.2012.
22. J. BERGER

Oncologie orale : de la théorie à la pratique.
Séminaire de la Société vaudoise de pharmacie, Formation continue FPH, Lausanne, 27.09.12.
23. M.P. SCHNEIDER

The challenge of medication adherence.
Executive MBA in Healthcare specialisation, Module « Risk management strategies for optimizing the performance of health care system, providers and industries », IEMS (University of Lausanne), Lausanne, 12.10.2012.
24. O. BUGNON

Preventing the risk of health care fragmentation – workshop on continuum of care.
Executive MBA in Healthcare specialisation, Module « Risk management strategies for optimizing the performance of health care system, providers and industries », IEMS (University of Lausanne), Lausanne, 13.10.2012.
25. O. BUGNON

Primary care safety incidents and drug related problems.
Executive MBA in Healthcare specialisation, Module « Risk management strategies for optimizing the performance of health care system, providers and industries », IEMS (University of Lausanne), Lausanne, 13.10.2012.
26. O. BUGNON

Improvement of medication efficiency by collaborative practice (Quality circles physicians-nurses-pharmacists; coaching of chronic patients).
Executive MBA in Healthcare specialisation, Module « Risk management strategies for optimizing the performance of health care system, providers and industries », IEMS (University of Lausanne), Lausanne, 13.10.2012.
27. J. BERGER

Prise en charge pharmacologique de la douleur.
Séminaire de la Société valaisanne de pharmacie, Formation continue FPH, Martigny, 18.10.2012.
28. M.-J. BARBALAT, J. BERGER

Gynécologie : cas pratiques de validations d'ordonnances.
Séminaire pharmActuel, formation continue FPH, 13.11.12.

29. O. BUGNON, J. BERGER, J.F. LOCCA
Accompagnement de patients chroniques en officine : études de cas pratiques (exemples de développements en cours à l'Unité de Pharmacie communautaire de l'Ecole de Pharmacie Genève-Lausanne).
 Conférence de l'Ordre neuchâtelois des pharmaciens, formation continue FPH, Neuchâtel, 20.11.2012.
30. O. BUGNON, A. NIQUILLE, C. ROSSIER
1. Bilan des résultats du cercle 2010-2011 : première analyse et fixation d'objectifs.
2. Optimiser le profil de prescriptions des antidiabétiques (IT 07.06).
 Cercle de qualité médecins-pharmaciens de Lausanne, Paudex, 21.11.2012.
31. O. BUGNON, J. BERGER
Nouveautés pharmaceutiques et pharmacovigilance en 2012.
 Conférence pharmActuel, formation continue FPH, Lausanne, 4.12.2012.
32. J. BERGER
Le patient sous traitement oncologique à l'officine (approfondissements).
 Séminaire CAP, formation continue FPH, Cully, 04.12.2012.
33. O. BUGNON
1. Bilan des résultats du cercle 2010-2011 : première analyse et fixation d'objectifs.
2. A propos de quelques projets interdisciplinaires vaudois en cours concernant l'adhésion thérapeutique et l'ordonnance de sortie.
3. Revue de nouveautés médicamenteuses commercialisées en 2012 et rappels de pharmacovigilance.
 Cercle de qualité médecins-pharmaciens d'Yvonand-Echallens, Courtion, 06.12.2012.
34. J. BERGER
Traitement pharmacologique des douleurs neurogènes.
 Colloques du Service de Stomatologie et Médecine Dentaire (SMD) de la PMU, Lausanne, 11.12.12.

4. THESIS PRESENTED

4.1. EXTRA-MUROS POSTGRADUATE FPH CERTIFICATE

1. M. SCHÜTZ
Violences conjugales envers les femmes: que peut faire le pharmacien d'officine?
 Pharmacie communautaire, Section des sciences pharmaceutiques, Université de Genève et Université de Lausanne.
 Unité de Médecine des violences, DUMSC, CHUV, Université de Lausanne
 Supervisor : Dr Marie-Claude Hofner

HOSPITAL PHARMACY



PROFESSORS

BONNABRY Pascal, Associate Professor **HUG** Pharmacy

PANNATIER André, Associate Professor **CHUV** Pharmacy

1.1A SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR) HUG	5
1.1B SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR) CHUV	9
1.2A SCIENTIFIC PUBLICATIONS (WITH OUTIMPACT FACTOR) HUG	9
1.2B SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR) CHUV	4
1.3A BOOKS OR BOOKS CHAPTERS HUG	1
1.3B BOOKS OR BOOKS CHAPTERS CHUV	1
2.1A POSTERS PRESENTATIONS HUG	29
2.1B POSTERS PRESENTATIONS CHUV	16
3.1A CONGRESSES & SYMPOSIA HUG	11
3.1B CONGRESSES & SYMPOSIA CHUV	8
3.2A CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES HUG	19
3.2B CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES CHUV	30
4.1A THESIS PRESENTED HUG	1
4.1B THESIS PRESENED CHUV	1

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

Pharmacoeconomics	2.66
Eur.J.Clin.Pharmacol.	2.85
Qual.Saf.Health Care	1.68
Pharmacotherapy	2.90
Am.J.Health-Syst.Pharm.	1.96
Ann.Pharmacother.	2.12
Int.J.Qual.Health Care	1.96
J.Pharm.Pharmacol.	2.17
Swiss Med.Wkly	1.89
Int. J. Clin. Pharm. (IJCP)	1.18

PR=peer reviewed

1.1A SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR) **HUG**

1. S. NUSSBAUMER, L. GEISER, F. SADEGHIPOUR, D. HOCHSTRASSER, P. BONNABRY, J.-L. VEUTHEY, S. FLEURY-SOUVERAIN. *Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces*. Analytical Bioanalytical Chemistry, 402, 2499-509, **2012**. 3.8
2. S. BERTHOUSOZ, L. BERGER, P. BONNABRY, A. PANNATIER. *The hospital pharmacist: an important contributor to improved patient safety in the hospital*. Chimia, 66, 300-3, **2012**. 1.1

3. L. GSCHWIND, V. ROLLASON, C. LOVIS, F. BOEHLEN, P. BONNABRY, P. DAYER, J.-A. DESMEULES. 2.8
Identification and weighting of most critical "real-life" drug-drug interactions with acenocoumarol in tertiary care hospital. European Journal of Clinical Pharmacology doi: 10.1007/s00228-012-1358-7, **2012**.
4. L. BOUCHOUD, C. FONZO-CHRISTE, M. KLINGMUELLER, P. BONNABRY. 3.3
Compatibility of intravenous medications with parenteral nutrition: in vitro evaluation. Journal of Parenteral and Enteral Nutrition doi: 10.1177/0148607112464239, **2012**
5. T. QUERUAU LAMERIE, S. NUSSBAUMER, B. DECAUDIN, S. FLEURY-SOUVERAIN, J.-F. GOOSSENS, 1.9
P. BONNABRY, P. ODOU. *In Vitro evaluation of decontamination efficacy of cleaning solutions on stainless steel and glass surfaces contaminated by 10 antineoplastic agents.* Annals of Occupational Hygiene, doi: 10.1093/annhyg/mes087, **2012**.

1.1B SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR) CHUV

1. A.-L. SIDLER-MOIX, T. MERCIER, L.-A. DECOSTERD, E. DI PAOLO, M. BERGER-GRYLLAKI, J. COTTING, A. PANNATIER. 1.97
A highly sensitive LC-tandem MS assay for the measurement in plasma and in urine of salbutamol administered by nebulization during mechanical ventilation in healthy volunteers. Biomed Chromatogr., 26(5), 672-80, **2012**.
2. C. PLÜSS-SUARD, A. PANNATIER, C. RUFFIEUX, G. KRONENBERG, K. MÜHLEMANN, G. ZANETTI. 4.84
Changes in the use of broad-spectrum antibiotics after cefepime shortage: a time series analysis. Antimicrob. Agents Chemother., 56(2), 989-994, **2012**.
3. J.-C. DEVAUD, M.M. BERGER, A. PANNATIER, P. MARQUES-VIDAL, L. TAPPY, N. RODONDI, R. CHIOLERO, P. VOIROL. 5.40
Hypertriglyceridemia: a potential side effect of propofol sedation in critical illness. Intensive Care Med, DOI 10.1007/s00134-012-2688-8; 38:1990–1998, **2012**
4. V. HUMBERT-DELALOYE, M. BERGER, P. VOIROL, A. PANNATIER. 0.15
In vitro compatibility of remifentanyl hydrochloride and sufentanil citrate with selected drugs. European Journal of Hospital Pharmacy, 19:57-64, **2012**.
5. F.L. MUNIER, M.-C. GAILLARD, A. BALMER, S. SOLIMAN, G. PODILSKY, A.P. MOULIN, M. BECK-POPOVIC. 2.90
Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol, 96, 1078-1083, **2012**.
6. E. DI PAOLO, M. GEHRI, L. OUEDRAOGO-RUCHET, G. SIBAILLY, N. LUTZ, A. PANNATIER. 1.89
Outpatient prescriptions practice and writing quality in a paediatric university hospital. Swiss Med Wkly, 142, 13564, **2012**.
7. S. PROT-LABARTHE, E. DI PAOLO, A. LAVOIE, S. QUENNERY, J.-F. BUSSIERES, F. BRION, O. BOURDON. 1.18
Pediatric drug-related problems: a multicenter study in four French-speaking countries. Int J Clin Pharm, DOI 10.1007/s11096-012-9740-1, **2012**
8. C. BEZ, N. PERROTTET, T. ZINGG, E.L. LEUNG KI, N. DEMARTINES, A. PANNATIER. 1.23
Stress ulcer prophylaxis in non-critically ill patients: a prospective evaluation of current practice in a general surgery department. J Eval Clin Pract, DOI 10.1111, **2012**.
9. S. BERTHOUSOZ, L. BERGER, P. BONNABRY, A. PANNATIER. 1.21
The Hospital Pharmacist : An Important Contributor to Improved Patient Safety in the Hospital. Chimia, 66(5), 300-303, **2012**.

1.2A SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR) HUG

1. T. QUERUAU LAMERIE, L. CARREZ, B. DECAUDIN, L. BOUCHOUD, J.-F. GOOSSENS, C. BARTHELEMY, P. BONNABRY, P. ODOU. *Multiple-test assessment of devices to protect healthcare workers when administering cytotoxic drugs to patients.* Journal of Oncology Pharmacy Practice, 18, 191-200, **2012**.

2. F. SADEGHIPOUR, K. ING LORENZINI, C. ZIEWITZ, M. DOBRINAS, M. FLEURY, P. BONNABRY. *Chemical contamination during the preparation of cytotoxics : Validation protocol for operators in hospital pharmacies*. Journal of Oncology Pharmacy Practice, 19, 57-64, **2012**.
3. L.-Z. KAESTLI, C. FONZO-CHRISTE, C. BONFILLON, J. DESMEULES, P. BONNABRY. *Development of a standardised method to recommend protective measures to handle hazardous drugs in hospitals*. European Journal of Hospital Pharmacy Science and Practice, doi: 10.1136/ejpharm-2012-000222, **2012**.
4. P. BONNABRY. *La recherche en pharmacie hospitalière*. Le Moniteur hospitalier, 237, 19-29, **2012**.
5. L.-Z. KAESTLI, C. FONZO-CHRISTE, P. BONNABRY, K. POSFAY-BARBE. *Confusion between valGANCiclovir (Valcyte®) and vALAcyclovir (Valtrex®)*, Swiss Medical Weekly, 142, 1-2, **2012**.
6. L. GSCHWIND, C. FONZO-CHRISTE, P. BONNABRY, R. PFISTER. *Administration de médicaments au nouveau-né par le cathéter ombilical*. Pharmactuel, 45, 175-8, **2012**.
7. J.-C. DEVAUD, T. SIGRIST, C. ZAUGG, A. PANNATIER, P. BONNABRY. *Proposition d'une marche à suivre pour la gestion et prévision d'extravasation d'agent non cytotoxiques*. Pharmactuel, 45, 132-6, **2012**.
8. K. ING LORENZINI, B. REUTEMANN, C.-F. SAMER, B. GUIGNARD, P. BONNABRY, P. DAYER, P. PERRIER, J. DESMEULES. *Quel programme informatique de détection des interactions médicamenteuses néfastes ?* Revue Médicale Suisse, 8, 1978-82, **2012**.
9. M. BERGMANN, B. GUIGNARD, C. RIBI. *Hypersensibilité aux inhibiteurs de la pompe à protons*. Revue Médicale Suisse, 8, 830-5, **2012**.

1.2B SCIENTIFIC PUBLICATIONS (WITHOUT IMPACT FACTOR) CHUV

- | | | |
|----|--|----|
| 1. | C. CARRON, P. VOIROL, EGGIMANN P., PANNATIER A., CHIOLERO R., WASSERFALLEN J.-B. <i>Five-Year Evolution of Drug Prescribing in a University Adult Intensive Care Unit</i> . Appl Health Econ Health Policy, 10(5), 355-358, 2012 . | PR |
| 2. | V. HUMBERT-DELAHOYE, S. MARTY, M. BERGER-GRYLLAKI, A. PANNATIER. <i>Mischung von Phenhydantol® Injektionslösung</i> . Krankenhauspharmazie, 33:68-72, 2012 | PR |
| 3. | J.-C. DEVAUD, T. SIGRIST, C. ZAUGG, B. GUIGNARD, A. PANNATIER, P. BONNABRY. <i>Proposition d'une marche à suivre pour la gestion et la prévention d'extravasation d'agents non cytotoxiques</i> . Pharmactuel, 45(2), 132-136, 2012 | PR |
| 4. | E.R. DI PAOLO, A. PANNATIER, G. HAFEN. <i>Quels sont les dangers liés à l'utilisation de suppositoires à base d'huiles essentielles chez les petits enfants ?</i> Paediatrica, 23(4), 35-36, 2012 | PR |

1.3A BOOKS OR BOOKS CHAPTERS HUG

1. B. GUIGNARD, C. CSAJKA, J. BENEY, O. BUGNON, P. BONNABRY. *La pharmacie Clinique en Suisse romande*. Pharmacie Clinique et thérapeutique. J. Calop, 4ème édition, Elsevier Masson, **2012**.

1.3B BOOKS OR BOOKS CHAPTERS CHUV

1. B. TESTA, A. PANNATIER. *Role of Phase I Metabolism in Drug Activation and Clinical Treatment Outcomes*. Encyclopedia of Drug Metabolism and Interactions, 6-Volume Set, First Edition, Chapter 11. Edited by Alexander V. Lyubimov. 2012 John Wiley & Sons, Inc. Published by John Wiley & Sons, Inc. P. 1-23, **2012**

2. PRESENTATIONS

2.1A POSTERS PRESENTATIONS HUG

1. C. FONZO-CHRISTE, A. COEHLO, C. ZAUGG, Y. LEVY-JAMET, R. PFISTER, P. RIMENSBERGER, B. GUIGNARD, P. BONNABRY. *Effects of clinical decision support on TDM of gentamicin and vancomycin in newborns*. 17th European Congress of the Association of Hospital Pharmacists, **2012**, Milano.
2. H. BAUDET, V. Mc LIN, P. PARVEX, H. CHEHADE, C. COMBESCURE, C. SAMER, P. BONNABRY, C. FONZO-CHRISTE, K. POSFAY-BARBE. *TDM and stabilization of pediatric patients in liver and kidney transplantation*. 17th European Congress of the Association of Hospital Pharmacists, **2012**, Milano.
3. H. BAUDET, J. LEHMANN, S. FLEURY-SOUVERAIN, S. SADEGHIPOUR, P. BONNABRY. *Preparation of capsules for individual patients: validation of the operator's accuracy*. 17th European Congress of the Association of Hospital Pharmacists, **2012**, Milano.
4. M. MATTIUZZO, S. NUSSBAUMER, F. SADEGHIPOUR, S. FLEURY-SOUVERAIN, P. BONNABRY. *Cytotoxic surface contamination in 24 Swiss hospital pharmacies*. 17th European Congress of the Association of Hospital Pharmacists, **2012**, Milano.
5. M. MATTIUZZO, L.-Z. KAESTLI, B. GUIGNARD, A.-F. WASILEWSKI-RASCA, C. FONZO-CHRISTE, P. BONNABRY. *A web page for community pharmacists to improve continuity of care between hospital and ambulatory care*. 17th European Congress of the Association of Hospital Pharmacists, **2012**, Milano.
6. M. MATTIUZZO, S. NUSSBAUMER, F. SADEGHIPOUR, S. FLEURY-SOUVERAIN, P. BONNABRY. *Chemical contamination during the preparation of cytotoxics: a multi-site simulation study*. 17th Congress of the Association of Hospital Pharmacists, **2012**, Milano.
7. N. VERNAZ, G. HALLER, F. GIRARDIN, B. HUTTNER, P. DAYER, D. MUSCIONICO, J.-L. SALOMON, P. BONNABRY. *Pseudo-Innovations ; une stratégie payante d'extension des brevets ?* 17^{èmes} Journées Franco-Suisses de Pharmacie Hospitalière, **2012**, Lons-Le-Saulnier.
8. S. SENHAJI, S. FLEURY-SOUVERAIN, F. SADEGHIPOUR, P. BONNABRY. *Validation de la conformité particulière non-viable (non-visible) des préparations de solutions injectables*. 17^{ème} Journées Franco-Suisses de Pharmacie Hospitalière **2012**, Lons-le-Saulnier.
9. O. FRANCOIS, L. CARREZ, L. GSCHWIND, P. BONNABRY. *Robotisation de la distribution globale des médicaments : impact sur le taux d'erreur*. 17^{ème} Journées Franco-Suisses de Pharmacie Hospitalière, **2012**, Lons-Le-Saulnier.
10. D. CARLI, H.-M. SEIDLING, C. LOVIS, P. BONNABRY. *Classification et recensement des aides à la décision implémentées dans les logiciels de prescription informatisée des établissements suisses*. 17^{èmes} Journées Franco-Suisses de Pharmacie Hospitalière, **2012**, Lons-Le-Saulnier.
11. S. FLEURY-SOUVERAIN, S. NUSSBAUMER, M. MATTIUZZO, P. BONNABRY. *Evaluation de la contamination chimique externe de flacons de cytotoxiques disponibles sur le marché suisse*. 17^{èmes} Journées Franco-Suisses de Pharmacie Hospitalière, **2012**, Lons-Le-Saulnier.
12. M. MATTIUZZO, O. FRANCOIS, C. COMBESCURE, R. PIGNEL, C. FONZO-CHRISTE, P. BONNABRY. *Utilisation d'un aérosol-doseur de salbutamol en chambre hyperbare*. 17^{èmes} Journées Franco-Suisses de Pharmacie Hospitalière, **2012**, Lons-Le-Saulnier.
13. M. MATTIUZZO, O. FRANCOIS, C. COMBESCURE, P. BONNABRY, C. FONZO-CHRISTE, R. PIGNEL. *Influence of hyperbaric pressure on salbutamol metered dose inhaler performances*. Société Suisse pour la médecine subaquatique et hyperbare, **2012**. Crans-Montana.
14. O. FRANCOIS, S. DUMONT, B. MUGNIER, C. PICOT, M.-F. METIVIER, P. CHOPARD, N. VERNAZ-HEGI, P. BONNABRY. *Automated dispensing systems: how could they improve the efficiency of drug logistic process ?* ISQUA'S 29th International conference, **2012**, Genève.
15. L. CINGRIA, L. CARREZ, J.-M. MENU, C. RACIOPPI, A. SCHROECKER, P. BONNABRY. *Prospective risk analysis of the drug distribution process: impact of information technologies*. ISQUA'S 29th International conference, **2012**, Genève.

16. Y.-M. DUPERTUIS, G. BENZAKOUR, L. BOUCHOUD, F. CAI, P. BONNABRY, C. PICHARD. *Measurement of particle release from different infusion sets during the outflow of parenteral nutrition*. 34th ESPEN congress on clinical nutrition and metabolism, **2012**, Barcelone.
17. O. EI-HADEUF GAOUAR, L. BOUCHOUD, V. ADAMO, H. SCHWEBEL, J.-C. DEVAUD, A. PANNATIER, P. BONNABRY. *Mise au point d'une forme sèche de nutrition parentérale pédiatrique destinée à des pays en développement*. 10^{èmes} Journées Francophones de Nutrition, **2012**, Lyon.
18. L. BOUCHOUD, C. FONZO-CHRISTE, M. KLINGMUELLER, P. BONNABRY. *Evaluation de la compatibilité physique entre une nutrition parentérale totale et 25 médicaments fréquemment co-administrés*. 10^{èmes} Journées Francophones de Nutrition, **2012**, Lyon.
19. Y. DUPERTUIS, G. BENZAKOUR, F. CAI, L. BOUCHOUD, P. BONNABRY, C. PICHARD. *Mesure de la désorption de particules pendant l'écoulement de la nutrition parentérale à travers différents sets de perfusion*. 10^{èmes} Journées Francophones de Nutrition, **2012**, Lyon.
20. C. FOLCH, L.-Z. KAESTLI, C. FONZO-CHRISTE, P. BONNABRY. *Evaluation d'une page Internet à l'interface des médecins hospitaliers et des pharmaciens d'officine*. Congrès GSASA, **2012**, Baden.
21. L.-Z. KAESTLI, C. FONZO-CHRISTE, S. CHARLIER, P. BONNABRY. *Continuité des soins en pédiatrie : étude clinique prospective à la sortie de l'hôpital*. Congrès GSASA, **2012**, Baden.
22. O. FRANCOIS, S. DUMONT, M.-F. METIVIER, N. VERNAZ-HEGI, P. BONNABRY. *Impact d'une armoire à pharmacie automatisée sur la logistique dans une unité de soins*. Congrès GSASA, **2012**, Baden.
23. O. FRANCOIS, C. FONZO-CHRISTE, S. JEAN-MAIRET, L. SUPPAN, E. GERMION, P. BONNABRY. *Médicaments et température dans un véhicule d'urgence : état des lieux*. Congrès GSASA, **2012**, Baden.
24. C. BRUGGMANN, L. CINGRIA, P. CARME, B. BURTIN, N. VERNAZ, P. BONNABRY. *Gestion des ruptures de médicaments : ampleur et coûts*. Congrès GSASA, **2012**, Baden.
25. M. FLEURY, L. BOUCHOUD, P. BONNABRY. *Experts, fonctionnels ou résistants : utilisateurs des technologies de l'information à l'hôpital, qui êtes-vous ?* Congrès GSASA, **2012**, Baden.
26. O. FRANCOIS, S. DUMONT, M.-F. METIVIER, N. VERNAZ-HEGI, P. BONNABRY. *Impact d'une armoire à pharmacie automatisée sur la logistique dans une unité de soins*. Congrès GSASA, **2012**, Baden.
27. B. GUIGNARD, C. SAMER, A. PERRIER, P. BONNABRY, P. DAYER, J. DESMEULES. *Drug-related problems in a general internal medicine service*. 41th European Symposium on clinical pharmacy (ESCP), **2012**, Barcelone.
28. N. VERNAZ, G. HALLER, F. GIRARDIN, B. HUTTNER, P. DAYER, D. MUSCIONICO, J.-L. SALOMON, P. BONNABRY. *Patented drug extension strategies on healthcare spending: A cost-evaluation analysis*. ISPOR 15th Annual European Congress, 2012, Berlin.
29. O. FRANCOIS, N. VERNAZ-HEGI, L. CINGRIA, B. BURTIN, D. TSCHOPP, J.-M. MENU, C. RACIOPPI, O. BOREL, B. GIVRY, P. BONNABRY. *Robotisation de la distribution des médicaments à la Pharmacie des HUG : une amélioration de la sécurité et de l'efficacité*. Journée Qualité HUG, **2012**, Genève.

2.2B POSTERS PRESENTATIONS CHUV

1. E. WEIBEL, I. DE GIORGI, M. BENMEBAREK, G. JAQUIER, A. DE RHAM, A. PANNATIER. *Analyse de risques du circuit de la méthadone et de son flux logistique en milieu carcéral et propositions de mesures d'amélioration*. Congrès de la GSASA, **2012**, Baden (Suisse).
2. E. WEIBEL, I. DE GIORGI, M. BENMEBAREK, G. JAQUIER, A. DE RHAM, B. GRAVIER, A. PANNATIER. *Analyse de risques du circuit et du flux logistique de la méthadone en milieu carcéral*. 15^e Journée de Recherche des départements de Psychiatrie de Lausanne et de Genève, **2012**, Belle-Idée, Chêne Bourg (Suisse).
3. P. PAVIE, M.C. GROUZMANN, S. LAMON, J.-C. DEVAUD, M. BERGER, R. CHIANESE, G. PODILSKY, A. PANNATIER. *Application d'une matrice occurrence-conséquence dans l'analyse de risque d'un processus de fabrication hospitalière*. 17^{èmes} JFSPH, **2012**, Lons-le-Saunier (France).
4. M.C. GROUZMANN, S. LAMON, G. PODILSKY, A. PANNATIER. *Batch or named-patient preparation: introduction of a decision algorithm*. 17^{ème} Congrès EAHP, **2012**, Milan (Italie).

5. C. ROSSIRE, E. DI PAOLO, L. BERGER, S. LAMON, G. HAFEN, A. PANNATIER. *Comparaison de trois diffuseurs portables pour l'administration de ceftazidime chez les enfants atteints de mucoviscidose.*
Congrès de la GSASA, **2012**, Baden (Suisse).
6. I. DE GIORGI, B. GRAVIER, A. PANNATIER. *Déploiement d'une politique pharmaceutique institutionnelle universitaire dans les prisons : partage d'expérience.*
Congrès de la GSASA, **2012**, Baden (Suisse).
7. M.-L. WEIBEL, J.-F. MALL, P. VOIROL, A. PANNATIER, A. VON GUNTEN, I. DE GIORGI. *Etat des lieux de la médication et prescription médicamenteuse inappropriée en psychiatrie de l'âge avancé.*
Congrès de la GSASA, **2012**, Baden (Switzerland).
8. S. GONZALEZ, M. GIKIC, P.-G. MEISTER, A. PANNATIER. *Evaluation de la prise en charge de la gestion de pharmacies d'unités de soins par des assistantes en pharmacie.*
Congrès de la GSASA, **2012**, Baden (Suisse).
9. A. HENRY, P. EGGIMANN, M.M. BERGER, A. PANNATIER, Y.A. QUE, P. VOIROL. *Evolution de l'utilisation des anti-infectieux chez les patients brûlés dans un Centre suisse de référence.*
Congrès de la GSASA, **2012**, Baden (Suisse).
Congrès de la SSMI, **2012**, Bâle (Suisse).
10. S. MARTIGNONI, G. PODILSKY, B. GAY, A. PANNATIER. *Intérêt du dose banding dans la préparation de diffuseurs portables de 5-FU en ambulatoire.*
Congrès de la GSASA, **2012**, Baden (Suisse). (poster primé)
11. P. PAPIN, P. VOIROL, A. PANNATIER, M. BERGER. *La sédation-analgésie chez le patient grand brûlé est-elle excessive ?*
17^{èmes} JFSPH, **2012**, Lons-le-Saunier (France).
12. P. VOIROL, L. GATTLEN, T. FUMEAUX, P. ECKERT. *SIPHAROM : un groupe de travail interdisciplinaire en Suisse latine sur l'utilisation des médicaments en soins intensifs.*
Congrès de la GSASA, **2012**, Baden (Suisse).
Congrès de la SSMI, **2012**, Bâle (Suisse).
13. C. ROSSIRE, L. BERGER, E. DI PAOLO, S. LAMON, G. HAFEN, A. PANNATIER. *Stabilité de la ceftazidime administrée à l'aide d'un diffuseur portable chez les enfants atteints de mucoviscidose.*
Congrès de la GSASA, **2012**, Baden (Suisse).
14. C. PLÜSS-SUARD, A. PANNATIER, A. KRONENBERG, K. MÜHLEMANN, G. ZANETTI. *Utilisation des antibiotiques et résistance des Pseudomonas Aeruginosa aux carbapénèmes dans les hôpitaux suisses.*
17^{èmes} JFSPH, **2012**, Lons-le-Saunier (France).
15. C. JOSEPH, M.-J. THEVENIN, P. VOIROL, G. ZANETTI, J.-P. REVELLY, P. EGGIMANN. *Sustained Reduction of Catheter-Related Infections after Introduction of Chlorhexidine (CHX)-Impregnated Dressings.*
52nd ICAAC, **2012**, San Francisco (USA).
16. M.A. VON SIEBENTHAL, E.R. DI PAOLO, J. COTTING. *Classification et évaluation de la gravité des erreurs médicamenteuses dans une unité de soins intensifs pédiatrique.*
7^{ème} Demi-journée de Recherche du Département médico-chirurgical de Pédiatrie du CHUV, **2012**, Lausanne (Suisse).

3. ORAL PRESENTATIONS

3.1A CONGRESSES & SYMPOSIA HUG

1. P. BONNABRY, S. FLEURY. *Contrôle des préparations : place des nouveaux outils analytiques – application à la nutrition parentérale.*
Congrès de la Société Française de Pharmacie Clinique (SFPC), **2012**, Bordeaux (France).
2. P. BONNABRY. *Logistique hospitalière des produits de santé : expérience genevoise.*
Journée de formation de l'APHBFC, **2012**, Dijon (France).
3. P. BONNABRY. *Comment convaincre la direction ? Vision d'un pharmacien hospitalier.*
Congrès de la GSASA, **2012**, Baden (Switzerland).
4. P. BONNABRY. *Scanning des chimiothérapies au lit du patient : de la RFID au Datamatrix.*
International RFID congress, **2012**, Nice (France).

5. O. FRANCOIS. *Automated dispensing system: how could they improve the efficiency of the drug logistic process ?*
ISQua – The International society for quality in healthcare, 29th international conference, **2012**, Geneva (Switzerland).
6. P. BONNABRY. *The safety and pharmacoeconomics of ready-to-administer injections.*
Aesculap academia, **2012**, Birmingham (United-Kingdom).
7. P. BONNABRY. *Référentiels d'auto-évaluation ou d'évaluation externe de la qualité – témoignage d'un utilisateur.*
Safety Day annuel Pfizer, **2012**, Namur (Belgium).
8. P. BONNABRY. *Critères de choix des préparations injectables fabriquées à l'hôpital.*
Congrès du GERPAC, **2012**, La Grande Motte (France).
9. P. BONNABRY. *Analyse prospective des risques : de la théorie à la pratique.*
Journées pharmaceutiques MSD France, **2012**, Nice (France).
10. P. BONNABRY. *Automatisation et robotisation du circuit du médicament : revenons sur terre...*
Colloque sur l'automatisation en pharmacie hospitalière, **2012**, Lausanne (Switzerland).
11. P. BONNABRY. *The safety and pharmacoeconomics of ready to administer injections.*
Congrès de l'EAHP, **2012**, Milano (Italy)

3.1B CONGRESSES & SYMPOSIA CHUV

1. E. WEIBEL, I. DE GIORGI, M. BENMEBAREK, G. JAQUIER, A. DE RHAM, B. GRAVIER, A. PANNATIER. *Etude du circuit de la méthadone et de son flux logistique en milieu carcéral et propositions de mesures d'améliorations.*
TD03, **2012**, Genève (Switzerland).
2. S. MARTIGNONI, G. PODILSKY, B. GAY, A. PANNATIER. *Interest of dose banding in preparation of 5-FU infusors in ambulatory care.*
Congrès de la GSASA, **2012**, Baden (Suisse). (présentation primée)
3. L. BOUCHOUD, W. EL-HADEUF, V. ADAMO, H. SCHWEBEL, J.-C. DEVAUD, A. PANNATIER, P. BONNABRY. *Mise au point d'une forme sèche de nutrition parentérale pédiatrique à destination des pays en développement.*
10^{èmes} JFN, **2012**, Lyon (France).
4. S. MARTIGNONI, G. PODILSKY, B. GAY, A. PANNATIER. *Preparation of 5 FU's infusors: from anarchy to dose banding.*
15^{èmes} journées du GERPAC / 10^{èmes} journées européennes du GERPAC, **2012**, La Grande Motte (France). (présentation primée)
5. C. ROSSIRE, L. BERGER, E. DI PAOLO, S. LAMON, G. HAFEN, A. PANNATIER. *Stabilité de la ceftazidime administrée à l'aide d'un diffuseur portable chez les enfants atteints de mucoviscidose.*
Congrès de la GSASA, **2012**, Baden (Suisse).
6. P. PAVIE, G. PODILSKY, J.-C. DEVAUD, A. PANNATIER. *Training and Qualification of Manufacturing Operators in French and Swiss Hospitals: A Survey.*
15^{èmes} journées du GERPAC / 10^{èmes} journées européennes du GERPAC, **2012**, La Grande Motte (France).
7. A. PANNATIER, S. LAMON. *Préparation des nutriments entéraux « à la carte » : De la cuisine à la pharmacotechnie.*
10^{èmes} Journée Francophones de Nutrition (SFNEP), **2012**, Lyon (France).
8. S. FERRARI, P. HILD, A. PANNATIER. *Atelier : L'administration des chimiothérapies - Les risques et les moyens de les gérer.*
15^{èmes} journées du GERPAC / 10^{èmes} journées européennes du GERPAC, **2012**, La Grande Motte (France).

3.2A CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES HUG

1. P. BONNABRY. *IT to improve the safety of the medication process at the hospital*. Berner Fachhochschule, **2012**, Geneva (Switzerland).
2. P. BONNABRY. *Analyse prospective des risques: application de la méthode AMDEC*. D.U.E.C. préparations aseptiques, Master techniques pharmaceutiques hospitalière. Université de Lille, **2012**, Lille (France).
3. P. BONNABRY. *Stratégie d'organisation de la recherche en pharmacie hospitalière*. D.U.E.C. préparations aseptiques, Master techniques pharmaceutiques hospitalière. Université de Lille, **2012**, Lille (France).
4. P. BONNABRY. *Analyse prospective des risques: application de la méthode AMDEC*. Diplôme universitaire (DU) d'analyse et de gestion des risques en santé. Université René Descartes, **2012**, Paris (France).
5. P. BONNABRY. *Stratégie de sécurisation du circuit du médicament : apport des technologies de l'information*. Diplôme universitaire (DU) d'analyse et de gestion des risques en santé, Université René Descartes, **2012**, Paris (France).
6. F. SADEGHIPOUR. *Le rôle de la pharmacie dans les essais cliniques*. BPEC, Cours des HUG / Faculté de médecine, Hôpital des Enfants, **2012**, Genève (Switzerland).
7. P. BONNABRY. *Stratégie d'amélioration de la sécurité du circuit du médicament*. Formation « Coordinateur sécurité des patients », **2012**, Lausanne (Switzerland).
8. P. BONNABRY. *Analyse prospective des risques : application de la méthode AMDEC*. Formation « Coordinateur sécurité des patients », **2012**, Lausanne (Switzerland).
9. B. GUIGNARD, C. FONZO-CHRISTE. *Désinfection*. Formation post-diplôme du domaine opératoire, Hôpitaux Universitaires de Genève, **2012**, Geneva (Switzerland).
10. L.-Z. KAESTLI, C. GUEGUENIAT-DUPESSEY, ET AL. *Médicaments: de la commande à l'administration*. Centre de formation, Hôpitaux Universitaires, **2012** (3 sessions), Geneva (Switzerland).
11. P. BONNABRY, F. SADEGHIPOUR, V. HERRERA, ET AL. *Maîtrise de la fabrication en milieu aseptique*. Pharmacie des Hôpitaux Universitaires de Genève, **2012**, Geneva (Switzerland).
11. C. FONZO. *TDM gentamicine et vancomycine en neonatologie et en pédiatrie*. Colloque hebdomadaire de pharmacologie et toxicologie cliniques, HUG, **2012**, Geneva (Switzerland).
12. P. BONNABRY, *Analyse prospective des risques: application de la méthode AMDEC*. Certificat qualité des soins, Université de Genève, **2012**, Geneva (Switzerland).
13. O. FRANCOIS, S. DUMONT. *Pharmacie automatisée : expérience dans une unité de soins*. Conférence CIPIQs, Améliorer la sécurité du processus médicament, **2012**, Geneva (Switzerland).
14. P. BONNABRY. *Seringues prêtes à l'emploi : construisons le futur ensemble*. Colloque d'anesthésiologie HUG, **2012**, Geneva (Switzerland).
15. P. BONNABRY, *Méthodes d'analyse prospective des risques : exemple en pharmacie hospitalière*. Formation des cadres au management « Gérer les incidents en milieu hospitalier » Hôpitaux Universitaires de Genève, **2012**, Geneva (Switzerland).
16. C. FONZO. *Particules : incompatibilités physico-chimiques et filtres en ligne*. Séminaire MAS de pharmacie hospitalière « Assistance pharmaceutique et pharmacie clinique ». Section des sciences pharmaceutiques, Université de Genève, **2012**, Genève (Switzerland).
17. T. SIGRIST, C. GUEGUENIAT-DUPESSEY. *Bonnes pratiques infirmières d'administration des médicaments*. Séminaire MAS de pharmacie hospitalière « Assistance pharmaceutique et pharmacie clinique ». Section des sciences pharmaceutiques, Université de Genève, **2012**, Genève (Switzerland).
18. C. FONZO, N. BOCHATON. *Pousses-seringues, smart-pumps et filtres en ligne*. Séminaire MAS de pharmacie hospitalière « Assistance pharmaceutique et pharmacie clinique ». Section des sciences pharmaceutiques, Université de Genève, **2012**, Genève (Switzerland).
19. B. GUIGNARD, M. PERREAULT. *Démarche d'analyse de pharmacotherapy*. Séminaire MAS de pharmacie hospitalière « Assistance pharmaceutique et pharmacie clinique ». Section des sciences pharmaceutiques, Université de Genève, **2012**, Genève (Switzerland).

3.2B CONTINUING EDUCATION & OPEN TO THE PUBLIC LECTURES CHUV

1. P. VOIROL. *Définition de la pharmacie clinique hospitalière en Suisse*. Séminaire MAS, HUG-EPGL, **2012**, Genève (Suisse).
2. P. VOIROL. *Coûts du fastfood versus gastronomie*. Journée de nutrition en Soins Intensifs, CHUV, **2012**, Lausanne (Suisse).
3. C. PLÜSS-SUARD. *Changes in the Use of Broad-Spectrum Antibiotics after Cefepime Shortage: a time-series analysis*. Club de Pathologie Infectieuse, Hôpital de l'Île, **2012**, Berne (Suisse).
4. C. PLÜSS-SUARD. *Antibiotic consumption and pattern of resistance*. Séminaire de pharmacie clinique, Hôpital cantonal, **2012**, Bruderholz (Suisse).
5. C. PLÜSS-SUARD. *Consommation des antibiotiques et résistances bactériennes : tendances en Suisse et en Europe*. Colloque PHA-PCL, CHUV, **2012**, Lausanne (Suisse).
6. E. DI PAOLO. *Sources d'information sur les médicaments, interactions et incompatibilités médicamenteuses*. Cours aux médecins des soins intensifs de pédiatrie, CHUV, **2012**, Lausanne (Suisse).
7. E. DI PAOLO. *Prescription des médicaments en pédiatrie*. Cours aux médecins-assistants du DMCP, HEL-CHUV, **2012**, Lausanne (Suisse).
8. E. DI PAOLO. *Incompatibilités physico-chimiques des médicaments injectables et administration des médicaments par sonde*. Cours aux infirmiers en Soins intensifs, CHUV, **2012**, Lausanne (Suisse).
9. E. DI PAOLO. *Pharmacologie du SNC et respiratoire*. Cours aux infirmières, Espace Compétences, **2012**, Cully (Suisse).
10. E. DI PAOLO. *Mode d'emploi de quelques dispositifs d'inhalation*. Pharmakey, **2012**, St-Sulpice (Suisse).
11. E. DI PAOLO. *Administration de médicaments en inhalation*. Séminaire MAS « Dispositifs médicaux et matériovigilance », CHUV, **2012**, Lausanne (Suisse).
12. E. DI PAOLO. *Gestion des médicaments en pédiatrie*. PHV : prévention des événements indésirables liés aux médicaments, **2012**, Prilly (Suisse).
13. E. DI PAOLO. *Médicaments inhalés*. Cours aux physiothérapeutes, HESAV, **2012**, Lausanne (Suisse).
14. A. PANNATIER. *La mise sur pied d'un essai clinique : aspects pharmaceutiques, gestion du produit, liste de randomisation*. Cours « L'essai clinique », Société suisse de pharmacologie et de toxicologie, séminaire MAS « Dispositifs médicaux et matériovigilance », CHUV, **2012**, Lausanne (Suisse).
15. T. BUCLIN, A. PANNATIER. *Aspects pharmaceutiques de Bonnes Pratiques Cliniques*. Certificat de formation continue en recherche clinique, Faculté de biologie et de médecine, UNIL, **2012**, Lausanne (Suisse).
16. A. PANNATIER. *Les ruptures d'approvisionnement : fatalité ou stratégie industrielle*. Colloques communs de Pharmacologie Clinique-Pharmacie, CHUV, **2012**, Lausanne (Suisse).
17. A. PANNATIER, E. DI PAOLO. *Les formes orales : spécificités de la pédiatrie*. DIU de pharmacotechnie hospitalière, Université René Descartes, **2012**, Paris (France).
18. A. PANNATIER. *Les formes orales : spécificités de la gériatrie*. DIU de pharmacotechnie hospitalière, Université René Descartes, **2012**, Paris (France).
19. A. PANNATIER, G. PODILSKY. *Administration des formes orales par sonde de nutrition*. DIU de pharmacotechnie hospitalière, Université René Descartes, **2012**, Paris (France).
20. P. PAVIE. *Latrogénie chez l'enfant, la femme enceinte et la personne âgée*. Cours aux APH, CHUV, **2012**, Lausanne (Suisse).
21. J.-C. DEVAUD. *Facteurs de risque de l'hypertriglycéridémie chez le patient agressé*. Journée Nutrition en soins intensifs : « Le point sur les éléments traces et les lipides en réanimation », CHUV, **2012**, Lausanne (Suisse).
22. J.-C. DEVAUD. *Maîtrise des risques*. Certificat d'Opérateur de Production Hospitalière, GPHR, **2012**, Lausanne (Suisse).
23. B. HIRSCHI. *Gestion des lots dans les unités de soins, à l'exemple des dérivés stables du sang*. Forum logistique des soins, **2012**, Lausanne (Suisse).

24. B. HIRSCHI. *Sécurisation du circuit du médicament à l'hôpital*. CAS en management de la santé, **2012**, Lausanne (Suisse).
25. G. Podilsky. *Administration de médicaments par voie entérale*. Séminaire MAS « Dispositifs médicaux et matériovigilance », CHUV, **2012**, Lausanne (Suisse).
26. G. Podilsky. *Atelier NEAD, la sonde naso-gastrique. Administration des médicaments*. Journées de printemps de la Société Française de Nutrition Clinique et Métabolisme, SFNEP, **2012**, Montpellier (France).
27. G. Podilsky. *Manipulation des cytotoxiques. Différencier les médicaments et règles pour la préparation*. Formation continue professionnelle, CHUV, **2012**, Lausanne (Suisse).
28. G. Podilsky. *Manipulation des cytotoxiques. Atelier accident*. Formation continue professionnelle, CHUV, **2012**, Lausanne (Suisse).
29. G. Podilsky. *Dis-moi ce que tu manges, je te dirai qui tu es. La nutrition par le tuyau*. Formation régionale pour les assistantes en pharmacie hospitalière, GPHR, **2012**, Lausanne (Suisse).
30. G. Podilsky. *Préparation des cytotoxiques*. Certificat d'Opérateur de Production Hospitalière, GPHR, **2012**, Lausanne (Suisse).

4. THESIS PRESENTED

4.1. INTRA-MUROS THESIS (HUG)

1. Liliane GSCHWIND
Anticoagulation par antivitamines K: analyse des interactions médicamenteuses et des polymorphismes génétiques à l'origine de la variabilité de la réponse et des risques liés à l'acénocoumarol
 University of Geneva – 2012 –
 Supervisor: Prof. J. DESMEULES
 Co-Supervisor: Prof. P. BONNABRY

4.2. INTRA-MUROS THESIS (CHUV)

1. Catherine PLÜSS-SUARD
Suivi de la consommation des antibiotiques pour la promotion de leur bon usage et la maîtrise de la résistance bactérienne en milieu hospitalier : mise en place et exemples d'utilisation.
 University of Geneva – **2012** –
 Supervisor: Prof. A. PANNATIER
 Co-supervisor: Prof. G. ZANETTI

HONORARY PROFESSORS



HONORARY PROFESSOR

GURNY Robert

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)	9
2.1 POSTERS PRESENTATIONS	10
3.1 CONGRESSES & SYMPOSIA	9

1. PUBLICATIONS

THE TOP TEN JOURNALS IN THE FIELD (WITH IMPACT FACTOR)

J Control Release	6.49
Int J Nanomed	3.13
Eur J Pharm Biopharm	4.26
Int J Pharmaceut	3.35
Eur J Pharm Sci	3.21
J Pharm Sci-US	3.05
J Drug Target	2.69
Life Sci	2.52
J Pharm Pharm Sci	1.64

PR=peer reviewed

1.1 SCIENTIFIC PUBLICATIONS (WITH IMPACT FACTOR)

1. A.O. KASIMOVA, G.M. PAVAN, A. DANANI, K. MONDON, A. CRISTIANI, L. SCAPOZZA, R. GURNY, AND M. MÖLLER *Validation of a novel molecular dynamics simulation approach for lipophilic drug incorporation into polymer micelles* J Phys Chem B, 116(14), 4338-4345 (2012)
DOI:10.1021/jp2104819, 3.69
2. M. RODRIGUEZ-ALLER, B. KAUFMANN, D. GUILLARME, C. STELLA, P. FURRER, S. RUDAZ, I. ELZAOUI, F. VALAMENESH, C. DI TOMMASO, F. BEHAR-COHEN, J-L. VEUTHEY, R. GURNY *In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease* Eur. J. Pharm. Biopharm, 80(3), 544-552 (2012).
DOI:10.1016/j.ejpb.2011.11.017; 4.26
3. S. DE VALENCE, J.-C. TILLE, D. MUGNAI, W. MROWCZYNSKI, R. GURNY, M. MÖLLER, B. H. WALPOTH *Long term performance of polycaprolactone vascular grafts in a rat abdominal aorta replacement model* Biomaterials 33, 38-47, 38-47 (2012).
Doi:10.1016/j.biomaterials.2011.09.024 ; 7.40
4. C. EENSCHOOTEN, A. VACCARO, F. DELIE, F. GUILLAUMIE, K. TØMMERAAS, G. M. KONTOTGEORGIS, K. SCHWACH-ABDELLAOUI, M. BORKOVEC, R.GURNY *Novel self-associative and multiphasic nanostructured soft carriers based on amphiphilic hyaluronic acid derivatives*. Carbohydrate Polymers 87, 444-451 (2012).
Doi 10.1016/j.carbpol.2011.08.004 ; 3.62

5. L.R. ASMUS, B. KAUFMANN, L. MELANDER, T. WEISS, G. SCHWACH, R. GURNY, M. MÖLLER *Single processing step toward injectable sustained-release formulations of Triptorelin based on a novel degradable semi-solid polymer*, Eur J Pharm Biopharm, 81(3), 591-599 (2012)
DOI:10.1016/j.ejpb.2012.04.015; 4.26
6. E. PATOIS, I.A. LARMOUR, S.E.J. BELL, C. PALAIS, M.A.H. CAPELLE, R. GURNY, T. ARVINTE *Ultraviolet resonance Raman spectroscopy used to study formulations of salmon calcitonin, a starch-peptide conjugate and TGF- β* Eur J Pharm Biopharm 81(2), 392-398 (2012)
DOI: 10.1016/j.ejpb.2012.02.016; 4.30
7. G. VACHER, C. GREMION, C. MOSER, S.A. STOFFEL, M. AMACKER, R. ZURBRIGGEN, R. GURNY, G. BORCHARD. *VIROSOMAL C. ALBICANS Vaccine for Vaginal Application: Formulation Development And Toxicity/Immunogenicity Studies*, Journal of Drug Delivery Science and Technology, 22 (5), 447-452 (2012) 0.62
8. C. DI TOMMASO, F. VALAMANESH, F. MILLER, P. FURRER, M. RODRIGUEZ-ALLER, F. BEHAR-COHEN, R. GURNY, M. MOELLER, *A Novel Cyclosporin A Aqueous Formulation For Dry Eye Treatment: In Vitro And In Vivo Evaluation IOVS*, 53(4), 2292-2299 (2012),
9. C. DI TOMMASO, J.-L. BOURGES, F. VALAMANESH, G. TRUBITSYN, A. TORRIGLIA, J.-C. JEANNY, F. BEHAR-COHEN, R. GURNY, M. MOELLER, *Novel micelle carriers for cyclosporin A topical ocular delivery: In vivo cornea penetration, ocular distribution and efficacy studies Eur J Pharm Biopharm*, 81(2), 257-264 (2012)
DOI:10.1016/j.ejpb.2012.02.014 4.30

2. PRESENTATIONS

2.1 POSTERS PRESENTATIONS

1. D. MUGNAI, J.-C. TILLE, W. MROWCZYNSKI, S. DE VALENCE, X. MONTET, R. GURNY, A. KALANGOS, M. MÖLLER, B. H. WALPOTH *Comparison of Biodegradable Polycaprolactone Vascular Grafts with ePTFE Grafts after Long-Term Implantation in the Rat Model*. 19th International Local Drug Delivery meeting and cardiovascular course on Revascularization and molecular strategies (LDDR). Geneva, Switzerland, February 2-4, 2012.
2. S. KADERLI, R. GURNY, L. SCAPOZZA, M. MÖLLER, *osteoarthritis viscosupplementation therapy: novel hyaluronic acid based hydrogels*, USGEB annual meeting, Lausanne, Switzerland, 2012
3. G. VACHER, E. SUBLET, M. KAESER, CH. MOSER, R. GURNY, G. BORCHARD *Set-up of a predictive in vitro sublingual model as a novel platform for screening of vaccines*, 5th Swiss Pharma Science Day, Berne, Switzerland, 2012
4. S. KADERLI, R. GURNY, L. SCAPOZZA, A.L. ROUGEMONT, J.P. GILBERTO, B. H. WALPOTH AND O. JORDAN, *Novel biocompatible Hyaluronic acid-chitosan hybrid hydrogel for osteoarthritis therapy*, PharmaScience Day, Bern, Switzerland, 2012
5. S. KADERLI, R. GURNY, L. SCAPOZZA, M. MÖLLER, *Novel hyaluronic acid-antioxidant conjugates for osteoarthritis therapy*, Swiss Chemical Society Fall meeting 2012, Zurich, Switzerland, 2012
6. M. RODRIGUEZ-ALLER, D. GUILLARME, S. RUDAZ, J.-L. VEUTHEY and R. GURNY *A Novel Water-Soluble Cyclosporine A Prodrug for Ophthalmic Application*, 39th Annual meeting of the Controlled Release society, Quebec City, Canada July 2012
7. M. RODRIGUEZ-ALLER, D. GUILLARME, R. NICOLI, S. RUDAZ, J.-L. VEUTHEY and R. GURNY *Analytical Challenges For In Vivo Investigations On A Rodent Ocular Model. Quantification Of Cyclosporine*, 27th International Symposium on MicroScale BioSeparations and Analyses, Geneva, 2012
8. M. RODRIGUEZ-ALLER, J.-L. VEUTHEY and R. GURNY, *Formulation of Poorly Water-Soluble Drugs for Ophthalmic Use, How to Improve animal studies in experimental biology*, Rigi Workshop 2012, Switzerland, 2012
9. GAELLE VACHER, EMMANUELLE SUBLET, MATTHIAS KAESER, CHRISTIAN MOSER, ROBERT GURNY AND GERRIT BORCHARD, *Set-up of a predictive in-vitro sublingual model as a novel platform for screening of vaccines*, Pharma Science Day, Berne, Switzerland, 2012

10. S. KADERLI, R. GURNY, L. SCAPOZZA, A.L. ROUGEMONT, J.P. GILBERTO, B. H. WALPOTH AND O. JORDAN, *Novel biocompatible Hyaluronic acid-chitosan hybrid hydrogel for osteoarthritis therapy*, PharmaScience Day, August 29th 2012, Bern, Switzerland, 2012

3. ORAL PRESENTATIONS

3.1. CONGRESSES AND SYMPOSIA

1. C. DI TOMMASO *et al.*, *Visualization of a novel micelle formulation after topical instillation on the eye: in vitro and in vivo qualitative and quantitative evaluations*, 8th Biopharmaceutics and Pharmaceutical Technology World meeting, March 19-22 2012, Istanbul, Turkey
2. M. VEURINK, L. ASMUS, B. KAUFMANN, M. MÖLLER, E. MENDRINOS, C.J. POURNARAS, R. GURNY *Investigation of a sustained release injectable for treatment of posterior segment eye diseases*. Swiss Galenic Meeting, 26-01-2012
3. M. VEURINK, *Targeting the retinal vasculature: ex vivo and in vivo sustained release of vasodilators from injectable polymers*. PhD Day, 15-06-2012
4. L. R. ASMUS
Ophthalmic Sustained-Release Formulations of Antibodies using Injectable Polyesters
CRS German Chapter Annual Meeting 2012, Würzburg/D, 29/03/2012 – 30/03/2012
5. S. DE VALENCE, *3D micro-architecture modification in Vascular Tissue Engineering*. 8th Swiss Experimental Surgery Symposium. Geneva, January 19-20, 2012.
6. S. DE VALENCE *Does Implantation Site Of Drug-Eluting Polymers Matter: Subcutaneous Vs. Aortic?* (Int J Artif Organs 2012;35(8):566). XXXIX Annual ESAO Congress 26-29 September 2012, Rostock, Germany
7. G. VACHER, *Oral Thin Film Formulations for Virosome-Based Vaccine Delivery: Potential and Limitations* 17TH RENCONTRE PHARMAPEPTIDES: Nanomedicine, Archamps, France (2012).
8. M. RODRIGUEZ-ALLER, *"A Novel Water-soluble Cyclosporine A Prodrug for Ophthalmic Application"*, PhD Day 2012, Hermance, Switzerland
9. G. VACHER, *Potential of virosome-based vaccine in mucosal application*, Swiss Galenic Meeting, Zürich, Suisse (2012).

4. AWARDS AND DISTINCTIONS

1. Best Oral Presentation Award: L.R. Asmus, *Ophthalmic sustained-release formulations of antibodies using injectable polyesters*; Annual CRS Chapter Meeting 2012, Würzburg, Germany; 2012